Trinucleotide cap analogs and methods of use thereof

By administering RNA molecules of specific trinucleotide cap analogs in vivo, the problem of mRNA5' cap structure regulation is solved, the translation efficiency and tolerance are improved, the safety and effectiveness of in vivo treatment are enhanced, and the mRNA is achieved. Efficient translation and security improvement.

CN118974070APending Publication Date: 2024-11-15TRILINK BIOTECH LLC
View PDF 0 Cites 3 Cited by

Patent Information

Application Number
CN202380030787.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-12-22
Filing Date
2023-01-25
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The prior art is difficult to effectively regulate the 5' cap structure of mRNA in vivo, affecting the translation efficiency and stability of mRNA, resulting in tolerance and safety challenges in in vivo applications.

Method used

A RNA molecule containing specific trinucleotide cap analogs was developed to enhance the translation efficiency and tolerance of mRNA by administering these RNA molecules to the subject, reducing dependence on double-stranded RNA, thereby improving in vivo treatment Safety and effectiveness.

Benefits of technology

By using specific trinucleotide cap analogs, the translation efficiency and tolerance of mRNA are improved, the dependence on double-stranded RNA is reduced, the safety and effectiveness of in vivo treatment are enhanced, and the in vivo translation of peptides is significantly improved level.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118974070A_ABST
    Figure CN118974070A_ABST
Patent Text Reader

Abstract

Novel trinucleotide cap analogs and methods of making and using the same are described herein. Also described herein is an RNA molecule comprising a 5 '-cap, wherein the 5'-cap comprises a trinucleotide cap analogue as described herein. Also described herein are methods of inducing a therapeutic effect in a subject comprising the step of administering to the subject an RNA molecule comprising the trinucleotide cap analogue.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Cross-reference to priority application

[0002] This application claims priority to U.S. Provisional Application No. 63 / 267,223, filed on January 27, 2022; U.S. Provisional Application No. 63 / 382,956, filed on November 9, 2022; and U.S. Provisional Application No. 63 / 476,787, filed on December 22, 2022, the contents of which are incorporated herein by reference in their entirety. Background Art

[0003] In vitro transcribed messenger RNA (mRNA) has many in vivo applications, such as vaccination, in which mRNA encoding a specific antigen is administered to elicit protective immunity in a patient; cell therapy, in which mRNA is transfected into cells ex vivo to alter cellular phenotype or function prior to delivering these altered cells to a patient; or replacement therapy, in which mRNA encoding a therapeutic protein is administered to the patient.

[0004] The main structural element of mRNA molecules for in vivo applications comprises a cap structure at the 5' end of the mRNA. The naturally occurring cap structure comprises a 7-methylguanosine ( 7m G or m7 G). The cap must be present for the mRNA to remain active as a template for protein synthesis. The chemical structure of the cap can regulate the efficiency of translation in the cell. Therefore, an effective cap structure is necessary. Summary of the invention

[0005] This summary is a brief overview of various aspects of the invention and introduces some concepts that are further described in the detailed description section below. This summary is not intended to identify key or essential features of the claimed subject matter, nor is it intended to be used alone to determine the scope of the claimed subject matter. The subject matter should be understood by reference to appropriate portions of the entire specification, any or all drawings, and each claim.

[0006] Described herein are trinucleotide cap analogs and methods of making and using the same. Provided herein is a compound having the formula:

[0007]

[0008] or any stereoisomer thereof, wherein: is a single bond or a double bond; R1 is H or CH3; R2 is H and R3 is OCH3 or F, or R2 and R3 are covalently bonded together and together with the intermediate atom form a 2'-O,4'-C methylene bridge; X1 is O or CH; X2 is CH2 or CH; X3 is O or S; each independent Y is H + or a cation; and n is 0, 1, 2, 3 or 4, wherein when X1 is CH, X2 is CH, and is a double bond. Optionally, the compound has the following structure:

[0009]

[0010]

[0011] or any stereoisomer thereof.

[0012] Also provided herein is a compound having the formula:

[0013]

[0014] or any stereoisomer thereof, wherein: R1 is H or CH3, X1 is O or S, and each independent Y is H + or a cation, n is 0, 1, 2, 3 or 4, wherein when X1 is S, R1 is CH3. Optionally, the compound has the following structure:

[0015]

[0016]

[0017] or any stereoisomer thereof.

[0018] Also provided herein is a compound having the formula:

[0019]

[0020] or any stereoisomer thereof, wherein: R1 is H or CH3; each independent Y is H + or a cation; and n is 0, 1, 2, 3 or 4. Optionally, the compound has the following structure:

[0021]

[0022]

[0023] or any stereoisomer thereof.

[0024] Additionally, there is provided herein a compound having the following formula:

[0025]

[0026] or any stereoisomer thereof, wherein: R1 is H or CH3; X1, X2 and X3 are each independently selected from O and S, wherein when one of X1, X2 or X3 is S, the rest of X1, X2 and X3 are O; each independent Y is H + or a cation; and n is 0, 1, 2, 3 or 4. Optionally, the compound has the following structure:

[0027]

[0028]

[0029] or any stereoisomer thereof.

[0030] Furthermore, the present invention also provides a compound having the following formula:

[0031]

[0032] or any stereoisomer thereof, wherein: R1 is H or CH3; R2 is H and R3 is F, or R2 and R3 are covalently bonded together and together with the intermediate atom form a 2'-O,4'-C methylene bridge; each independent Y is H + or a cation; and n is 0, 1, 2, 3 or 4, wherein when R2 is H and R3 is F, R1 is not H. Optionally, the compound has the following structure:

[0033]

[0034]

[0035] or any stereoisomer thereof.

[0036] Also provided herein is a compound having the formula:

[0037]

[0038] or any stereoisomer thereof, wherein: R1 is H or CH3; X1, X2, X3 and X4 are each independently selected from O and S; each independent Y is H + or a cation; and n is 0, 1, 2, 3 or 4, wherein one of X1, X2, X3 and X4 is S. Optionally, the compound has the following structure:

[0039]

[0040]

[0041]

[0042] or any stereoisomer thereof.

[0043] Furthermore, the present invention also provides a compound having the following formula:

[0044]

[0045] or any stereoisomer thereof, wherein R1 and R2 are each independently selected from H and CH3; each independent Y is H + or a cation; and n is 0, 1, 2, 3 or 4, wherein at least one of R1 or R2 is CH3. Optionally, the compound has the following structure:

[0046]

[0047]

[0048] or any stereoisomer thereof.

[0049] Also provided herein is a compound having the formula:

[0050]

[0051] or any stereoisomer thereof, wherein: R1 and R2 are each independently selected from H and CH3; each independent Y is H + or a cation; and n is 0, 1, 2, 3 or 4. Optionally, the compound has the following structure:

[0052]

[0053] or any stereoisomer thereof.

[0054] Additionally, there is provided herein a compound having the following formula:

[0055]

[0056] or any stereoisomer thereof, wherein R1 is H or CH3; R2 is OH, F, substituted or unsubstituted alkoxy or thio; R3 is H or CH3; each independent Y is H + or a cation; and n is 0, 1, 2, 3 or 4, wherein when R2 is OH, R1 is not H. Optionally, the compound has the following structure:

[0057]

[0058]

[0059]

[0060] or any stereoisomer thereof.

[0061] Also provided herein is a compound having the formula:

[0062]

[0063] or any stereoisomer thereof, wherein R1 is H and CH3; each independent Y is H + or a cation; and n is 0, 1, 2, 3 or 4. Optionally, the compound has the following structure:

[0064]

[0065] or any stereoisomer thereof.

[0066] Additionally, there is provided herein a compound having the following formula:

[0067]

[0068] or any stereoisomer thereof, wherein R1 is H and CH3; each independent Y is H + or a cation; and n is 0, 1, 2, 3 or 4. Optionally, the compound has the following structure:

[0069]

[0070] or any stereoisomer thereof.

[0071] Also provided herein is a compound having the formula:

[0072]

[0073] or any stereoisomer thereof, wherein R1 and R2 are each independently selected from H and CH3; each independent Y is H + or a cation; and n is 0, 1, 2, 3, 4 or 5. Optionally, the compound has the following structure:

[0074]

[0075] or any stereoisomer thereof.

[0076] Deuterated forms of the disclosed compounds are also described herein. For example, a compound is provided herein, the compound being selected from the group consisting of:

[0077]

[0078]

[0079] or any stereoisomer thereof.

[0080] Also described herein is a pharmaceutical composition comprising a compound as described herein and a pharmaceutically acceptable carrier. Also provided is an RNA molecule comprising a 5'-cap, wherein the 5'-cap comprises a compound as described herein. Optionally, the RNA molecule is a messenger RNA (mRNA) molecule or a self-amplifying RNA (saRNA) molecule. Also provided is a method for inducing a therapeutic effect in a subject. The method includes administering an RNA molecule (e.g., mRNA or saRNA molecule) as described herein to the subject. The RNA administered may contain a certain amount of immunogenic double-stranded RNA (dsRNA). The amount of dsRNA is calculated per ug of RNA administered.

[0081] Further provided herein are methods of administering to an animal a therapeutic dosage unit of an mRNA molecule comprising a 5'-cap. In some instances, the 5'-cap comprises a compound as described herein. In some instances, the 5'-cap comprises a compound selected from the group consisting of:

[0082]

[0083]

[0084]

[0085] Wherein, in some instances, the therapeutic dosage unit (e.g., therapeutic mRNA dosage unit) comprises less than 7ng / μg of double-stranded RNA (dsRNA), and wherein, in some instances, the subject exhibits increased tolerance to the administered therapeutic dosage unit of the mRNA molecule compared to an equivalent therapeutic dosage unit of the mRNA molecule comprising 7ng / μg or more dsRNA. Optionally, the increased tolerance is determined by measuring one or more of the following for a certain period of time before and after the administration: body weight, organ weight, aspartate aminotransferase (AST) level, alanine aminotransferase (ALT) level, C-reactive protein (CRP) level, procalcitonin (PCT) level, interleukin-6 (IL-6) level, erythrocyte sedimentation rate (ESR), serum amyloid A level, and serum ferritin level. Optionally, the increased tolerance is measured by testing in a standard in vivo assay. In some examples, the increased tolerability is an increase of at least 20% over the tolerability of the administered dose unit as measured by testing in a standard in vivo assay, an increase of at least 25% over the tolerability of the administered dose unit as measured by testing in a standard in vivo assay, an increase of at least 30% over the tolerability of the administered dose unit as measured by testing in a standard in vivo assay, an increase of at least 35% over the tolerability of the administered dose unit as measured by testing in a standard in vivo assay, an increase of at least 40% over the tolerability of the administered dose unit as measured by testing in a standard in vivo assay, an increase of at least 45% over the tolerability of the administered dose unit as measured by testing in a standard in vivo assay, an increase of at least 50% over the tolerability of the administered dose unit as measured by testing in a standard in vivo assay, an increase of at least 10% over the tolerability of the administered dose unit as measured by testing in a standard in vivo assay, An increase of at least 55% over the tolerability of the administered dose unit as measured by testing in a standard in vivo assay, an increase of at least 60% over the tolerability of the administered dose unit as measured by testing in a standard in vivo assay, an increase of at least 65% over the tolerability of the administered dose unit as measured by testing in a standard in vivo assay, an increase of at least 70% over the tolerability of the administered dose unit as measured by testing in a standard in vivo assay, an increase of at least 75% over the tolerability of the administered dose unit as measured by testing in a standard in vivo assay, an increase of at least 80% over the tolerability of the administered dose unit as measured by testing in a standard in vivo assay, an increase of at least 85% over the tolerability of the administered dose unit as measured by testing in a standard in vivo assay, an increase of at least 90% over the tolerability of the administered dose unit as measured by testing in a standard in vivo assay, or an increase of at least 95% over the tolerability of the administered dose unit as measured by testing in a standard in vivo assay.

[0086] Optionally, the therapeutic dosage unit of the mRNA molecule comprises less than 6.9 ng / μg of double-stranded RNA (dsRNA), less than 6.8 ng / μg of double-stranded RNA (dsRNA), less than 6.7 ng / μg of double-stranded RNA (dsRNA), less than 6.6 ng / μg of double-stranded RNA (dsRNA), less than 6.5 ng / μg of double-stranded RNA (dsRNA), less than 6.4 ng / μg of double-stranded RNA (dsRNA), less than 6.3 ng / μg of double-stranded RNA (dsRNA), less than 6.2 ng / μg of double-stranded RNA (dsRNA), less than 6.1 ng / μg of double-stranded RNA (dsRNA), less than 6.0 ng / μg of double-stranded RNA (dsRNA). / μg of double-stranded RNA (dsRNA), less than 5.9ng / μg of double-stranded RNA (dsRNA), less than 5.8ng / μg of double-stranded RNA (dsRNA), less than 5.7ng / μg of double-stranded RNA (dsRNA), less than 5.6ng / μg of double-stranded RNA (dsRNA), less than 5.5ng / μg of double-stranded RNA (dsRNA), less than 5.4ng / μg of double-stranded RNA (dsRNA), less than 5.3ng / μg of double-stranded RNA (dsRNA), less than 5.2ng / μg of double-stranded RNA (dsRNA), less than 5.1ng / μg of double-stranded RNA (dsRNA), less than 5.0ng / μg of double-stranded RNA NA(dsRNA), less than 4.9ng / μg double-stranded RNA(dsRNA), less than 4.8ng / μg double-stranded RNA(dsRNA), less than 4.7ng / μg double-stranded RNA(dsRNA), less than 4.6ng / μg double-stranded RNA(dsRNA), less than 4.5ng / μg double-stranded RNA(dsRNA), less than 4.4ng / μg double-stranded RNA(dsRNA), less than 4.3ng / μg double-stranded RNA(dsRNA), less than 4.2ng / μg double-stranded RNA(dsRNA), less than 4.1ng / μg double-stranded RNA(dsRNA), less than 4.0ng / μg double-stranded RNA(dsRNA A), less than 3.9 ng / μg of double-stranded RNA (dsRNA), less than 3.8 ng / μg of double-stranded RNA (dsRNA), less than 3.7 ng / μg of double-stranded RNA (dsRNA), less than 3.6 ng / μg of double-stranded RNA (dsRNA), less than 3.5 ng / μg of double-stranded RNA (dsRNA), less than 3.4 ng / μg of double-stranded RNA (dsRNA), less than 3.3 ng / μg of double-stranded RNA (dsRNA), less than 3.2 ng / μg of double-stranded RNA (dsRNA), less than 3.1 ng / μg of double-stranded RNA (dsRNA), less than 3.0 ng / μg of double-stranded RNA (dsRNA), less than 2.9ng / μg double-stranded RNA (dsRNA), less than 2.8ng / μg double-stranded RNA (dsRNA), less than 2.7ng / μg double-stranded RNA (dsRNA), less than 2.6ng / μg double-stranded RNA (dsRNA), less than 2.5ng / μg double-stranded RNA (dsRNA), less than 2.4ng / μg double-stranded RNA (dsRNA), less than 2.3ng / μg double-stranded RNA (dsRNA), less than 2.2ng / μ g of double-stranded RNA (dsRNA), less than 2.1ng / μg of double-stranded RNA (dsRNA), less than 2.0ng / μg of double-stranded RNA (dsRNA), less than 1.9ng / μg of double-stranded RNA (dsRNA), less than 1.8ng / μg of double-stranded RNA (dsRNA), less than 1.7ng / μg of double-stranded RNA (dsRNA), less than 1.6ng / μg of double-stranded RNA (dsRNA), less than 1.5 ...8ng / μg of double-stranded RNA (dsRNA), less than 1.7ng / μg of double-stranded RNA (dsRNA), less than 1.6ng / μg of double-stranded RNA (dsRNA), less than 0.4 ng / μg of double-stranded RNA (dsRNA), less than 0.3 ng / μg of double-stranded RNA (dsRNA), less than 0.2 ng / μg of double-stranded RNA (dsRNA), less than 0.1 ng / μg of double-stranded RNA (dsRNA), less than 0.1 ng / μg of double-stranded RNA (dsRNA), less than 0.9 ng / μg of double-stranded RNA (dsRNA), less than 0.8 ng / μg of double-stranded RNA (dsRNA), less than 0.7 ng / μg of double-stranded RNA (dsRNA), less than 0.6 ng / μg of double-stranded RNA (dsRNA), less than 0.5 ng / μg of double-stranded RNA (dsRNA), less than 0.4 ng / μg of double-stranded RNA (dsRNA), less than 0.3 ng / μg of double-stranded RNA (dsRNA), less than 0.2 ng / μg of double-stranded RNA (dsRNA), or less than 0.1 ng / μg of double-stranded RNA (dsRNA). .

[0087] Further provided herein is a method for increasing the in vivo translation of a polypeptide in a subject, the method comprising administering to the subject a therapeutic dosage unit comprising an effective amount of an mRNA encoding the polypeptide, wherein the mRNA comprises a 5'-cap having the formula:

[0088]

[0089] wherein the therapeutic dosage unit administered is at least 20% lower than the therapeutic dosage unit required to elicit the same response in the subject when a control mRNA encoding the polypeptide is administered, wherein the control mRNA comprises a 5'-cap having the formula:

[0090]

[0091] Also provided herein is a method for increasing the in vivo translation of a polypeptide in a subject, the method comprising administering to the subject a therapeutic dosage unit comprising an effective amount of an mRNA encoding a polypeptide, wherein the mRNA comprises a 5'-cap having the formula:

[0092]

[0093] wherein the therapeutic dosage unit administered is at least 20% lower than the therapeutic dosage unit required to elicit the same response in the subject when a control mRNA encoding the polypeptide is administered, wherein the control mRNA comprises a 5'-cap having the formula:

[0094]

[0095] Further provided herein is a method for increasing the in vivo translation of a polypeptide in a subject, the method comprising administering to the subject a therapeutic dosage unit comprising an effective amount of an mRNA encoding a polypeptide, wherein the mRNA comprises a 5'-cap having the formula:

[0096]

[0097] wherein the therapeutic dosage unit administered is at least 20% lower than the therapeutic dosage unit required to elicit the same response in the subject when a control mRNA encoding the polypeptide is administered, wherein the control mRNA comprises a 5'-cap having the formula:

[0098]

[0099] Also provided herein is a method for increasing the in vivo translation of a polypeptide in a subject, the method comprising administering to the subject a therapeutic dosage unit comprising an effective amount of an mRNA encoding the polypeptide, wherein the mRNA comprises a 5'-cap having the formula:

[0100]

[0101] wherein the therapeutic dosage unit administered is at least 20% lower than the therapeutic dosage unit required to elicit the same response in the subject when a control mRNA encoding the polypeptide is administered, wherein the control mRNA comprises a 5'-cap having the formula:

[0102]

[0103] Optionally, said subject exhibits increased tolerance to the administered therapeutic dose unit compared to said therapeutic dose unit required to elicit said same response in said subject when said control mRNA is administered, as measured by testing in a standard in vivo assay. In some cases, the increased tolerability is an increase of at least 20% over the tolerability of the administered therapeutic dose unit as measured by testing in a standard in vivo assay, an increase of at least 25% over the tolerability of the administered therapeutic dose unit as measured by testing in a standard in vivo assay, an increase of at least 30% over the tolerability of the administered therapeutic dose unit as measured by testing in a standard in vivo assay, an increase of at least 35% over the tolerability of the administered therapeutic dose unit as measured by testing in a standard in vivo assay, an increase of at least 40% over the tolerability of the administered therapeutic dose unit as measured by testing in a standard in vivo assay, an increase of at least 45% over the tolerability of the administered therapeutic dose unit as measured by testing in a standard in vivo assay, an increase of at least 50% over the tolerability of the administered therapeutic dose unit as measured by testing in a standard in vivo assay, an increase of at least 10% over the tolerability of the administered therapeutic dose unit as measured by testing in a standard in vivo assay, An increase of at least 55% over the tolerability of the administered therapeutic dose unit as measured by testing in a standard in vivo assay, an increase of at least 60% over the tolerability of the administered therapeutic dose unit as measured by testing in a standard in vivo assay, an increase of at least 65% over the tolerability of the administered therapeutic dose unit as measured by testing in a standard in vivo assay, an increase of at least 70% over the tolerability of the administered therapeutic dose unit as measured by testing in a standard in vivo assay, an increase of at least 75% over the tolerability of the administered therapeutic dose unit as measured by testing in a standard in vivo assay, an increase of at least 80% over the tolerability of the administered therapeutic dose unit as measured by testing in a standard in vivo assay, an increase of at least 85% over the tolerability of the administered therapeutic dose unit as measured by testing in a standard in vivo assay, an increase of at least 90% over the tolerability of the administered therapeutic dose unit as measured by testing in a standard in vivo assay, or an increase of at least 95% over the tolerability of the administered therapeutic dose unit as measured by testing in a standard in vivo assay.

[0104] Optionally, the administered therapeutic dosage unit comprises less than 6.9 ng / μg of double-stranded RNA (dsRNA), less than 6.8 ng / μg of double-stranded RNA (dsRNA), less than 6.7 ng / μg of double-stranded RNA (dsRNA), less than 6.6 ng / μg of double-stranded RNA (dsRNA), less than 6.5 ng / μg of double-stranded RNA (dsRNA), less than 6.4 ng / μg of double-stranded RNA (dsRNA), less than 6.3 ng / μg of double-stranded RNA (dsRNA), less than 6.2 ng / μg of double-stranded RNA (dsRNA), less than 6.1 ng / μg of double-stranded RNA (dsRNA), less than 6.0 ng / μg of Double-stranded RNA (dsRNA), less than 5.9 ng / μg of double-stranded RNA (dsRNA), less than 5.8 ng / μg of double-stranded RNA (dsRNA), less than 5.7 ng / μg of double-stranded RNA (dsRNA), less than 5.6 ng / μg of double-stranded RNA (dsRNA), less than 5.5 ng / μg of double-stranded RNA (dsRNA), less than 5.4 ng / μg of double-stranded RNA (dsRNA), less than 5.3 ng / μg of double-stranded RNA (dsRNA), less than 5.2 ng / μg of double-stranded RNA (dsRNA), less than 5.1 ng / μg of double-stranded RNA (dsRNA), less than 5.0 ng / μg of double-stranded RNA ( dsRNA), less than 4.9 ng / μg double-stranded RNA (dsRNA), less than 4.8 ng / μg double-stranded RNA (dsRNA), less than 4.7 ng / μg double-stranded RNA (dsRNA), less than 4.6 ng / μg double-stranded RNA (dsRNA), less than 4.5 ng / μg double-stranded RNA (dsRNA), less than 4.4 ng / μg double-stranded RNA (dsRNA), less than 4.3 ng / μg double-stranded RNA (dsRNA), less than 4.2 ng / μg double-stranded RNA (dsRNA), less than 4.1 ng / μg double-stranded RNA (dsRNA), less than 4.0 ng / μg double-stranded RNA (dsRNA) ), less than 3.9ng / μg double-stranded RNA (dsRNA), less than 3.8ng / μg double-stranded RNA (dsRNA), less than 3.7ng / μg double-stranded RNA (dsRNA), less than 3.6ng / μg double-stranded RNA (dsRNA), less than 3.5ng / μg double-stranded RNA (dsRNA), less than 3.4ng / μg double-stranded RNA (dsRNA), less than 3.3ng / μg double-stranded RNA (dsRNA), less than 3.2ng / μg double-stranded RNA (dsRNA), less than 3.1ng / μg double-stranded RNA (dsRNA), less than 3.0ng / μg double-stranded RNA (dsRNA), less than 2.9ng / μg double-stranded RNA (dsRNA), less than 2.8ng / μg double-stranded RNA (dsRNA), less than 2.7ng / μg double-stranded RNA (dsRNA), less than 2.6ng / μg double-stranded RNA (dsRNA), less than 2.5ng / μg double-stranded RNA (dsRNA), less than 2.4ng / μg double-stranded RNA (dsRNA), less than 2.3ng / μg double-stranded RNA (dsRNA), less than 2.2ng / μ g of double-stranded RNA (dsRNA), less than 2.1ng / μg of double-stranded RNA (dsRNA), less than 2.0ng / μg of double-stranded RNA (dsRNA), less than 1.9ng / μg of double-stranded RNA (dsRNA), less than 1.8ng / μg of double-stranded RNA (dsRNA), less than 1.7ng / μg of double-stranded RNA (dsRNA), less than 1.6ng / μg of double-stranded RNA (dsRNA), less than 1.5 ...8ng / μg of double-stranded RNA (dsRNA), less than 1.7ng / μg of double-stranded RNA (dsRNA), less than 1.6ng / μg of double-stranded RNA (dsRNA), less than 0.4 ng / μg of double-stranded RNA (dsRNA), less than 0.3 ng / μg of double-stranded RNA (dsRNA), less than 0.2 ng / μg of double-stranded RNA (dsRNA), less than 0.1 ng / μg of double-stranded RNA (dsRNA), less than 0.1 ng / μg of double-stranded RNA (dsRNA), less than 0.9 ng / μg of double-stranded RNA (dsRNA), less than 0.8 ng / μg of double-stranded RNA (dsRNA), less than 0.7 ng / μg of double-stranded RNA (dsRNA), less than 0.6 ng / μg of double-stranded RNA (dsRNA), less than 0.5 ng / μg of double-stranded RNA (dsRNA), less than 0.4 ng / μg of double-stranded RNA (dsRNA), less than 0.3 ng / μg of double-stranded RNA (dsRNA), less than 0.2 ng / μg of double-stranded RNA (dsRNA), or less than 0.1 ng / μg of double-stranded RNA (dsRNA). .

[0105] Further described herein are methods for synthesizing trinucleotide compounds. In one example, the method for synthesizing a trinucleotide compound comprises mixing N7-methyl-guanosine-5'-diphosphate with an activating reagent to form an active intermediate; reacting the active intermediate with imidazole to form an activated intermediate; and adding a salt reagent (e.g., a chloride salt such as magnesium chloride or zinc chloride) and a dinucleotide to the activated intermediate to form a trinucleotide compound, wherein the method is a one-pot synthesis method. In some examples, the method for synthesizing a trinucleotide compound comprises mixing N7-methyl-guanosine-5'-diphosphate having the following structure:

[0106]

[0107] wherein X1 and X2 are each independently selected from the group consisting of O and S; X3 is O; R1 and R2 are each independently selected from H, OH, N3, F, substituted or unsubstituted alkoxy and thio, wherein R1 and R2 are optionally combined to form a heterocycle, mixed with an activating reagent and imidazole to form an activated intermediate; and adding a salt reagent (e.g., a chloride salt such as magnesium chloride or zinc chloride) and a dinucleotide having the following structure:

[0108]

[0109] in is a single bond or a double bond; X4 and X6 are each independently selected from the group consisting of O and S; X5 is O, S or CH; X7 is CH or CH2; R3 is OH, OMe, F, and R4 is H, or wherein R3 and R4 are covalently bonded together and form a 2'-O,4'-C methylene bridge together with the intermediate atom; B1 and B2 are each independently selected from the group consisting of a purine ring and a pyrimidine ring, and are added to the activated intermediate to form a trinucleotide compound having the following structure:

[0110]

[0111] The method described therein is a one-pot synthesis method.

[0112] In other examples, the method of synthesizing a trinucleotide compound comprises reacting a dinucleotide having the following structure:

[0113] in

[0114] is a single bond or a double bond; X4 is O; X6 is O or S; X5 is O, S or CH; X7 is CH or CH2; R3 is OH, OMe, F, and R4 is H, or wherein R3 and R4 are covalently bonded together and together with the intermediate atom form a 2'-O,4'-C methylene bridge; and B1 and B2 are each independently selected from the group consisting of a purine ring and a pyrimidine ring, mixed with an activating agent and imidazole to form an activated phosphoimidazole having the following structure:

[0115] as well as

[0116] A salt reagent (e.g., a chloride salt such as magnesium chloride or zinc chloride) and a compound having the following structure:

[0117] in

[0118] X1 and X2 are each independently selected from the group consisting of O and S; X3 is S; R1 and R2 are each independently selected from H, OH, N3, F, substituted or unsubstituted alkoxy and thio, wherein R1 and R2 are optionally combined to form a heterocycle, added to the activated phosphoimidazolide to form the trinucleotide compound having the following structure:

[0119]

[0120] In other examples, the method of synthesizing a trinucleotide compound comprises reacting a dinucleotide diphosphate having the structure:

[0121] in

[0122] is a single bond or a double bond; X3 is O; X4 and X6 are each independently selected from O and S; X5 is O, S or CH; X7 is CH or CH2; R3 is OH, OMe, F, and R4 is H, or wherein R3 and R4 are covalently bonded together and together with the intermediate atom form a 2'-O,4'-C methylene bridge; and B1 and B2 are each independently selected from the group consisting of a purine ring and a pyrimidine ring, mixed with an activating agent and imidazole to form an activated phosphoimidazole having the following structure:

[0123] as well as

[0124] A salt reagent (e.g., a chloride salt such as magnesium chloride or zinc chloride) and a compound having the following structure:

[0125] in

[0126] X1 and X2 are each independently selected from O and S; and R1 and R2 are each independently selected from H, OH, N3, F, substituted or unsubstituted alkoxy and thio, wherein R1 and R2 are optionally combined to form a heterocycle, added to the activated phosphoimidazole to form the trinucleotide compound having the following structure:

[0127]

[0128] The method described therein is a one-pot synthesis method.

[0129] The details of one or more implementations are set forth in the accompanying drawings and the description below. Other features, objects, and advantages will be apparent from the description and drawings, and from the claims. BRIEF DESCRIPTION OF THE DRAWINGS

[0130] Figure 1is a bar graph showing in vitro translation of cap analogs as described herein using wheat germ extract, a cell-free translation system. The data demonstrate that protein expression of the cap analogs is comparable or enhanced compared to mRNA produced by a control cap.

[0131] Figure 2 Is a bar graph showing luciferase expression in mice injected with LNPs containing mRNA produced by cap analogs as described herein and mRNA produced by control caps. The data demonstrate that in vivo luciferase expression is comparable or enhanced compared to mRNA produced by control caps.

[0132] Figure 3 A representative animal from a cohort of five animals is shown across five imaging time points following LNP:mRNA and luciferin injection. The luminescence intensity scale is on the right.

[0133] Figure 4 Containing cap analogs shown m7 Diagram showing that 3'OMe modification on the G moiety results in increased translation in vivo. m7 GpppA 2'OMe pG(control) relative to m7 G 3'Ome pppA 2'OMe pG (compound 29) was measured, and the compound was m7 G has a 3'OMe group m7 GpppA 2'OMe pG(control) (first column); m7 Gppp m6 A 2'OMe pG (compound 31) relative to m7 G 3' OMe ppp m6 A 2'OMe pG (compound 30) was measured in m7 G has a 3'OMe group m7 Gppp m6 A 2' OMe pG (compound 31) (second column); m7 GpppA 2',4'-LNA pG (compound 1) relative to m7 G 3'OMe pppA 2',4'-LNA pG (compound 2) was measured in m7 G has a 3'OMe group m7 GpppA 2',4'-LNA pG(Compound 1) (third column); andm7 Gppp (diaminopurine) 2'OMe pG (compound 7) relative to m7 G 3'OMe ppp (diaminopurine) 2'OMe pG (compound 8) was measured in m7 G has a 3'OMe group m7 Gppp (diaminopurine) 2'OMe pG (Compound 7) (fourth column). DETAILED DESCRIPTION

[0134] Novel trinucleotide cap analogs and compositions and methods of using the same are described herein. Also described herein is an RNA molecule comprising a 5'-cap, wherein the 5'-cap comprises a trinucleotide cap analog as described herein. Also described herein is a method of inducing a therapeutic effect in a subject, the method comprising the step of administering to the subject a trinucleotide cap analog or an RNA molecule comprising the trinucleotide cap analog.

[0135] The following description lists various examples of the method of the present invention. The specific examples are not intended to limit the scope of the method. Instead, these are non-limiting exemplary methods. The description will be read from the perspective of a person of ordinary skill in the art; therefore, it does not necessarily include information well known to the technician.

[0136] I. Definitions

[0137] Unless otherwise specified, all terms used herein have the same meaning as commonly understood by those skilled in the art to which the present disclosure belongs.All patents, patent applications and publications mentioned in the present disclosure are incorporated herein by reference in their entirety.

[0138] As used in the specification and the appended claims, the singular forms "a", "an", and "the" include plural referents unless the context clearly dictates otherwise. For example, reference to "a transcript" or "the transcript" may include a plurality of transcripts.

[0139] The use of any and all examples, or exemplary language (eg, "such as") provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed.

[0140] The terms "may," "may be," "can," and "can b," and related terms are intended to convey that the subject matter referenced is optional (i.e., the subject matter is present in some instances and not in other instances), rather than a reference to the ability or probability of the subject matter, unless the context clearly indicates otherwise.

[0141] The terms “optional” and “optionally” mean that the subsequently described event, circumstance, or material may or may not occur or exist, and that the description includes instances where the event, circumstance, or material occurs or exists and instances where it does not.

[0142] The terms "including," "comprising," or "having," and variations thereof herein are meant to encompass the elements listed thereafter and equivalents thereof as well as additional elements. Embodiments recited as "including," "comprising," or "having" certain elements are also contemplated as "consisting essentially of" and "consisting of" those specified elements. As used herein, "and / or" refers to and encompasses any and all possible combinations of one or more of the associated listed items as well as the lack of a combination when interpreted in an alternative ("or").

[0143] As used herein, the transitional phrase "consisting essentially of" (and grammatical variations) should be interpreted to cover the listed materials or steps "and those materials or steps that do not materially affect one or more of the basic and novel characteristics of the claimed invention." See In re Herz, 537 F.2d 549, 551-52, 190 USPQ 461, 463 (CCPA 1976) (emphasis original); see also MPEP §2111.03. Therefore, as used herein, the term "consisting essentially of" should not be interpreted as equivalent to "comprising."

[0144] In this article, range can be expressed as from one specific value and / or to another specific value.When expressing such a range, unless the context clearly states otherwise, it is also specifically contemplated and regarded as disclosing a range from one specific value and / or to another specific value.Finally, it should be understood that unless the context clearly states otherwise, all single values ​​and sub-ranges of values ​​contained in the explicit disclosure range are also specifically contemplated and should be regarded as disclosed.Further, it should be understood that all ranges refer to the listed ranges as ranges, and refer to the set of single digits from the first endpoint (and including the first endpoint) to the second endpoint (and including the second endpoint).In the latter case, it should be understood that any single digit in the single digit can be selected as a form of the quantity, value or feature indicated by the range.In this way, the range describes a group of numbers or values ​​from the first endpoint (and including the first endpoint) to the second endpoint (and including the second endpoint), and a single member of the group (that is, a single digit) can be selected from the endpoint as the quantity, value or feature indicated by the range.

[0145] As used herein in conjunction with numerical values, the use of the term "about" is intended to describe values ​​that are within a range of approximately + / - 10% above or below the stated value; in other instances, the value may be within a range of approximately + / - 5% above or below the stated value; in other instances, the value may be within a range of approximately + / - 2% above or below the stated value; in other instances, the value may be within a range of approximately + / - 1% above or below the stated value.

[0146] As used herein, the term "cap analog" means a structural derivative of an RNA cap.

[0147] As used herein, the terms "complement", "complementary" or "complementarity" refer to specific base pairing between nucleotides or nucleic acids. Complementary nucleotides are typically A and T (or A and U) and G and C. For example, the complementarity between a capping oligonucleotide primer and a DNA template can be "complete" or "full", in which all nucleotide bases of the two nucleic acid chains match according to recognized base pairing rules, it can be "partial", in which only some of the nucleotide bases of the starting capping oligonucleotide primer and the DNA template match according to recognized base pairing rules, or it can be "non-complementary", in which the nucleotide bases of the two nucleic acid chains do not match according to recognized base pairing rules. Complementarity can also be "substantially complementary", in which the nucleotide bases of the two nucleic acids match according to recognized base pairing rules, but include one or more mismatches (e.g., 1, 2, 3, 4) from the full complementarity.

[0148] As used herein, "deoxyribonuclease (DNase)" is an enzyme that catalyzes the hydrolytic cleavage of phosphodiester bonds in the DNA backbone, thereby degrading the DNA.

[0149] As used herein, the term "hybridization" or "specific hybridization" refers to the process in which the initial trinucleotide primer anneals to the DNA template under appropriate stringent conditions during the transcription reaction. Hybridization with DNA is performed with an initial capping oligonucleotide primer, and in certain embodiments, the primer has a length of 3-10 nucleotides, including a 5'-5' reverse cap structure. Nucleic acid hybridization techniques are well known in the art (e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Press, Plainview, NY (1989); Ausubel, FM et al., Current Protocols in Molecular Biology, John Wiley & Sons, Secaucus, NJ (1994)).

[0150] As used herein, the term "impurity" refers to a substance (eg, mRNA transcript) that has a different chemical composition than the target material. Impurities are also referred to as contaminants.

[0151] "Inorganic pyrophosphatase" refers to an enzyme that catalyzes the conversion of one pyrophosphate ion to two phosphate ions, thereby inhibiting aggregation and, in some cases, preventing the interaction of pyrophosphate with magnesium ions during the T7 transcription reaction.

[0152] As used herein, the term "internucleotide linkage" refers to the bond linking two nucleosides of an oligonucleotide or nucleic acid, and may be a natural phosphodiester bond or a modified bond.

[0153] As used herein, the term "in vitro" refers to a process that occurs outside of a living organism (eg, a multicellular organism such as a human or non-human animal) (eg, in a test tube, culture dish, or elsewhere outside of a living organism).

[0154] As used herein, the term "in vivo" refers to events that occur within a living organism.

[0155] As used herein, the term "in vivo assay" refers to a method for detecting and / or measuring one or more compounds or molecules including compounds (e.g., mRNA molecules in a therapeutic dose) relative to a control to increase or decrease the ability of a characteristic (e.g., biomarker level). Optionally, in vivo assays as described herein can be used to determine the tolerance level of a subject to a given compound or molecule. Exemplary measurements for assessing tolerance include one or more of the following: body weight, organ weight, aspartate aminotransferase (AST) level, alanine aminotransferase (ALT) level, C-reactive protein (CRP) level, procalcitonin (PCT) level, interleukin-6 (IL-6) level, erythrocyte sedimentation rate (ESR), serum amyloid A level, and serum ferritin level. Optionally, in vivo assays can be characterized as "standard in vivo assays" herein, and can be optionally performed using the conditions outlined in Examples 2 and 3 of the application.

[0156] As used herein, the term "label" or "detectable label" refers to any compound or combination of compounds that can be attached or otherwise associated with a molecule so that the molecule can be detected directly or indirectly by detecting the label. The detectable label can be a radioactive isotope (e.g., carbon, phosphorus, iodine, indium, sulfur, tritium, etc.), a mass isotope (e.g., H 2 , C 13 or N 15 ), a dye or fluorophore (e.g., a cyanine, fluorescein, or a coumarin), a hapten (e.g., biotin), or any other directly or indirectly detectable agent.

[0157] As used herein, "locked nucleic acid" (LNA) refers to a ribonucleotide with a bridge between the 2'0 and 4'C methylene bicyclic nucleotide monomers. The LNA portion may have the following structure:

[0158]

[0159] As used herein, a "messenger RNA transcript" or "mRNA transcript" is a transcript transcribed from a DNA template encoding a desired polypeptide. The mRNA transcript may contain a coding region and a non-coding region. For example, the DNA template may include an RNA polymerase promoter sequence, a 5'UTR sequence, an open reading frame, and a 3'UTR sequence. In some instances, the DNA template also includes a nucleic acid sequence encoding a poly(A) tail.

[0160] As used herein, the term "modified NTP" refers to a nucleoside 5'-triphosphate having a chemical moiety group that is combined at any position or substituted at any position (including sugar, base, triphosphate chain or any combination of these three positions). Optionally, the chemical moiety group can be a group of any nature compatible with the transcription process. Examples of such NTPs include inosine triphosphate, dihydrouridine triphosphate, 2'-fluoro-2'-deoxycytidine triphosphate, pseudouridine triphosphate, N1-methyl pseudouridine triphosphate and 5-methyluridine triphosphate, and can be found in, for example, "Nucleoside triphosphates and their analogs: Chemistry, Biotechnology and Biological Applications", Vaghefi, M. ed., Taylor and Francis, Boca Raton (2005).

[0161] As used herein, the term "modified oligonucleotide" or "modified trinucleotide" includes, for example, oligonucleotides containing modified nucleosides, modified internucleotide bonds, or any combination of modified nucleosides and internucleotide bonds. Examples of internucleotide bond modifications include phosphorothioates, phosphotriesters, and methylphosphonate derivatives (Stec, WJ et al., Chem. Int. Ed. Engl., 33: 709-722 (1994); Lebedev, AV et al., E., Perspect. Drug Discov. Des., 4: 17-40 (1996); and Zon et al., U.S. Patent Application No. 20070281308). Other examples of internucleotide bond modifications can be found in Waldner et al., Bioorg. Med. Chem. Letters 6: 2363-2366 (1996).

[0162] As used herein, the term "nucleoside" refers to a nitrogenous base linked to a 5-carbon sugar (e.g., ribose or deoxyribose). The term includes all nucleosides, including all forms of nucleoside bases and furanose. The base ring includes a purine ring and a pyrimidine ring. The purine ring includes, for example, adenine (also referred to herein as "A"), guanine (also referred to herein as "G"), and N6-methyladenine (also referred to herein as " m6 A”). The pyrimidine ring includes, for example, cytosine (also referred to herein as “C”), thymine (also referred to herein as “T”), 5-methylcytosine (also referred to herein as “ m5C") and pseudouracil (also referred to herein as "ψ"). Other nucleosides include, but are not limited to, ribose, 2'-O-methyl or 2'-deoxyribose derivatives of adenosine, guanosine, cytidine, thymidine, uridine, inosine, 7-methylguanosine or pseudouridine.

[0163] As used herein, the term "nucleoside analogs", "modified nucleosides" or "nucleoside derivatives" include synthetic nucleosides as described herein. Nucleoside derivatives also include nucleosides with modified bases and / or sugar moieties, with or without protecting groups, including, for example, 2'-deoxy-2'-fluorouridine, 5-fluorouridine, etc. The compounds and methods provided herein include such base rings and synthetic analogs thereof, as well as non-natural heterocyclic substituted base sugars and acyclic substituted base sugars. Other nucleoside derivatives that can be used with the present disclosure include, for example, LNA nucleosides, halogen substituted purines (e.g., 6-fluoropurine), halogen substituted pyrimidines, N 6 -ethyladenine, N 4 -(Alkyl)-cytosine, 5-ethylcytosine, etc. (U.S. Patent No. 6,762,298).

[0164] As used herein, the term "nucleoside triphosphate", "nucleoside 5' triphosphate" or "NTP" refers to a nucleoside linked to three phosphate groups. The term encompasses natural NTPs (e.g., adenosine triphosphate (ATP), uridine triphosphate (UTP), guanine triphosphate (GTP), and cytosine triphosphate (CTP)) as well as modified NTPs.

[0165] As used herein, "oligo dT purification" is an affinity chromatography method used to purify mRNA that contains or includes a poly-A tail.

[0166] As used herein, "phosphorothioate bond" refers to a bond between nucleosides wherein the phosphodiester bond is modified by replacing one of the oxygen atoms attached to the phosphorus atom with a sulfur atom.

[0167] "Primary RNA" or "primary RNA transcript" means an RNA molecule newly synthesized in vitro by RNA polymerase and having a triphosphate on the 5' carbon of its 5'-most nucleotide.

[0168] As used herein, the term "prematurely terminated RNA transcript" refers to an incomplete product of an in vitro transcription reaction. A prematurely terminated RNA sequence can be any length that is less than the expected length of the desired transcription product.

[0169] As used herein, the term "promoter" refers to a nucleotide sequence in a DNA template that directs and controls the initiation of transcription of a specific DNA sequence. A promoter is usually adjacent to (or partially overlaps) the DNA sequence to be transcribed. The promoter sequence is usually directly located upstream or 5' end of the transcription initiation site. The nucleotide position in the promoter is the (position + 1) specified relative to the transcription initiation site where DNA transcription begins.

[0170] As used herein, the term "purified" or "purification" refers to separating a substance from at least some of the components (e.g., impurities or contaminants) with which it was originally associated when it was produced. For example, RNA transcripts are purified by removing contaminating proteins or other undesirable nucleic acid species (e.g., double-stranded RNA, DNA, and / or incomplete or terminated RNA transcripts). Purified material (e.g., capped mRNA transcripts) can be separated from 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more of other components with which they were originally associated.

[0171] As used herein, the term "RNase inhibitor" or "ribonuclease inhibitor" refers to a protein that inhibits RNase activity, for example, during an in vitro transcription reaction.

[0172] As used herein, the term "RNA polymerase" refers to an enzyme that synthesizes RNA using a DNA template. For in vitro transcription methods, single-subunit phage RNA polymerases derived from T7, T3, SP6, K1-5, K1E, K1F or K11 phages or variants thereof are typically used. This polymerase family has a simple minimal promoter sequence of about 17 nucleotides, does not require auxiliary proteins, and has minimal restrictions on the starting nucleotide sequence.

[0173] As described herein, salts of one or more compounds (e.g., primers) can be used in the disclosed methods. As used herein, the term "salt" refers to a derivative of a compound described herein prepared by reacting an acidic or basic portion of a compound with an inorganic acid or inorganic base or an organic acid or organic base. Optionally, the salt can be a pharmaceutically acceptable salt. As used herein, the term "pharmaceutically acceptable salt" refers to those salts of a compound described herein or its derivatives and a zwitterionic form of a compound described herein (if possible), which is within the scope of reasonable medical judgment, suitable for contact with the tissue of the object without undue toxicity, irritation, allergic reaction, etc., has a reasonable benefit / risk ratio, and is effective for its intended use. These salts can be prepared in situ during the separation and purification of the compound, or prepared by reacting the purified compound in the form of a free base with an appropriate organic or inorganic acid alone and separating the salt formed thereby. Representative salts include hydrobromide, hydrochloride, sulfate, bisulfate, nitrate, acetate, oxalate, valerate, oleate, palmitate, stearate, laurate, borate, benzoate, lactate, phosphate, toluenesulfonate, citrate, maleate, fumarate, succinate, tartrate, naphthoate, methanesulfonate, glucoheptonate, lactobionate, methanesulfonate and laurylsulfonate, etc. Salts include alkali metal or alkaline earth metal based cations, such as sodium, lithium, potassium, calcium, magnesium, etc.; as well as non-toxic ammonium, quaternary ammonium cations and amine cations, including but not limited to ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, etc. (See SM Barge et al., J. Pharm. Sci. (1977) 66, 1; and Remington: The Science and Practice of Pharmacy, 23rd ed., Adejare et al., eds., Academic Press (2020); the references are incorporated herein by reference in their entireties).

[0174] As used herein, "self-amplifying RNA" or "saRNA" is a linear single-stranded RNA molecule that encodes a gene of interest. SaRNA is a type of mRNA, but also includes non-structural proteins that encode viral replicases. Viral replicases enable RNA to replicate itself after delivery into cells.

[0175] As used herein, the term "specificity" when used to refer to the initial trinucleotide primer sequence and its ability to hybridize to a DNA template refers to a sequence that has at least 50% sequence identity with a portion of the DNA template when the initial trinucleotide primer and the DNA strand are aligned. Higher levels of sequence identity include at least 66%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 99% and optionally 100% sequence identity.

[0176] As used herein, the term "substantially free" refers to a state in which a relatively small amount or no undesirable substance (e.g., prematurely terminated RNA sequences, DNA and / or double-stranded RNA) is present in a sample. "Substantially free of impurities" means that the content of impurities in the sample is less than about 5%, 4%, 3%, 2%, 1.0%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1% or less (w / w). For example, "substantially free of double-stranded RNA" means that the content of double-stranded RNA in the sample is less than about 5%, 4%, 3%, 2%, 1.0%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1% or less (w / w).

[0177] As used herein, "tangential flow filtration (TFF)" is a type of filtration in which the material to be filtered passes tangentially through the filter, rather than through the filter. In TFF, the undesirable permeate passes through the filter, while the desired retentate passes along the filter and is collected downstream. In TFF, the desired material is generally contained in the retentate, which is contrary to the situation encountered when performing traditional membrane filtration or dead-end filtration.

[0178] As used herein, the term "transcription" refers to enzymatic preparation or synthesis of RNA complementary to a DNA template, thereby producing a large number of RNA copies of a DNA sequence. The RNA molecule synthesized in the transcription reaction is an "RNA transcript," "primary transcript," or "transcript." Transcription reactions involving the compositions and methods provided herein use the initial capping oligonucleotide primers described herein. The transcription of the DNA template can be exponential, nonlinear, or linear. The DNA template can be double-stranded linear DNA, partially double-stranded linear DNA, circular double-stranded DNA, DNA plasmid, PCR amplification product, or a modified nucleic acid template compatible with RNA polymerase.

[0179] As used herein, the terms "universal base," "degenerate base," "universal base analog," and "degenerate base analog" include, for example, nucleoside analogs having artificial bases that, in certain embodiments, can be recognized by RNA polymerase as a substitute for one of the natural NTPs (e.g., ATP, UTP, CTP, and GTP) or other specific NTPs. Universal bases or degenerate bases are disclosed in the following: Loakes, D., Nucleic Acids Res., 29:2437-2447 (2001); Crey-Desbiolles, C. et al., Nucleic Acids Res., 33:1532-1543 (2005); Kincaid, K. et al., Nucleic Acids Res., 33:2620-2628 (2005); Preparata, FP, Oliver, JS, J. Comput. Biol. 753-765 (2004); and Hill, F. et al., Proc Natl Acad. Sci. USA, 95:4258-4263 (1998).

[0180] As used herein, the term "unsubstituted" or "unmodified" in the context of starting capping oligonucleotide primers and NTPs refers to starting capping oligonucleotide primers and NTPs that have not been modified.

[0181] References in the specification and in the concluding claims to parts by weight of a particular element or component in a composition denote the weight relationship between that element or component and any other elements or components in the composition or article, for which parts by weight are expressed. Thus, in a compound containing 2 parts by weight of component X and 5 parts by weight of component Y, X and Y are present in a weight ratio of 2:5, and are present in such a ratio regardless of whether other components are present in the compound.

[0182] Unless specifically stated to the contrary, the weight percent (wt. %) of a component is based on the total weight of the formulation or composition including the component.

[0183] As used herein, the terms "optional" or "optionally" mean that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances where it does not.

[0184] As used herein, the term "subject" can be a vertebrate, such as a mammal, fish, bird, reptile or amphibian. Therefore, the subject of the methods disclosed herein can be a human, non-human primate, horse, pig, rabbit, dog, sheep, goat, cow, cat, guinea pig or rodent. The term does not indicate a specific age or gender. Therefore, it is intended to cover adult subjects and newborn subjects and fetuses, whether male or female. On the one hand, the subject is a mammal. Patient refers to a subject suffering from a disease or condition. The term "patient" includes human subjects and livestock subjects.

[0185] As used herein, the term "treatment" refers to the medical management of a patient, with the aim of curing, improving, stabilizing or preventing a disease, pathological condition or disorder. This term includes symptomatic treatment, i.e. treatment specifically for the improvement of a disease, pathological condition or disorder, and also includes etiological treatment, i.e. treatment for the removal of the cause of the disease, pathological condition or disorder. In addition, this term includes palliative treatment, i.e. treatment designed to relieve symptoms rather than cure a disease, pathological condition or disorder; preventive treatment, i.e. treatment intended to minimize or partially or completely inhibit the development of a disease, pathological condition or disorder; and supportive treatment, i.e. treatment for another specific therapy that supplements the improvement of a disease, pathological condition or disorder. In various aspects, the term encompasses any treatment of an object including a mammal (e.g., a human), and includes: (i) preventing the disease from occurring in an object that may be prone to the disease but has not yet been diagnosed as having the disease; (ii) inhibiting the disease, i.e., preventing its development; or (iii) alleviating the disease, i.e., causing the disease to regress. In one aspect, the subject is a mammal, such as a primate, and in another aspect, the subject is a human. The term "subject" also includes domestic animals (e.g., cats, dogs, etc.), livestock (e.g., cattle, horses, pigs, sheep, goats, etc.) and laboratory animals (e.g., mice, rabbits, rats, guinea pigs, fruit flies, etc.).

[0186] As used herein, the term "prevent" or "preventing" means to hinder, prevent, avoid, preempt, stop or hinder something from happening, especially by preemptive action. It should be understood that where reduce, inhibit or prevent are used herein, unless otherwise expressly indicated, the use of the other two words is also expressly disclosed.

[0187] As used herein, the term "diagnosed" means having undergone physical examination by a skilled artisan, such as a physician, and found to have a condition that can be diagnosed or treated by a compound, composition, or method disclosed herein.

[0188] As used herein, the terms "administering" and "administration" refer to any method of providing a pharmaceutical formulation to a subject. Such methods are well known to those skilled in the art and include, but are not limited to, oral administration, transdermal administration, administration by inhalation, nasal administration, topical administration, intravaginal administration, ocular administration, intraaural administration, intracerebral administration, rectal administration, sublingual administration, oral administration, and parenteral administration, including injectable, such as intravenous administration, intraarterial administration, intramuscular administration, and subcutaneous administration. Administration may be continuous or intermittent. In various aspects, the formulation may be administered therapeutically; that is, the formulation is administered to treat an existing disease or condition. In various other aspects, the formulation may be administered prophylactically; that is, the formulation is administered to prevent a disease or condition.

[0189] As used herein, the term "effective amount" and "amount effective" refer to an amount sufficient to achieve a desired result or to act on an undesirable condition. For example, a "therapeutically effective amount" refers to an amount sufficient to achieve a desired therapeutic result or to act on an undesirable symptom but generally insufficient to cause adverse side effects. The specific therapeutically effective dosage level for any particular patient will depend on a variety of factors, including the severity of the condition and the condition being treated; the specific composition used; the patient's age, weight, general health, sex and diet; the time of administration, the route of administration, the excretion rate of the specific compound used; the duration of treatment; the drugs used in combination or simultaneously with the specific compound used, and similar factors well known in the medical field. For example, it is entirely within the technical scope of the art to start administration of the compound at a dosage level lower than those required to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved. If desired, the effective daily dose can be divided into multiple doses for the purpose of administration. Therefore, a single-dose composition may contain such an amount or its submultiple to constitute a daily dose. In the case of any contraindications, the dosage may be adjusted by an individual physician. The dosage may vary and may be administered in one or more doses per day for one or several days. Guidance on appropriate dosages for a given class of pharmaceutical products can be found in the literature.In further various aspects, the formulations may be administered in a "prophylactically effective amount"; that is, an amount effective to prevent a disease or condition.

[0190] As used herein, "dosage form" means a pharmacologically active material in a medium, carrier, vehicle or device suitable for administration to a subject. The dosage form may comprise a compound disclosed herein, a product of a disclosed preparation method, or a salt, solvate or polymorph thereof in combination with a pharmaceutically acceptable excipient, such as a preservative, a buffer, physiological saline or phosphate buffered saline. The dosage form may be prepared using conventional pharmaceutical manufacturing and compounding techniques. The dosage form can include inorganic or organic buffers (e.g., sodium or potassium salts of phosphate, carbonate, acetate or citrate) and pH adjusters (e.g., hydrochloric acid, sodium or potassium hydroxide, citrate or acetate, amino acids and their salts), antioxidants (e.g., ascorbic acid, α-tocopherol), surfactants (e.g., polysorbate 20, polysorbate 80, polyoxyethylene 9-10 nonylphenol, sodium deoxycholate), solution and / or freezing / lyophilization stabilizers (e.g., sucrose, lactose, mannitol, trehalose), osmotic regulators (e.g., salts or sugars), antimicrobial agents (e.g., benzoic acid, phenol, gentamicin), antifoaming agents (e.g., polydimethylsiloxane), preservatives (e.g., thimerosal, 2-phenoxyethanol, EDTA), polymeric stabilizers and viscosity modifiers (e.g., polyvinyl pyrrolidone, poloxamer 488, carboxymethyl cellulose) and cosolvents (e.g., glycerol, polyethylene glycol, ethanol). Dosage forms formulated for injectable use may be prepared by suspending the disclosed compound, the product of the disclosed preparation process, or a salt, solvate or polymorph thereof in sterile saline solution for injection together with a preservative.

[0191] As used herein, terms such as "elevate", "increase", "decrease" and "lower" are generally considered to be relative to a control or normal state. However, when terms such as "decrease" or "lower" are used herein relative to a treatment, they are normalized to a control or normal state, and may include partial or complete normalization.

[0192] As used herein, "test kit" means a collection of at least two components that constitute a test kit. These components together constitute a functional unit for a given purpose. Individual member components can be physically packaged together or separately. For example, a test kit containing instructions for using the test kit may or may not physically include instructions with other individual member components. Instead, instructions may be supplied as individual member components in paper form or in electronic form that can be supplied on a computer-readable memory device or downloaded from an Internet website, or as a recorded presentation.

[0193] As used herein, "instructions" means a document describing the relevant materials or methods associated with a test kit. These materials may include any combination of background information, a list of components and their availability information (purchase information, etc.), a brief or detailed scheme for using the test kit, troubleshooting, references, technical support, and any other related files. Instructions may be supplied with the test kit or as a separate member component in paper form or in electronic form that may be supplied on a computer-readable memory device or downloaded from an internet website, or as a recorded presentation. Instructions may include one or more documents and are intended to include future updates.

[0194] As used herein, the term "therapeutic agent" includes any synthetic or naturally occurring biologically active compound or composition of matter that, when administered to an organism (human or non-human animal), induces a desired pharmacological, immunogenic and / or physiological effect by local and / or systemic action. The term therefore encompasses those compounds or chemicals that are traditionally considered to include drugs, vaccines and biopharmaceuticals such as proteins, peptides, hormones, nucleic acids, gene constructs and other molecules. Examples of therapeutic agents are described in well-known references such as the Merck Index (14th edition), the Physicians' Desk Reference (64th edition), and the Pharmacological Basis of Therapeutics (12th edition), and they include, but are not limited to, drugs; vitamins; mineral supplements; substances used to treat, prevent, diagnose, cure or alleviate diseases or disorders; substances that affect body structure or function, or prodrugs that become biologically active or more active after being placed in a physiological environment. For example, the term "therapeutic agent" includes compounds or compositions used in all major therapeutic areas, including but not limited to adjuvants; anti-infectives such as antibiotics and antivirals; analgesics and analgesic combinations, anorectics, anti-inflammatory drugs, anti-epileptic drugs, local and general anesthetics, hypnotics, sedatives, antipsychotics, neuroleptics, antidepressants, anxiolytics, antagonists, neuroleptics, antidepressants, anti-anxiety drugs, antagonists, neuroleptics, anticholinergics and cholinergic mimetics, antimuscarinics and muscarinics, antiadreners, antiarrhythmics, antihypertensives, hormones and nutrients, antiarthritics, antiasthmatics, anticonvulsants, antihistamines, antinausea agents, antineoplastics, antipruritics, antipyretics; antispasmodics, cardiovascular agents (including calcium channel blockers, beta-blockers, , β-agonists and antiarrhythmics), antihypertensives, diuretics, vasodilators; central nervous system stimulants; cough and cold preparations; decongestants; diagnostic agents; hormones; bone growth stimulants and bone resorption inhibitors; immunosuppressants; muscle relaxants; psychostimulants; sedatives; tranquilizers; proteins, peptides and fragments thereof (whether naturally occurring, chemically synthesized or recombinantly produced); and nucleic acid molecules (polymer forms of two or more nucleotides (ribonucleotides (RNA) or deoxyribonucleotides (DNA)), including double-stranded and single-stranded molecules, gene constructs, expression vectors, antisense molecules, etc.), small molecules (e.g., doxorubicin) and other biologically active macromolecules, such as proteins and enzymes. The pharmaceutical agent can be a biologically active agent used in medical (including veterinary) applications and agriculture (such as plants) and other fields.The term "therapeutic agent" also includes, but is not limited to, drugs; vitamins; mineral supplements; substances used to treat, prevent, diagnose, cure, or ameliorate disease or disorder; or substances that affect the structure or function of the body; or prodrugs, which become biologically active or more active after being placed in a predetermined physiological environment.

[0195] The term "pharmaceutically acceptable" describes a material that is not biologically or otherwise undesirable, ie, does not cause unacceptable levels of undesired biological effects or interact in a deleterious manner.

[0196] As used herein, the term "derivative" refers to a compound whose structure is derived from the structure of a parent compound (e.g., a compound disclosed herein), and whose structure is sufficiently similar to that disclosed herein, and based on this similarity, a person skilled in the art would expect the compound to exhibit the same or similar activity and utility as the claimed compound, or to induce the same or similar activity and utility as a precursor to the claimed compound. Exemplary derivatives include salts, esters, amides, salts of esters or amides, and N-oxides of the parent compound.

[0197] As used herein, the term "pharmaceutically acceptable carrier" refers to a sterile aqueous or non-aqueous solution, dispersion, suspension or emulsion, and a sterile powder for reconstitution into a sterile injectable solution or dispersion before use. Examples of suitable aqueous and non-aqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, etc.), carboxymethyl cellulose and suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters, such as ethyl oleate. Appropriate fluidity can be maintained by, for example, using a coating material (such as lecithin), by maintaining the required particle size in the case of a dispersion and by using a surfactant. These compositions can also contain adjuvants, such as preservatives, wetting agents, emulsifiers and dispersants. Various antibacterial and antifungal agents can be included, such as parabens, chlorobutanol, phenol, sorbic acid, etc. to ensure the prevention of microbial effects. It can also be desirable to include isotonic agents, such as sugar, sodium chloride, etc. Prolonged absorption of injectable drug forms can be achieved by including agents that delay absorption (such as aluminum monostearate and gelatin). Injectable reservoir-type (depot) forms are prepared by forming a microcapsule matrix of the drug in a biodegradable polymer, such as lactic acid-co-glycolic acid copolymer, poly (orthoester) and poly (anhydride). According to the ratio of the drug to the polymer and the properties of the specific polymer used, the rate of drug release can be controlled. Depot-type injectable formulations are also prepared by trapping the drug in liposomes or microemulsions compatible with body tissues. Injectable formulations can be sterilized, for example, by filtering through a bacterial retention filter, or by incorporating a sterilizing agent in the form of a sterile solid composition, which can be dissolved or dispersed in sterile water or other sterile injectable media before being used. Suitable inert carriers can include sugars, such as lactose. Desirably, the effective particle size of at least 95% by weight of the active ingredient particles is in the range of 0.01 to 10 microns.

[0198] As used herein, the term "substituted" is intended to include all permissible substituents of organic compounds. In a broad sense, permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic and aromatic and non-aromatic substituents of organic compounds. Illustrative substituents include, for example, substituents described below. For appropriate organic compounds, permissible substituents may be one or more and may be the same or different. For the purposes of this disclosure, heteroatoms such as nitrogen may have hydrogen substituents and / or any permissible substituents of organic compounds described herein, which will satisfy the valence of heteroatoms. This disclosure is not intended to be limited in any way to permissible substituents of organic compounds. Moreover, the term "substituted" or "substituted by..." includes implicit conditions: such substitution is consistent with the permissible valence of the substituted atom and substituent, and the substitution produces a stable compound, such as a compound that does not spontaneously undergo transformation (e.g., by rearrangement, cyclization, elimination, etc.). It is also contemplated that, in certain aspects, unless explicitly stated to the contrary, individual substituents may be further optionally substituted (ie, further substituted or unsubstituted).

[0199] In defining various terms, “A 1 ”, “A 2 ”, “A 3 ” and “A 4 " are used as general symbols herein to represent various specific substituents. These symbols can be any substituents, not limited to the substituents disclosed herein, and when these symbols are defined as certain substituents in one case, they can be defined as some other substituents in another case.

[0200] As used herein, the term "aliphatic" or "aliphatic group" means a hydrocarbon portion that can be straight chain (i.e., unbranched), branched or cyclic (including fused, bridged and spiro-fused polycyclic) and can be fully saturated or can contain one or more unsaturated units but is not aromatic. Unless otherwise indicated, aliphatic groups contain 1-20 carbon atoms. Aliphatic groups include, but are not limited to, straight or branched alkyl, alkenyl and alkynyl groups and hybrids thereof, such as (cycloalkyl) alkyl, (cycloalkenyl) alkyl or (cycloalkyl) alkenyl.

[0201] As used herein, the term "alkyl" is a branched or unbranched saturated hydrocarbon group having 1 to 24 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, sec-pentyl, neopentyl, hexyl, heptyl, octyl, nonyl, decyl, dodecyl, tetradecyl, hexadecyl, eicosyl, tetracosyl, etc. The alkyl group can be cyclic or acyclic. The alkyl group can be branched or unbranched. The alkyl group can also be substituted or unsubstituted. For example, the alkyl group can be substituted by one or more groups, including but not limited to alkyl, cycloalkyl, alkoxy, amino, ether, halide, hydroxyl, nitro, silyl, sulfo-oxo, thio or mercaptan, as described herein. "Low alkyl" is an alkyl group containing one to six (e.g., one to four) carbon atoms. The term alkyl may also be C1 alkyl, C1-C2 alkyl, C1-C3 alkyl, C1-C4 alkyl, C1-C5 alkyl, C1-C6 alkyl, C1-C7 alkyl, C1-C8 alkyl, C1-C9 alkyl, C1-C10 alkyl and the like up to and including C1-C24 alkyl.

[0202] Throughout this specification, "alkyl" is generally used to refer to both unsubstituted alkyl and substituted alkyl; however, substituted alkyl is also specifically mentioned herein by identifying one or more specific substituents on the alkyl. For example, the term "halogenated alkyl" or "haloalkyl" specifically refers to an alkyl substituted by one or more halides, such as fluorine, chlorine, bromine or iodine. Alternatively, the term "monohaloalkyl" specifically refers to an alkyl substituted by a single halide, such as fluorine, chlorine, bromine or iodine. The term "polyhaloalkyl" specifically refers to an alkyl independently substituted by two or more halides, that is, each halide substituent need not be the same as another halide substituent, and multiple instances of halide substituents do not need to be on the same carbon. The term "alkoxyalkyl" specifically refers to an alkyl substituted by one or more alkoxy groups, as described below. The term "aminoalkyl" specifically refers to an alkyl substituted by one or more amino groups. The term "hydroxyalkyl" specifically refers to an alkyl substituted by one or more hydroxy groups. When "alkyl" is used in one instance and a specific term such as "hydroxyalkyl" is used in another instance, this is not meant to imply that the term "alkyl" also does not refer to the specific term such as "hydroxyalkyl" and the like.

[0203] This practice also applies to other groups described herein. That is, although terms such as "cycloalkyl" refer to both unsubstituted and substituted cycloalkyl moieties, the substituted moieties may be otherwise specifically identified herein; for example, a specifically substituted cycloalkyl may be referred to as, for example, "alkylcycloalkyl". Similarly, a substituted alkoxy may be specifically referred to as, for example, "halogenated alkoxy", and a specifically substituted alkenyl may be, for example, "alkenyl alcohol", etc. Again, the practice of using general terms such as "cycloalkyl" and specific terms such as "alkylcycloalkyl" is not meant to imply that the general term also does not include the specific term.

[0204] As used herein, the term "cycloalkyl" is a non-aromatic carbon-based ring consisting of at least three carbon atoms. Examples of cycloalkyl include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, norbornyl, etc. The term "heterocycloalkyl" is a type of cycloalkyl as defined above, and is included in the meaning of the term "cycloalkyl", wherein at least one carbon atom in the carbon atoms of the ring is replaced by a heteroatom, such as but not limited to nitrogen, oxygen, sulfur or phosphorus. Cycloalkyl and heterocycloalkyl can be substituted or unsubstituted. Cycloalkyl and heterocycloalkyl can be substituted by one or more groups, including but not limited to alkyl, cycloalkyl, alkoxy, amino, ether, halide, hydroxyl, nitro, silyl, sulfo-oxo, thio or thiol as described herein.

[0205] As used herein, the terms "alkoxy" and "alkoxyl" refer to an alkyl or cycloalkyl group bonded through an ether bond; that is, an "alkoxy" group can be defined as -OA 1 , where A 1 is an alkyl or cycloalkyl group as defined above. "Alkoxy" also includes polymers of the alkoxy groups just described; that is, the alkoxy group may be a polyether, such as -OA 1 —OA 2 or—OA 1 —(OA 2 ) a —OA 3 , wherein "a" is an integer from 1 to 200, and A 1 , A 2 and A 3 is an alkyl group and / or a cycloalkyl group.

[0206] As used herein, the term "alkenyl" is a hydrocarbon group having 2 to 24 carbon atoms and a structural formula containing at least one carbon-carbon double bond. 1 A 2 )C=C(A 3 A 4) are intended to include both E and Z isomers. This may be assumed in the structural formula herein where an asymmetric olefin is present, or it may be explicitly indicated by the bond symbol C=C. The alkenyl group may be substituted with one or more groups including, but not limited to, alkyl, cycloalkyl, alkoxy, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, heteroaryl, aldehyde, amino, carboxylic acid, ester, ether, halide, hydroxyl, ketone, azide, nitro, silyl, sulfo-oxo, thioxo, or thiol as described herein.

[0207] As used herein, the term "cycloalkenyl" is a non-aromatic carbon-based ring consisting of at least three carbon atoms and containing at least one carbon-carbon double bond, i.e., C=C. Examples of cycloalkenyl groups include, but are not limited to, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclopentadienyl, cyclohexenyl, cyclohexadienyl, norbornenyl, and the like. The term "heterocycloalkenyl" is a type of cycloalkenyl as defined above and is included within the meaning of the term "cycloalkenyl" in which at least one of the carbon atoms of the ring is replaced by a heteroatom, such as, but not limited to, nitrogen, oxygen, sulfur, or phosphorus. Cycloalkenyl and heterocycloalkenyl groups may be substituted or unsubstituted. The cycloalkenyl and heterocycloalkenyl groups may be substituted with one or more groups including, but not limited to, alkyl, cycloalkyl, alkoxy, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, heteroaryl, aldehyde, amino, carboxylic acid, ester, ether, halide, hydroxy, ketone, azide, nitro, silyl, sulfo-oxo, thio, or thiol as described herein.

[0208] As used herein, the term "alkynyl" is a hydrocarbon group having 2 to 24 carbon atoms, the structural formula of which contains at least one carbon-carbon triple bond. Alkynyl groups may be unsubstituted or substituted with one or more groups, including but not limited to alkyl, cycloalkyl, alkoxy, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, heteroaryl, aldehyde, amino, carboxylic acid, ester, ether, halide, hydroxyl, ketone, azide, nitro, silyl, sulfo-oxo, thio or thiol as described herein.

[0209] The term "cycloalkynyl" as used herein is a non-aromatic carbonyl ring consisting of at least seven carbon atoms and containing at least one carbon-carbon triple bond. Examples of cycloalkynyl include, but are not limited to, cycloheptynyl, cyclooctynyl, cyclononynyl, etc. The term "heterocycloalkynyl" is a type of cycloalkynyl as defined above, and is included in the meaning of the term "cycloalkynyl", wherein at least one carbon atom in the carbon atoms of the ring is replaced by a heteroatom, such as but not limited to nitrogen, oxygen, sulfur or phosphorus. Cycloalkynyl and heterocycloalkynyl can be substituted or unsubstituted. Cycloalkynyl and heterocycloalkynyl can be substituted by one or more groups, including, but not limited to, alkyl, cycloalkyl, alkoxy, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, heteroaryl, aldehyde, amino, carboxylic acid, ester, ether, halide, hydroxyl, ketone, azide, nitro, silyl, sulfo-oxo, thio or thiol as described herein.

[0210] As used herein, the term "aryl" is a group containing any carbon-based aromatic group, including but not limited to benzene, naphthalene, phenyl, biphenyl, anthracene, etc. Aryl can be substituted or unsubstituted. Aryl can be substituted by one or more groups, including but not limited to alkyl, cycloalkyl, alkoxy, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, heteroaryl, aldehyde, -NH2, carboxylic acid, ester, ether, halide, hydroxyl, ketone, azide, nitro, silyl, sulfo-oxo, thio or thiol as described herein. The term "biaryl" is a specific type of aryl and is included in the definition of "aryl". In addition, aryl can be a monocyclic structure or contain a polycyclic structure, which can be a condensed ring structure or connected by one or more bridging groups, such as carbon-carbon bonds. For example, biaryl can be two aryls connected by condensed ring structures as in naphthalene or by one or more carbon-carbon bonds as in biphenyl.

[0211] The term "aldehyde" as used herein is represented by the formula -C(O)H. Throughout this specification, "C(O)" is a shorthand notation for a carbonyl group (ie, C=O).

[0212] As used herein, the term "amine" or "amino group" is represented by the formula -NA 1 A 2 Indicates that A 1 and A 2 can independently be hydrogen or alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl or heteroaryl as described herein. A specific example of amino is -NH2.

[0213] The term "alkylamino" as used herein is represented by the formula -NH(-alkyl), wherein alkyl is as described herein. Representative examples include, but are not limited to, methylamino, ethylamino, propylamino, isopropylamino, butylamino, isobutylamino, (sec-butyl)amino, (tert-butyl)amino, pentylamino, isopentylamino, (tert-pentyl)amino, hexylamino, and the like.

[0214] The term "dialkylamino" as used herein is represented by the formula -N(-alkyl)2, wherein alkyl is as described herein. Representative examples include, but are not limited to, dimethylamino, diethylamino, dipropylamino, diisopropylamino, dibutylamino, diisobutylamino, di(sec-butyl)amino, di(tert-butyl)amino, dipentylamino, diisopentylamino, di(tert-pentyl)amino, dihexylamino, N-ethyl-N-methylamino, N-methyl-N-propylamino, N-ethyl-N-propylamino, and the like.

[0215] The term "carboxylic acid" as used herein is represented by the formula -C(O)OH.

[0216] As used herein, the term "ester" is a ester of the formula -OC(O)A 1 or -C(O)OA 1 Indicates that A 1 It can be an alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl or heteroaryl as described herein. The term "polyester" as used herein is represented by the formula -(A 1 O(O)CA 2 -C(O)O) a -or-(A 1 O(O)CA 2 -OC(O)) a - indicates that A 1 and A 2 can independently be alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl or heteroaryl as described herein, and "a" is an integer from 1 to 500. "Polyester" is a term used to describe a group produced by the reaction between a compound having at least two carboxylic acid groups and a compound having at least two hydroxyl groups.

[0217] As used herein, the term "ether" is a 1 OA 2 Indicates that A 1 and A 2 can be independently alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl or heteroaryl as described herein. As used herein, the term "polyether" is a group of formula -(A 1 OA 2 O) a - indicates that A1 and A 2 may independently be alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl or heteroaryl as described herein, and "a" is an integer from 1 to 500. Examples of polyethers include polyethylene oxide, polypropylene oxide and polybutylene oxide.

[0218] As used herein, the terms "halo," "halogen," or "halide" are used interchangeably and refer to F, Cl, Br, or I.

[0219] As used herein, the term "heteroalkyl" refers to an alkyl group containing at least one heteroatom. Suitable heteroatoms include, but are not limited to, O, N, Si, P, and S, wherein nitrogen atoms, phosphorus atoms, and sulfur atoms are optionally oxidized, and nitrogen heteroatoms are optionally quaternized. Heteroalkyl groups may be substituted as defined above for alkyl groups.

[0220] As used herein, the term "heteroaryl" refers to an aromatic group having at least one heteroatom incorporated into the ring of an aromatic group. Examples of heteroatoms include, but are not limited to, nitrogen, oxygen, sulfur, and phosphorus, wherein N-oxides, sulfur oxides, and dioxides are permissible heteroatom substitutions. Heteroaryl can be substituted or unsubstituted. Heteroaryl can be substituted by one or more groups, including but not limited to alkyl, cycloalkyl, alkoxy, amino, ether, halide, hydroxyl, nitro, silyl, sulfo-oxo, thio or thiol as described herein. Heteroaryl can be a monocyclic or alternatively fused ring system. Heteroaryl groups include, but are not limited to, furanyl, imidazolyl, pyrimidinyl, tetrazolyl, thienyl, pyridinyl, pyrrolyl, N-methylpyrrolyl, quinolyl, isoquinolyl, pyrazolyl, triazolyl, thiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, isothiazolyl, pyridazinyl, pyrazinyl, benzofuranyl, benzodioxolyl, benzothienyl, indolyl, indazolyl, benzimidazolyl, imidazopyridinyl, pyrazolopyridinyl, and pyrazolopyrimidinyl. Additional non-limiting examples of heteroaryl groups include, but are not limited to, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, phenylthio, pyrazolyl, imidazolyl, benzo[d]oxazolyl, benzo[d]thiazolyl, quinolinyl, quinazolinyl, indazolyl, imidazo[1,2-b]pyridazinyl, imidazo[1,2-a]pyrazinyl, benzo[c][1,2,5]thiadiazolyl, benzo[c][1,2,5]oxadiazolyl, and pyrido[2,3-b]pyrazinyl.

[0221] As used herein, the terms "heterocycle" or "heterocyclyl" may be used interchangeably and refer to monocyclic and polycyclic aromatic or non-aromatic ring systems in which at least one of the ring members is not carbon. Thus, the term includes, but is not limited to, "heterocycloalkyl", "heteroaryl", "bicyclic heterocycle", and "polycyclic heterocycle". Heterocycles include pyridine, pyrimidine, furan, thiophene, pyrrole, isoxazole, isothiazole, pyrazole, oxazole, thiazole, imidazole, oxazole (including 1,2,3-oxadiazole, 1,2,5-oxadiazole and 1,3,4-oxadiazole), thiadiazole (including 1,2,3-thiadiazole, 1,2,5-thiadiazole and 1,3,4-thiadiazole), triazole (including 1,2,3-triazole, 1,3,4-triazole), tetrazole (including 1,2,3,4-tetrazole and 1,2,4,5-tetrazole), pyridazine, pyrazine, triazine (including 1,2,4-triazine and 1,3,5-triazine), tetrazine (including 1,2,4,5-tetrazine), pyrrolidine, piperidine, piperazine, morpholine, azetidine, tetrahydropyran, tetrahydrofuran, dioxane and the like. The term heterocyclyl can also be C2 heterocyclyl, C2-C3 heterocyclyl, C2-C4 heterocyclyl, C2-C5 heterocyclyl, C2-C6 heterocyclyl, C2-C7 heterocyclyl, C2-C8 heterocyclyl, C2-C9 heterocyclyl, C2-C10 heterocyclyl, C2-C11 heterocyclyl, etc. up to and including C2-C18 heterocyclyl. For example, C2 heterocyclyl includes groups with two carbon atoms and at least one heteroatom, including but not limited to aziridinyl, diazetidinyl, dihydrodiazetyl, oxirane, thiiranyl, etc. Alternatively, for example, C5 heterocyclyl includes groups with five carbon atoms and at least one heteroatom, including but not limited to piperidinyl, tetrahydropyranyl, tetrahydrothiopyranyl, diazepanyl, pyridinyl, etc. It is to be understood that the heterocyclyl group may be bonded via a heteroatom in the ring (where chemically possible) or via one of the carbon atoms comprising the heterocyclyl ring.

[0222] As used herein, the term "bicyclic heterocycle" or "bicyclic heterocyclyl" refers to a ring system in which at least one of the ring members is not carbon. Bicyclic heterocyclyl encompasses ring systems in which one aromatic ring is fused to another aromatic ring, or one aromatic ring is fused to a non-aromatic ring. Bicyclic heterocyclyl encompasses ring systems in which a benzene ring is fused to a 5- or 6-membered ring containing 1, 2, or 3 ring heteroatoms or in which a pyridine ring is fused to a 5- or 6-membered ring containing 1, 2, or 3 ring heteroatoms. Bicyclic heterocyclyl groups include, but are not limited to, indolyl, indazolyl, pyrazolo[1,5-a]pyridinyl, benzofuranyl, quinolinyl, quinoxalinyl, 1,3-benzodioxolyl, 2,3-dihydro-1,4-benzodioxinyl, 3,4-dihydro-2H-chromenyl, 1H-pyrazolo[4,3-c]pyridin-3-yl; 1H-pyrrolo[3,2-b]pyridin-3-yl; and 1H-pyrazolo[3,2-b]pyridin-3-yl.

[0223] As used herein, term "heterocycloalkyl" refers to aliphatic, partially unsaturated or fully saturated 3-14 ring systems, including monocycles and bicyclic and tricyclic systems of 3 to 8 atoms.Heterocycloalkyl ring system includes one to four heteroatoms independently selected from oxygen, nitrogen and sulfur, wherein nitrogen and sulfur heteroatoms can be optionally oxidized and nitrogen heteroatoms can be optionally substituted.Representative heterocycloalkyl includes but is not limited to pyrrolidinyl, pyrazolyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, piperidinyl, piperazinyl, oxazolidinyl, isoxazolidinyl, morpholinyl, thiazolidinyl, isothiazolidinyl and tetrahydrofuranyl.

[0224] As used herein, the term "hydroxy" or "hydroxyl group" is represented by the formula -OH.

[0225] As used herein, the term "ketone" is a 1 C(O)A 2 Indicates that A 1 and A 2 and alkyl, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, or heteroaryl as described herein.

[0226] As used herein, the term "azide" or "azido" is represented by the formula -N3.

[0227] As used herein, the term "nitro" is represented by the formula -NO2.

[0228]

[0046] The term "nitrile" or "cyano" as used herein is represented by the formula -CN.

[0229] As used herein, the term "silyl group" is a group consisting of the formula -SiA 1 A 2 A 3Indicates that A 1 , A 2 and A 3 and X is 1, 2 or 3. ...

[0230] As used herein, the term "sulfo-oxo" is a group consisting of the formula -S(O)A 1 、-S(O)2A 1 、-OS(O)2A 1 or -OS(O)2OA 1 Indicates that A 1 It can be hydrogen or an alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl or heteroaryl as described herein. Throughout this specification, "S(O)" is a shorthand notation for S=O. The term "sulfonyl" is used herein to refer to a sulfonyl radical of the formula -S(O)2A 1 A sulfo-oxy group represented by 1 It can be hydrogen or an alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl or heteroaryl group as described herein. As used herein, the term "sulfone" is a radical of formula A 1 S(O)2A 2 Indicates that A 1 and A 2 may be independently alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl or heteroaryl as described herein. As used herein, the term "sulfoxide" is a sulfoxide of formula A 1 S(O)A 2 Indicates that A 1 and A 2 and alkyl, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, or heteroaryl as described herein.

[0231] As used herein, the term "thio" is a compound of the formula -SA 1 Indicates that A 1 It may be alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl or heteroaryl as described herein.

[0232] The term "thiol" as used herein is represented by the formula -SH.

[0233] As used herein, “R 1 ”, “R 2 ”, “R 3 ”, “R n " ”(where n is an integer) may independently have one or more of the groups listed above. For example, if R 1If it is a straight chain alkyl, one of the hydrogen atoms of the alkyl can be optionally substituted by hydroxyl, alkoxy, alkyl, halide, etc. Depending on the selected group, the first group can be incorporated into the second group, or alternatively, the first group can be a side group of the second group (i.e., connected to the second group). For example, for the phrase "an alkyl group including an amino group", the amino group can be incorporated into the main chain of the alkyl. Alternatively, the amino group can be connected to the main chain of the alkyl. The nature of the selected group will determine whether the first group is embedded in the second group or connected to the second group.

[0234] As described herein, the compounds of the present disclosure may contain an "optionally substituted" part. Typically, the term "substituted", whether or not preceded by the term "optionally", means that one or more hydrogens of the specified part are replaced by suitable substituents. Unless otherwise indicated, an "optionally substituted" group may have a suitable substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted by more than one substituent selected from a specified group, at each position, the substituent may be the same or different. The combination of substituents contemplated by the present disclosure is preferably a combination of substituents that result in the formation of a stable or chemically feasible compound. It is also contemplated that, in some aspects, unless explicitly indicated to the contrary, individual substituents may be further optionally substituted (i.e., further substituted or unsubstituted).

[0235] As used herein, the term "stable" refers to compounds that do not substantially change when subjected to conditions that allow them to be produced, detected, and in some aspect recovered, purified, and used for one or more of the purposes disclosed herein.

[0236] The term "leaving group" refers to an atom (or group of atoms) with electron-withdrawing ability that can be displaced as a stable species and simultaneously takes away bonding electrons. Examples of suitable leaving groups include halides and sulfonates, including but not limited to trifluoromethanesulfonate, mesylate, tosylate and brosylate.

[0237] The term "hydrolyzable group" and "hydrolyzable moiety" refer to a functional group that can be hydrolyzed, for example, under alkaline or acidic conditions. Examples of hydrolyzable residues include, but are not limited to, acid halides, activated carboxylic acids, and various protecting groups known in the art (see, for example, "Greene's Protective Groups in Organic Synthesis", PGM Wuts, Wiley, 2014).

[0238] The compounds described herein may contain one or more double bonds and may therefore give rise to cis / trans (E / Z) isomers, as well as other conformational isomers. Unless otherwise specified, the compounds described herein include all such possible isomers, as well as mixtures of such isomers.

[0239] Unless otherwise stated, formulas with chemical bonds shown only as solid lines, rather than wedges or dashed lines, encompass every possible isomer, such as every enantiomer and diastereomer, as well as mixtures of isomers, such as racemic mixtures or scalemic mixtures. The compounds described herein may contain one or more asymmetric centers, and thus may produce diastereomers and optical isomers. Unless otherwise stated, the present disclosure includes all of these possible diastereomers and racemic mixtures thereof, their substantially pure resolved enantiomers, all possible geometric isomers, and pharmaceutically acceptable salts thereof. Also included are mixtures of stereoisomers and isolated specific stereoisomers. During the course of the synthetic processes used to prepare such compounds, or during racemization or epimerization processes known to those skilled in the art, the products of these processes may be mixtures of stereoisomers.

[0240] Many organic compounds exist in optically active forms with the ability to rotate the plane of vibration of plane polarized light. When describing optically active compounds, prefixes D and L or R and S are used to represent the absolute configuration of the molecule around its chiral center. Prefixes d and l or (+) and (-) are used to represent the rotation sign of the compound to plane polarized light, wherein (-) or l represent that the compound is left-handed. Compounds prefixed with (+) or d are right-handed. For a given chemical structure, these compounds referred to as stereoisomers are identical, except that they are mirror images that cannot overlap each other. Specific stereoisomers may also be referred to as enantiomers, and mixtures of such isomers are generally referred to as enantiomeric mixtures. A 50:50 mixture of enantiomers is referred to as a racemic mixture. Many compounds described herein may have one or more chiral centers, and therefore may exist in different enantiomeric forms. When the bond to a chiral atom is depicted as a straight line in the disclosed formula, it should be understood that both (R) and (S) configurations of the chiral atom, and therefore both enantiomers and mixtures thereof are included in the formula. As used in the art, when it is desired to specify the absolute configuration around a chiral atom, one of the bonds to the chiral atom can be depicted as a wedge (the bond to the atom above the plane), and the other bond can be depicted as a series of short parallel lines or wedges (the bond to the atom below the plane). The Cahn-Ingold-Prelog system can be used to determine the (R) or (S) configuration of a chiral atom.

[0241] When the disclosed compounds contain one chiral center, the compounds exist in two enantiomeric forms. Unless specifically stated to the contrary, the disclosed compounds include both enantiomers and mixtures of enantiomers, such as the specific 50:50 mixture known as a racemic mixture. Enantiomers can be resolved by methods known to those skilled in the art, such as forming diastereomeric salts that can be separated, for example, by crystallization (see David Kozma's CRC Handbook of Optical Resolutions via Diastereomeric Salt Formation (CRC Press, 2001)); forming diastereomeric derivatives or complexes that can be separated, for example, by crystallization, gas-liquid or liquid chromatography; selective reaction of one enantiomer with an enantiomer-specific reagent, such as enzymatic esterification; or in a chiral environment, such as on a chiral support such as silica with a bound chiral ligand, or in the presence of a chiral solvent, by gas-liquid or liquid chromatography. It will be appreciated that when the desired enantiomer is converted to another chemical entity by one of the above separation procedures, an additional step may liberate the desired enantiomeric form. Alternatively, a specific enantiomer may be synthesized by asymmetric synthesis using optically active reagents, substrates, catalysts or solvents, or by converting one enantiomer to the other by asymmetric transformation.

[0242] The designation of the specific absolute configuration at the chiral atom in the disclosed compound is understood to mean that the designated enantiomeric form of the compound can be provided with enantiomeric excess (allowable error). As used herein, enantiomeric excess is that the amount of a specific enantiomer is greater than 50%, for example, greater than 60%, greater than 70%, greater than 75%, greater than 80%, greater than 85%, greater than 90%, greater than 95%, greater than 98% or greater than 99%. On the one hand, the designated enantiomer is substantially free of another enantiomer. For example, the "R" configuration of a compound can be substantially free of the "S" configuration of the compound, and is therefore in enantiomeric excess relative to the "S" configuration. On the contrary, the "S" configuration of a compound can be substantially free of the "R" configuration of the compound, and is therefore in enantiomeric excess relative to the "R" configuration.

[0243] When the disclosed compound has two or more chiral atoms, the compound can have more than two optical isomers and can exist in diastereomeric form. For example, when there are two chiral atoms, the compound can have up to four optical isomers and two pairs of enantiomers ((S, S) / (R, R) and (R, S) / (S, R)). Enantiomer pairs (for example, (S, S) / (R, R)) are mirror image stereoisomers of each other. Stereoisomers that are not mirror images (for example, (S, S) and (R, S)) are diastereomers. Diastereoisomer pairs can be separated by methods known to those skilled in the art, for example, chromatography or crystallization, and each enantiomer in each pair can be separated as described above. Unless otherwise explicitly excluded, the disclosed compound includes each diastereomer of such compounds and mixtures thereof.

[0244] Compounds according to the present disclosure can use groups such as alkoxy, amino acids as prodrug forming parts to form prodrugs at hydroxyl or amino functional groups. For example, the hydroxymethyl position can form monophosphate, diphosphate or triphosphate and these phosphates can form prodrugs again. The preparation of such prodrug derivatives is discussed in various literature sources (examples are: Alexander et al., Journal of Medicinal Chemistry (J.Med.Chem.) 1988, 31, 318; Aligas-Martin et al., PCT WO2000 / 041531, page 30). The nitrogen functional group converted when preparing these derivatives is one (or more) nitrogen atoms of the compounds of the present disclosure.

[0245] "Derivatives" of the compounds disclosed herein are pharmaceutically acceptable salts, prodrugs, deuterated forms, radiolabeled forms, isomers, solvates, and combinations thereof. "Combinations" mentioned in this context refer to derivatives belonging to at least two of the following groups: pharmaceutically acceptable salts, prodrugs, deuterated forms, radiolabeled forms, isomers, and solvates. Examples of radiolabeled forms include compounds labeled with tritium, phosphorus-32, iodine-129, carbon-11, fluorine-18, and the like.

[0246] The compounds described herein contain atoms both in their natural isotopic abundance and in unnatural abundance. The disclosed compounds may be isotopically labeled or isotopically substituted compounds, which are identical to those described, but for the fact that one or more atoms are replaced by atoms having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into the compounds of the present disclosure include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine, and chlorine, such as 2 H. 3 H. 13 C. 14 C.15 N. 18 O. 17 O. 35 S. 18 F and 36 Cl. The compound further includes its prodrug, and pharmaceutically acceptable salts of the compound or the prodrug containing the above-mentioned isotopes and / or other isotopes of other atoms are within the scope of the present disclosure. Certain isotopically labeled compounds of the present disclosure, for example, in which a radioactive isotope is incorporated, such as 3 H and 14 C, can be used in drug and / or substrate tissue distribution assays. 3 H) and carbon-14 (i.e., 14 C) isotopes are particularly preferred because of their ease of preparation and detectability. Further, the use of heavier isotopes, such as deuterium (i.e., 2 H) may afford certain therapeutic advantages resulting from greater metabolic stability, such as increased in vivo half-life or reduced dosage requirements, and thus may be preferred in some circumstances. Isotopically labeled compounds of the present disclosure and prodrugs thereof can generally be prepared by carrying out the following procedure: substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.

[0247] Compounds described herein can exist as solvates. In some cases, the solvent used to prepare the solvate is an aqueous solution, and then the solvate is generally referred to as a hydrate. Compounds can exist as hydrates, which can be obtained, for example, by crystallization from a solvent or aqueous solution. In this regard, one, two, three or any arbitrary number of solvents or water molecules can be combined with compounds according to the present disclosure to form solvates and hydrates.

[0248] It is also understood that certain compounds described herein may exist as an equilibrium of tautomers. For example, a ketone with an α-hydrogen may exist in an equilibrium of a keto form and an enol form.

[0249]

[0250] Likewise, amides having an N-hydrogen may exist in an equilibrium of the amide form and the imidic acid form.

[0251]

[0252] As another example, pyrazole can exist in two tautomeric forms as shown below: 1 - Unsubstituted 3-A 3 and N 1 - Unsubstituted 5-A 3 .

[0253]

[0254] Unless stated to the contrary, the present disclosure includes all such possible tautomers.

[0255] Chemical substances are known to form solids that exist in different ordered states, which are referred to as polymorphic forms or variants. Different variants of polymorphic materials may differ greatly in their physical properties. Compounds according to the present disclosure may exist in different polymorphic forms, wherein a particular variant may be metastable. Unless otherwise stated, the present disclosure includes all these possible polymorphic forms.

[0256] Certain materials, compounds, compositions and components disclosed herein are either commercially available or readily synthesized using techniques generally known to those skilled in the art. For example, starting materials and reagents used in preparing the disclosed compounds and compositions are available from commercial suppliers such as Aldrich Chemical Co. (Milwaukee, Wis.), Acros Organics (Morris Plains, NJ), Strem Chemicals (Newburyport, MA), Fisher Scientific (Pittsburgh, Pa.), or Sigma (St. Louis, Mo.) or are prepared by methods known to those skilled in the art following the procedures set forth in references such as Fieser and Fieser's Reagents for Organic Synthesis, Vols. 1-17 (John Wiley and Sons, Inc.). Sons, 1991); Rodd's Chemistry of Carbon Compounds, Volumes 1-5 and Supplementary Volumes (Elsevier Science Publishers, 1989); Organic Reactions, Volumes 1-40 (John Wiley & Sons, 1991); March's Advanced Organic Chemistry, (John Wiley & Sons, 4th Edition); and Larock's Comprehensive Organic Transformations (VCH Publishers, 1989).

[0257] Unless otherwise expressly stated, it is not intended that any method described herein be construed as requiring that its steps be performed in a particular order. Therefore, in the event that a method claim does not actually recite the order in which its steps are to be followed or the steps are not otherwise specifically stated in the claims or specification to be limited to a particular order, no order is intended to be inferred in any respect. This applies to any possible non-express basis for interpretation, including: matters of logic with respect to the arrangement of steps or operational flow; plain meaning derived from grammatical structure or punctuation; and the number or type of embodiments described in the specification.

[0258] II.Compounds

[0259] One class of compounds described herein is represented by Formula I:

[0260] or any stereoisomer thereof.

[0261] In Formula I, Is a single bond or a double bond.

[0262] Also in Formula I, R1 is H or CH3.

[0263] Additionally, in Formula I, R2 is H and R3 is OCH3 or F, or R2 and R3 are covalently bonded together and together with the intermediate atom form a 2'-0,4'-C methylene bridge.

[0264] Further, in Formula I, X1 is O or CH.

[0265] Also in Formula I, X2 is CH2 or CH.

[0266] Additionally, in Formula I, X3 is O or S.

[0267] Further, in Formula I, each independent Y is H + or a cation, and n is 0, 1, 2, 3 or 4. Optionally, the cation is a pharmaceutically acceptable cation (e.g., Na + , K + , Li + or TEAH + ).

[0268] In Formula I, when X1 is CH, then X2 is CH and It's a double bond.

[0269] As will be appreciated by those skilled in the art, the structures shown for the compounds described herein are representations of one form of the compounds. Although such compounds may be drawn or described in a protonated (free acid) form, an ionized (anionic) form, or an ionized and associated form with one or more cations (salt form), aqueous solutions of such compounds exist in equilibrium between such forms. For example, the phosphate bonds of the compounds described herein exist in equilibrium in aqueous solution in free acid, anionic, and salt forms.

[0270] Optionally, Formula I may be depicted in the protonated (free acid) form as shown below:

[0271]

[0272] in

[0273] R1, R2, R3, X1, X2 and X3 are as defined above for Formula I.

[0274] Optionally, Formula I may be described in ionized (anionic) form as shown below:

[0275]

[0276] in

[0277] R1, R2, R3, X1, X2 and X3 are as defined above for Formula I.

[0278] Optionally, Formula I may be depicted in ionized form and in association with one or more cations (salts), as shown below, where a compound having the following structure is associated with a sodium ion (for purposes of illustration only and not limitation):

[0279]

[0280] in

[0281] R1, R2, R3, X1, X2 and X3 are as defined above for Formula I. As will be appreciated by those skilled in the art, cationic salt forms may exist in which one, two, three or four cations are present.

[0282] Unless otherwise stated, the compounds described herein are intended to include all such forms. In addition, some compounds have several such bonds, each of which is in equilibrium. Therefore, the compound exists in multiple forms in multiple locations in solution, all in equilibrium. The drawn structure necessarily depicts a single form. However, unless otherwise stated, such drawings are also intended to include corresponding forms. Herein, the structure depicting the free acid of the compound followed by the term "or its salt" explicitly includes all such forms that may be fully or partially protonated / deprotonated / associated with cations. In some cases, one or more specific cations are determined. In some methods, the compounds disclosed herein are in aqueous solution with sodium. In some methods, the compounds are in aqueous solution with potassium. In some methods, the compounds are in aqueous solution with lithium. In some methods, the compounds are in aqueous solution with triethylammonium.

[0283] As described above, Formula I may include compounds wherein R2 and R3 are covalently bonded together and together with the intermediate atom form a 2'-0,4'-C methylene bridge. The 2'-0,4'-C methylene bridge portion may also be referred to herein as a linked nucleic acid (LNA) portion. Optionally, the compound of Formula I or a salt thereof having an LNA portion is represented by Structure IA as shown below:

[0284]

[0285] In Structure IA, R1 and X3 are as defined above for Formula I. Examples of Structure IA include the following compounds and salts thereof:

[0286] m7 GpppA 2',4'-LNA pG:

[0287]

[0288] m7 G 3'OMe pppA 2',4'-LNA pG:

[0289]

[0290] m7 GpppA 2'-4'-LNA p(s)G:

[0291]

[0292] As described above, Formula I may include compounds wherein X1 is CH. In these examples, X2 is also CH, such that X1 and X2 form a vinyl moiety (-CH=CH-). Optionally, the compound of Formula I or a salt thereof having a vinyl moiety is represented by Structure IB as shown below:

[0293]

[0294] In Structure IB, R1 is as defined above for Formula I. Examples of Structure IB include the following compounds and salts thereof: m7 GpppA 2'OMe-5'乙烯基 pG:

[0295]

[0296] m7 G 3'-OMe pppA 2'OMe-5'乙烯基 pG:

[0297]

[0298] Additional examples of Formula I include Compound 6 and salts thereof as shown below:

[0299] m7 GpppA 2'F p(s)G*:

[0300]

[0301] * m7 GpppA 2'F p(s)G contains a chiral phosphorothioate moiety and is separated into two diastereoisomers: m7 GpppA 2'F p(s Rp )G and m7 GpppA 2'F p(s sp )G.

[0302] One class of compounds described herein is represented by Formula II:

[0303]

[0304] or any stereoisomer thereof.

[0305] In Formula II, R1 is H or CH3.

[0306] Also in Formula II, X1 is O or S.

[0307] Alternatively, in Formula II, each independent Y is H + or a cation, and n is 0, 1, 2, 3 or 4. Optionally, the cation is a pharmaceutically acceptable cation (e.g., Na + , K + , Li + or TEAH + ).

[0308] Optionally, in Formula II, when X1 is S, R1 is CH3.

[0309] Optionally, Formula II may be depicted in the protonated (free acid) form as shown below:

[0310] in

[0311] R1 and X1 are as defined above for Formula II.

[0312] Optionally, Formula II may be described in ionized (anionic) form as shown below:

[0313] in

[0314] R1 and X1 are as defined above for Formula II.

[0315] Optionally, Formula II may be depicted in ionized form and in association with one or more cations (salts), as shown below, where a compound having the following structure is associated with a sodium ion (for purposes of illustration only and not limitation):

[0316] in

[0317] R1 and X1 are as defined above for Formula II.

[0318] Examples of Formula II include the following compounds and salts thereof:

[0319] m7 Gppp (diaminopurine) 2'OMe pG:

[0320]

[0321] m7 G 3'OMe ppp (diaminopurine) 2'OMe pG:

[0322]

[0323] m7 G 3'OMe ppp (diaminopurine) 2'OMe p(s)G*:

[0324]

[0325] * m7 G 3'OMe ppp (diaminopurine) 2'OMep(s)G contains a chiral phosphorothioate moiety and is separated into two diastereoisomers: m7 G 3'OMe ppp (diaminopurine) 2'OMe p(s Rp )G and m7 G 3'OMe ppp (diaminopurine) 2'OMe p(s Sp )G.

[0326] One class of compounds described herein is represented by Formula III:

[0327]

[0328] or any stereoisomer thereof.

[0329] In Formula III, R1 is H or CH3.

[0330] Alternatively, in Formula III, each independent Y is H + or a cation, and n is 0, 1, 2, 3 or 4. Optionally, the cation is a pharmaceutically acceptable cation (e.g., Na + , K + , Li + or TEAH + ).

[0331] Optionally, Formula III may be depicted in the protonated (free acid) form as shown below:

[0332] in

[0333] R 1 As defined above for Formula III.

[0334] Optionally, Formula III may be described in ionized (anionic) form as shown below:

[0335] in

[0336] R 1 As defined above for Formula III.

[0337] Optionally, Formula III may be depicted in ionized form and in association with one or more cations (salts), as shown below, where a compound having the following structure is associated with a sodium ion (for purposes of illustration only and not limitation):

[0338] Where R 1 As defined above for Formula III.

[0339] Examples of Formula III include the following compounds and salts thereof:

[0340] m7 Gppp m6 A 2'OMe pA:

[0341]

[0342] m7 G 3'OMe ppp m6 A 2'OMe pA:

[0343]

[0344] One class of compounds described herein is represented by Formula IV:

[0345]

[0346] or any stereoisomer thereof.

[0347] In Formula IV, R1 is H or CH3.

[0348] Also in Formula IV, X1, X2 and X3 are each independently selected from O and S, wherein when one of X1, X2 or X3 is S, the remainder of X1, X2 and X3 are O. Optionally, X1 is S, and both X2 and X3 are O. Optionally, X2 is S, and both X1 and X3 are O. Optionally, X3 is S, and both X1 and X2 are O.

[0349] Alternatively, in Formula IV, each independent Y is H + or a cation, and n is 0, 1, 2, 3 or 4.

[0350] Optionally, Formula IV may be depicted in the protonated (free acid) form as shown below:

[0351] in

[0352] R1, X1, X2 and X3 are as defined above for Formula IV.

[0353] Optionally, Formula IV may be described in ionized (anionic) form as shown below:

[0354] in

[0355] R1, X1, X2 and X3 are as defined above for Formula IV.

[0356] Optionally, Formula IV may be depicted in ionized form and in association with one or more cations (salts), as shown below, where a compound having the following structure is associated with a sodium ion (for purposes of illustration only and not limitation):

[0357] in

[0358] R1, X1, X2 and X3 are as defined above for Formula IV.

[0359] Examples of Formula IV include the following compounds and salts thereof:

[0360] m7 G 3'OMe5'-硫代 ppp m6 A 2'OMe pG:

[0361]

[0362] m7 G 3'OMe pp(s)p m6 A 2'OMe pG*:

[0363]

[0364] * m7 G 3'OMe pp(s)p m6 A 2'OMe pG contains a chiral phosphorothioate moiety and is separated into two diastereomers: m7 G 3'OMe pp(s Rp ) m6 A 2'OMe pG and

[0365] m7 G 3'OMe pp(s sp ) m6 A 2'OMe pG.

[0366] m7 G 3'OMe ppp m6 A 2'OMe5'硫代 pG:

[0367]

[0368] m7 G 3'OMe pppA 2'OMe5'硫代 pG:

[0369]

[0370] One class of compounds described herein is represented by Formula V:

[0371]

[0372] or any stereoisomer thereof.

[0373] In Formula V, R1 is H or CH3.

[0374] Also in Formula V, R2 is H and R3 is F, or R2 and R3 are covalently bonded together and together with the intermediate atom form a 2'-0,4'-C methylene bridge.

[0375] Alternatively, in Formula V, each independent Y is H + or a cation, and n is 0, 1, 2, 3 or 4. Optionally, the cation is a pharmaceutically acceptable cation (e.g., Na + , K + , Li + or TEAH + ).

[0376] Further, in Formula V, when R2 is H and R3 is F, R1 is not H.

[0377] Optionally, Formula V may be depicted in the protonated (free acid) form as shown below:

[0378] in

[0379] R1, R2 and R3 are as defined above for Formula V.

[0380] Optionally, Formula V may be depicted in the ionized (anionic) form as shown below:

[0381] in

[0382] R1, R2 and R3 are as defined above for Formula V.

[0383] Optionally, Formula V may be depicted in ionized form and in association with one or more cations (salts), as shown below, where a compound having the following structure is associated with a sodium ion (for purposes of illustration only and not limitation):

[0384] in

[0385] R1, R2 and R3 are as defined above for Formula V.

[0386] As described above, Formula V may include compounds wherein R2 and R3 are covalently bonded together and together with the intermediate atom form a 2'-0,4'-C methylene bridge (also referred to herein as a linked nucleic acid (LNA) moiety). Optionally, the compound of Formula V or a salt thereof having an LNA moiety is represented by Structure IA as shown below:

[0387]

[0388] In Structure VA, R1 is as defined above for Formula V. Examples of Structure VA include the following compounds and salts thereof: m7 GpppA 2'4'LNA pU:

[0389]

[0390] m7 G 3'OMe pppA 2'4'LNA pU:

[0391]

[0392] Additional examples of Formula V include Compound 17 and salts thereof as shown below: m7 G 3'OMe pppA 2'F pU:

[0393]

[0394] One class of compounds described herein is represented by Formula VI:

[0395]

[0396] or any stereoisomer thereof.

[0397] In Formula VI, R1 is H or CH3.

[0398] Also in Formula VI, X1, X2, X3 and X4 are each independently selected from O and S.

[0399] Alternatively, in Formula VI, each independent Y is H + or a cation, and n is 0, 1, 2, 3 or 4. Optionally, the cation is a pharmaceutically acceptable cation (e.g., Na + , K + , Li + or TEAH + ).

[0400] In Formula VI, one of X1, X2, X3 and X4 is S.

[0401] Optionally, Formula VI may be depicted in the protonated (free acid) form as shown below:

[0402] in

[0403] R1, X1, X2, X3 and X4 are as defined above for Formula VI.

[0404] Optionally, Formula VI may be depicted in the ionized (anionic) form as shown below:

[0405] in

[0406] R1, X1, X2, X3 and X4 are as defined above for Formula VI.

[0407] Optionally, Formula VI may be depicted in ionized form and in association with one or more cations (salts), as shown below, where a compound having the following structure is associated with a sodium ion (for purposes of illustration only and not limitation):

[0408] wherein R1, X1, X2, X3 and X4 are as defined above for Formula VI.

[0409] Examples of Formula VI include the following compounds and salts thereof:

[0410] m7 G 3'OMe p(s)ppA 2'OMe pG*:

[0411]

[0412] * m7 G 3'OMe p(s)ppA 2'OMe pG contains a chiral phosphorothioate moiety and is separated into two diastereomers: m7 G 3'OMe p(s Rp )ppA 2'OMe pG and m7 G 3'OMe p(s Sp )ppA 2'OMe pG.

[0413] m7 G 3'OMe pp(s)pA 2'OMe pG*:

[0414]

[0415] * m7 G 3'OMe pp(s)pA2'OMe pG contains a chiral phosphorothioate moiety and is separated into two diastereomers: m7 G 3'OMe pp(s Rp )pA 2'OMe pG and m7 G 3'OMe pp(s Sp )pA 2'OMe pG.

[0416] m7 G 3'OMe ppp(s)A 2'OMe pG*:

[0417]

[0418] * m7 G 3'OMe ppp(s)A 2'OMe pG contains a chiral phosphorothioate moiety and is separated into two diastereomers: m7 G 3'OMe ppp(s Rp )A 2'OMe pG and m7 G 3'OMe ppp(s Sp )A 2'OMe pG.

[0419] m7 G 3'OMe pppA 2'OMe p(s)G*:

[0420]

[0421] * m7 G 3'OMe pppA 2'OMe p(s)G contains a chiral phosphorothioate moiety and is separated into two diastereoisomers: m7 G 3'OMe pppA 2'OMe p(s Rp )G and m7 G 3'OMe pppA 2'OMe p(s Sp )G.

[0422] m7 G 3'OMe ppp m6 A 2'OMe p(s)G*:

[0423]

[0424] * m7 G 3'OMe ppp m6 A 2'OMe p(s)G contains a chiral phosphorothioate moiety and is separated into two diastereoisomers: m7 G 3'OMe ppp m6 A 2'OMe p(s Rp )G and

[0425] m7 G 3'OMe ppp m6 A 2'OMe p(s Sp )G.

[0426] m7 G 3'OMe p(s)pp m6 A 2'OMe pG:

[0427]

[0428] * m7 G 3'OMe p(s)pp m6 A 2'OMe pG contains a chiral phosphorothioate moiety and is divided into two

[0429] Diastereomers: m7 G 3'OMe p(s Rp )pp m6 A 2'OMe pG and

[0430] m7 G 3'OMe p(s Sp )pp m6 A 2'OMe pG.

[0431] One class of compounds described herein is represented by Formula VII:

[0432]

[0433] or any stereoisomer thereof.

[0434] In Formula VII, R1 is H or CH3.

[0435] Also in Formula VII, R2 is H or CH3.

[0436] In Formula VII, at least one of R1 or R2 is CH3. In other words, R1 and R2 are not H at the same time.

[0437] Alternatively, in Formula VII, each independent Y is H + or a cation, and n is 0, 1, 2, 3 or 4. Optionally, the cation is a pharmaceutically acceptable cation (e.g., Na + , K + , Li + or TEAH + ).

[0438] Optionally, Formula VII may be depicted in the protonated (free acid) form as shown below:

[0439] in

[0440] R1 and R2 are as defined above for Formula VII.

[0441] Optionally, Formula VII may be depicted in the ionized (anionic) form as shown below:

[0442] in

[0443] R1 and R2 are as defined above for Formula VII.

[0444] Optionally, Formula VII may be depicted in ionized form and in association with one or more cations (salts), as shown below, where a compound having the following structure is associated with a sodium ion (for purposes of illustration only and not limitation):

[0445] in

[0446] R1 and R2 are as defined above for Formula VII.

[0447] Examples of Formula VII include the following compounds and salts thereof: m7 G 3'OMe pppA 2'OMe pU:

[0448]

[0449] m7 Gppp m6 A 2'OMe pU:

[0450]

[0451] m7 G 3'OMe ppp m6 A 2'OMe pU:

[0452]

[0453] One class of compounds described herein is represented by Formula VIII:

[0454]

[0455] or any stereoisomer thereof.

[0456] In Formula VIII, R1 and R2 are each independently selected from H and CH3.

[0457] Also in Formula VIII, each independent Y is H + or a cation, and n is 0, 1, 2, 3 or 4. Optionally, the cation is a pharmaceutically acceptable cation (e.g., Na + , K + , Li + or TEAH + ).

[0458] Optionally, Formula VIII may be depicted in the protonated (free acid) form as shown below:

[0459] in

[0460] R1 and R2 are as defined above for Formula VIII.

[0461] Optionally, Formula VIII may be depicted in the ionized (anionic) form as shown below:

[0462] in

[0463] R1 and R2 are as defined above for Formula VIII.

[0464] Optionally, Formula VIII may be depicted in ionized form and in association with one or more cations (salts), as shown below, where a compound having the following structure is associated with a sodium ion (for purposes of illustration only and not limitation):

[0465] in

[0466] R1 and R2 are as defined above for Formula VIII.

[0467] Examples of Formula VIII include the following compounds and salts thereof:

[0468] m7 G 2'OMe3'OMe pppA 2'OMe pG:

[0469]

[0470] m7 G 2'OMe pppA 2'OMe pG:

[0471]

[0472] m7 G 2'OMe3'OMe ppp m6 A 2'OMe pG:

[0473]

[0474] m7 G 2'OMe ppp m6 A 2'OMe pG:

[0475]

[0476] Other compounds useful in certain methods described herein include the following compounds or any stereoisomers thereof:

[0477] m7 G 3'OMe pppA 2'OMe pG:

[0478]

[0479] m7 G 3'OMe ppp m6 A 2'OMe pG:

[0480] m7 Gppp m6 A 2'OMe pG:

[0481] m7 G 2'4'-LNA pppA 2'OMe pG:

[0482]

[0483] m7 GpppA 2'F pU:

[0484]

[0485] Optionally, the compound used in certain methods is not a compound according to Compound 29, Compound 30, Compound 31, Compound 32 and / or Compound 33.

[0486] One class of compounds described herein is represented by Formula IX:

[0487]

[0488] or any stereoisomer thereof.

[0489] In Formula IX, R1 is H or CH3.

[0490] Also in Formula IX, R2 is OH, F, substituted or unsubstituted alkoxy or thio. Optionally, the substituted or unsubstituted alkoxy may be methoxy, methoxyethoxy or azidomethoxy.

[0491] Also in Formula IX, R3 is H or CH3.

[0492] In Formula IX, when R2 is OH, R1 is not H.

[0493] Likewise in Formula IX, each independent Y is H + or a cation, and n is 0, 1, 2, 3 or 4. Optionally, the cation is a pharmaceutically acceptable cation (e.g., Na + , K + , Li + or TEAH + ).

[0494] Optionally, Formula IX may be depicted in the protonated (free acid) form as shown below:

[0495] in

[0496] R1, R2 and R3 are as defined above for Formula IX.

[0497] Optionally, Formula IX may be depicted in the ionized (anionic) form as shown below:

[0498] in

[0499] R1, R2 and R3 are as defined above for Formula IX.

[0500] Optionally, Formula IX may be depicted in ionized form and in association with one or more cations (salts), as shown below, where a compound having the following structure is associated with a sodium ion (for purposes of illustration only and not limitation):

[0501] in

[0502] R1, R2 and R3 are as defined above for Formula IX.

[0503] Examples of Formula IX include the following compounds and salts thereof:

[0504] m7 G 3'SMe pppA 2'OMe pG:

[0505]

[0506] m7 G 2'OH,2'Me pppA 2'OMe pG:

[0507]

[0508] m 7 G 3'AZM ppp m6 A 2'OMe pG:

[0509]

[0510] m7 G 3'F ppp m6 A 2'OMe pG:

[0511]

[0512] m7 G 3'MOE ppp m6 A 2'OMe pG:

[0513] m7 G 3'SMe ppp m6 A 2'OMe pG:

[0514]

[0515] m7 G 2'OH,2'Me ppp m6 A 2'OMe pG:

[0516]

[0517] One class of compounds described herein is represented by formula X:

[0518]

[0519] or any stereoisomer thereof.

[0520] In formula X, R1 is H or CH3.

[0521] Alternatively, in Formula X, each independent Y is H + or a cation, and n is 0, 1, 2, 3 or 4.

[0522] Optionally, Formula X may be depicted in the protonated (free acid) form as shown below:

[0523] in

[0524] R1 is as defined above for Formula X.

[0525] Optionally, Formula X may be described in ionized (anionic) form as shown below:

[0526] in

[0527] R1 is as defined above for Formula X.

[0528] Optionally, Formula X may be depicted in ionized form and in association with one or more cations (salts), as shown below, where a compound having the following structure is associated with a sodium ion (for purposes of illustration only and not limitation):

[0529] in

[0530] R1 is as defined above for Formula X.

[0531] Examples of Formula X include the following compounds and salts thereof:

[0532] m7 (L-sugar isomer)GpppA 2'OMe pG:

[0533]

[0534] m7 (L-Sugar isomer) Gppp m6 A 2'OMe pG:

[0535]

[0536] One class of compounds described herein is represented by Formula XI:

[0537]

[0538] In Formula XI, R1 is H or CH3.

[0539] Likewise in Formula XI, each independent Y is H +or a cation, and n is 0, 1, 2, 3 or 4. Optionally, the cation is a pharmaceutically acceptable cation (e.g., Na + , K + , Li + or TEAH + ).

[0540] Optionally, Formula XI may be depicted in the protonated (free acid) form as shown below:

[0541] in

[0542] R1 is as defined above for Formula XI.

[0543] Optionally, Formula XI may be depicted in the ionized (anionic) form as shown below:

[0544] in

[0545] R1 is as defined above for Formula XI.

[0546] Optionally, Formula XI may be depicted in ionized form and in association with one or more cations (salts), as shown below, where a compound having the following structure is associated with a sodium ion (for purposes of illustration only and not limitation):

[0547] wherein R1 is as defined above for Formula XI.

[0548] Examples of Formula XI include the following compounds and salts thereof:

[0549] m7 (Acyclic)GpppA 2'OMe pG:

[0550]

[0551] m7 (Acyclic)Gppp m6 A 2'OMe pG:

[0552]

[0553] One class of compounds described herein is represented by Formula XII:

[0554]

[0555] In Formula XII, R1 and R2 are each independently selected from H and CH3.

[0556] Likewise in Formula XII, each independent Y is H +or a cation, and n is 0, 1, 2, 3, 4 or 5. Optionally, the cation is a pharmaceutically acceptable cation (e.g., Na + , K + , Li + or TEAH + ).

[0557] Optionally, Formula XII may be depicted in the protonated (free acid) form as shown below:

[0558] in

[0559] R1 and R2 are as defined above for Formula XII.

[0560] Optionally, Formula XII may be depicted in the ionized (anionic) form as shown below:

[0561] in

[0562] R1 and R2 are as defined above for Formula XII.

[0563] Optionally, Formula XII may be depicted in ionized form and in association with one or more cations (salts), as shown below, where a compound having the following structure is associated with a sodium ion (for purposes of illustration only and not limitation):

[0564] in

[0565] R1 and R2 are as defined above for Formula XII.

[0566] Examples of Formula XII include the following compounds and salts thereof:

[0567] m7 G 3'OMe ppppA 2'OMe pG:

[0568]

[0569] m7 G 3'OMe pppp m6 A 2'OMe pG:

[0570]

[0571] In some examples, the compounds described herein include deuterated forms of the compounds, wherein at least one (e.g., one or more, two or more, three or more, four or more, five or more) hydrogen atom is replaced by deuterium. Exemplary deuterated forms include, for example, the following compounds shown as representative examples:

[0572] m7 G 3'OCD3 pppA 2'OMe pG:

[0573]

[0574] m7 G 3'OMe ppp (CD3)6 A 2'OMe pG:

[0575]

[0576] III. Methods of preparing compounds

[0577] The compounds described herein can be prepared in a variety of ways. The compounds can be synthesized using a variety of synthetic methods. At least some of these methods are known in the field of synthetic organic chemistry. The compounds described herein can be prepared from readily available starting materials. Optimal reaction conditions may vary with the specific reactants or solvents used, but such conditions can be determined by those skilled in the art through routine optimization procedures.

[0578] Variants of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX, formula X, formula XI and formula XII include the increase, reduction or movement of various components as described for each compound. Similarly, when there are one or more chiral centers in a molecule, all possible chiral variants are included. Additionally, compound synthesis may involve the protection and deprotection of various chemical groups. Those skilled in the art can determine the use of protection and deprotection and the selection of appropriate protecting groups. The chemical properties of protecting groups can be found in (e.g., Wuts, "Protective Groups in Green's Organic Synthesis", 5th edition, Wiley & Sons, Inc., 2014), which is incorporated herein by reference in its entirety.

[0579] The reactions used to produce the compounds described herein can be carried out in a solvent, which can be selected by a person skilled in the art of organic synthesis. The solvent can be substantially non-reactive with the starting materials (reactants), intermediates or products under the conditions under which the reactions are carried out, i.e., temperature and pressure. The reactions can be carried out in one solvent or in a mixture of more than one solvent. The formation of products or intermediates can be monitored according to any suitable method known in the art. For example, the formation of products or intermediates can be monitored by spectroscopic means, such as nuclear magnetic resonance spectroscopy (e.g., 1 H or 13C), infrared spectroscopy, spectrophotometry (eg, UV-visible), or mass spectrometry or by chromatography, such as high performance liquid chromatography (HPLC) or thin layer chromatography.

[0580] The compounds described herein can be prepared by a two-step process, including an activation stage, followed by a coupling stage. In the activation stage, a modified N7-methyl-guanosine-5'-diphosphate (optionally as a triethylammonium salt (TEAH)) is added. + ); N7-Me-GDP) compounds, wherein R1 is H or CH3, are dissolved in a solvent mixture to achieve the desired concentration. An activating agent, such as 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC.HCl salt), is then added to form an active intermediate in situ, which is then reacted with imidazole. After a certain period of time, an activated intermediate is formed and is ready for the coupling step. See Scheme A below.

[0581] Option A: Activation

[0582]

[0583] In the coupling step, the activated intermediate is reacted with a desired dinucleotide (wherein R2 is H, R3 is OCH3 or F, or R2 and R3 are covalently bonded together and form a 2'-O,4'-C methylene bridge with the intermediate atom) to couple the activated intermediate, and the mixture is reacted for a certain period of time. The final product is then obtained, as shown in Scheme B below.

[0584] Scheme B: Coupling

[0585]

[0586] Schemes A and B shown above are for representative purposes only, and one of ordinary skill in the art will appreciate that the schemes can be applied to any of the formulae described herein (i.e., Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, Formula IX, Formula X, Formula XI, and Formula XII) with modifications within the purview of one of ordinary skill in the art and the disclosure of the Examples section. For example, while Scheme B reflects a dinucleotide comprising adenosine and guanosine (pApG dinucleotide), the methods described herein can be similarly applied to other dinucleotides (e.g., p m6 ApG dinucleotide, pp m6ApG dinucleotide, ppApG dinucleotide, pDAP (diaminopurine) pG dinucleotide, pApA dinucleotide, pApU dinucleotide, and other dinucleotides as described herein). Similarly, the two-step method shown above depicts a phosphorus bond; however, the two-step method can be similarly applied to phosphorothioate bonds according to Formula I, Formula II, Formula IV, and Formula VI using appropriate reagents.

[0587] The synthetic methods described herein can be performed in a one-pot synthesis process, such that all steps are performed in a single reactor, wherein there is no isolation of intermediate products during the course of the synthetic method. In some examples, the method of synthesizing a trinucleotide compound comprises reacting N7-methyl-guanosine-5'-diphosphate having the following structure:

[0588]

[0589] wherein X1 and X2 are each independently selected from the group consisting of O and S; X3 is O; R1 and R2 are each independently selected from H, OH, N3, F, substituted or unsubstituted alkoxy and thio, wherein R1 and R2 are optionally combined to form a heterocycle, mixed with an activating reagent and imidazole to form an activated intermediate; and a salt reagent (e.g., a chloride salt such as MgCl2 or ZnCl2) and a dinucleotide having the following structure:

[0590]

[0591] in is a single bond or a double bond; X4 and X6 are each independently selected from the group consisting of O and S; X5 is O, S or CH; X7 is CH or CH2; R3 is OH, OMe, F, and R4 is H, or wherein R3 and R4 are covalently bonded together and form a 2'-O,4'-C methylene bridge together with the intermediate atom; B1 and B2 are each independently selected from the group consisting of a purine ring and a pyrimidine ring, and are added to the activated intermediate to form a trinucleotide compound having the following structure:

[0592]

[0593] The method described therein is a one-pot synthesis method.

[0594] In other examples, the method of synthesizing a trinucleotide compound comprises reacting a dinucleotide having the following structure:

[0595] in

[0596] is a single bond or a double bond; X4 is O; X6 is O or S; X5 is O, S or CH; X7 is CH or CH2; R3 is OH, OMe, F, and R4 is H, or wherein R3 and R4 are covalently bonded together and together with the intermediate atom form a 2'-O,4'-C methylene bridge; and B1 and B2 are each independently selected from the group consisting of a purine ring and a pyrimidine ring, mixed with an activating agent and imidazole to form an activated phosphoimidazole having the following structure:

[0597] as well as

[0598] A salt reagent (e.g., a chloride salt such as magnesium chloride or zinc chloride) and a compound having the following structure:

[0599] in

[0600] X1 and X2 are each independently selected from the group consisting of O and S; X3 is S; R1 and R2 are each independently selected from H, OH, N3, F, substituted or unsubstituted alkoxy and thio, wherein R1 and R2 are optionally combined to form a heterocycle, added to the activated phosphoimidazolide to form the trinucleotide compound having the following structure:

[0601]

[0602] In other examples, the method of synthesizing a trinucleotide compound comprises reacting a dinucleotide diphosphate having the structure:

[0603] in

[0604] is a single bond or a double bond; X3 is O; X4 and X6 are each independently selected from O and S; X5 is O, S or CH; X7 is CH or CH2; R3 is OH, OMe, F, and R4 is H, or wherein R3 and R4 are covalently bonded together and together with the intermediate atom form a 2'-O,4'-C methylene bridge; and B1 and B2 are each independently selected from the group consisting of a purine ring and a pyrimidine ring, mixed with an activating agent and imidazole to form an activated phosphoimidazole having the following structure:

[0605] as well as

[0606] A salt reagent (e.g., a chloride salt such as magnesium chloride or zinc chloride) and a compound having the following structure:

[0607] in

[0608] X1 and X2 are each independently selected from O and S; and R1 and R2 are each independently selected from H, OH, N3, F, substituted or unsubstituted alkoxy and thio, wherein R1 and R2 are optionally combined to form a heterocycle, added to the activated phosphoimidazole to form the trinucleotide compound having the following structure:

[0609]

[0610] The method described therein is a one-pot synthesis method.

[0611] Exemplary procedures for synthesizing compounds as described herein are provided in Example 1 below.

[0612] IV. Pharmaceutical Formulations

[0613] Compounds described herein or derivatives thereof can be provided in pharmaceutical compositions. Depending on the intended mode of administration, pharmaceutical compositions can be in the form of solid, semisolid or liquid dosage forms, such as tablets, suppositories, pills, capsules, powders, solutions or suspensions, preferably in a unit dosage form suitable for single administration of precise doses. The composition will include a therapeutically effective amount of compounds described herein or derivatives thereof and a pharmaceutically acceptable carrier, and in addition, other medicaments, pharmaceutical preparations, carriers or diluents may also be included. Pharmaceutically acceptable means not biologically or otherwise undesirable materials, which can be applied to individuals together with the selected compound without causing undesirable biological effects or without interacting with other components of the pharmaceutical composition contained therein in a harmful manner.

[0614] As used herein, the term "carrier" encompasses any excipient, diluent, filler, salt, buffer, stabilizer, solubilizer, lipid, stabilizer or other material known in the art for use in pharmaceutical formulations. The selection of carriers for the composition will depend on the intended route of administration of the composition. The preparation of pharmaceutically acceptable carriers and formulations containing these materials is described in, for example, Remington: Pharmacy Technology and Practice, 22nd edition, edited by Loyd et al., Pharmaceutical Press and Philadelphia College of Pharmacyat University of the Sciences (2012). Examples of physiologically acceptable carriers include buffers such as phosphate buffer, citrate buffer, and buffers with other organic acids; antioxidants including ascorbic acid; low molecular weight (less than about 10 residues) polypeptides; proteins such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and / or nonionic surfactants such as (ICI, Inc.; Bridgewater, New Jersey), polyethylene glycol (PEG), and PLURONICS TM (BASF; Florham Park, NJ).

[0615] Compositions containing compounds described herein or derivatives thereof suitable for parenteral injection may include physiologically acceptable sterile aqueous solutions or sterile non-aqueous solutions, dispersions, suspensions or emulsions and sterile powders for reconstitution into sterile injectable solutions or dispersions. Examples of suitable aqueous and non-aqueous carriers, diluents, solvents or excipients include water, ethanol, polyols (propylene glycol, polyethylene glycol, glycerol, etc.), suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters (such as ethyl oleate). For example, by using a coating (such as lecithin), by maintaining the desired particle size in the case of a dispersion, and by using a surfactant, appropriate fluidity can be maintained.

[0616] These compositions may also contain adjuvants such as preservatives, wetting agents, emulsifiers and dispersants. Protection against the action of microorganisms may be facilitated by various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, sorbic acid, etc. Isotonic agents may also be included, such as sugars, sodium chloride, etc. Prolonged absorption of injectable drug forms may be achieved by using agents that delay absorption (e.g., aluminum monostearate and gelatin).

[0617] Solid dosage forms for oral administration of the compounds described herein or their derivatives include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the compounds described herein or their derivatives are mixed with: at least one inert conventional excipient (or carrier) such as sodium citrate or dicalcium phosphate or (a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol and silicic acid; (b) binders such as carboxymethylcellulose, alginates, gelatin, polyvinyl pyrrolidone, sucrose and acacia; (c) wetting agents such as glycerol; (d) disintegrants such as agar, calcium carbonate, potato starch or tapioca starch, alginic acid, certain complex silicates and sodium carbonate; (e) solution retarders such as paraffin; (f) absorption promoters such as quaternary ammonium compounds; (g) wetting agents such as cetyl alcohol and glyceryl monostearate; (h) adsorbents such as kaolin and bentonite; and (i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate or mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents.

[0618] Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.

[0619] Solid dosage forms such as tablets, dragees, capsules, pills and granules can be prepared with coatings and shells, such as enteric coatings and other coatings known in the art. The dosage form can contain an emulsifier and its composition can also make the dosage form release one or more active compounds in a delayed manner in a specific part of the intestinal tract. Examples of embedding compositions that can be used are polymeric substances and waxes. The active compound can also be in microencapsulated form, if appropriate, with one or more of the above-mentioned excipients.

[0620] Liquid dosage forms for oral administration of the compounds described herein or their derivatives include pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs. In addition to the active compound, the liquid dosage form may contain inert diluents commonly used in the art, such as water or other solvents, solubilizers and emulsifiers, for example, ethanol, isopropanol, diethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils, specifically cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil and sesame oil, glycerol, tetrahydrofurfuryl alcohol, polyethylene glycol and fatty acid esters of sorbitan, or mixtures of these substances, and the like.

[0621] Besides such inert diluents, the composition may also include additional agents such as wetting agents, emulsifying agents, suspending agents, sweetening agents, flavoring agents, or perfuming agents.

[0622] In addition to the active compounds, the suspensions may contain additional agents such as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth, or mixtures of these and the like.

[0623] Compositions of the compounds described herein or their derivatives for rectal administration are optionally suppositories which can be prepared by mixing the compound with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol, or a suppository base which is solid at ordinary temperatures but liquid at body temperature and therefore melts in the rectum or vaginal cavity and releases the active ingredients.

[0624] The dosage forms for topical administration of the compounds described herein or their derivatives include ointments, powders, sprays, inhalants and skin patches. Under sterile conditions, the compounds described herein or their derivatives are mixed with a physiologically acceptable carrier and any preservatives, buffers or propellants (if necessary). Ophthalmic formulations, ointments, powders and solutions are also considered to be within the scope of the composition.

[0625] Optionally, the compound described herein can be included in a drug reservoir. The drug reservoir comprises a physical structure that promotes implantation and is retained in a desired position (e.g., synovial joint, intervertebral space, spinal canal, abdominal region, patient tissue, etc.). The drug reservoir can provide an optimal concentration gradient of the compound at a distance of up to about 0.1cm to about 5cm from the implantation site. Reservoirs as used herein include but are not limited to capsules, microspheres, microparticles, microcapsules, microfiber particles, nanospheres, nanoparticles, coatings, matrix, film wafers, pills, micropills, emulsions, liposomes, micelles, gels, antibody-compound conjugates, protein-compound conjugates or other drug delivery compositions. Suitable materials for reservoirs include pharmaceutically acceptable biodegradable materials, and the material is preferably FDA approved or GRAS materials. These materials can be polymeric or non-polymeric and synthetic or naturally occurring or a combination thereof. Reservoirs can optionally include drug pumps.

[0626] The composition may include one or more compounds described herein and a pharmaceutically acceptable carrier. As used herein, the term pharmaceutically acceptable salt refers to those salts of the compounds described herein or their derivatives and zwitterionic forms of the compounds described herein (if possible), which are suitable for contact with the tissues of the subject without undue toxicity, irritation, allergic response, etc., within the scope of reasonable medical judgment, with a reasonable benefit / risk ratio, and are effective for their intended use. The term salt refers to relatively nontoxic inorganic and organic acid addition salts of the compounds described herein. These salts can be prepared in situ during the separation and purification of the compound, or by reacting the purified compound in the form of a free base with an appropriate organic or inorganic acid alone and separating the salts thus formed. Representative salts include hydrobromide, hydrochloride, sulfate, bisulfate, nitrate, acetate, oxalate, valerate, oleate, palmitate, stearate, laurate, borate, benzoate, lactate, phosphate, toluenesulfonate, citrate, maleate, fumarate, succinate, tartrate, naphthoate, methanesulfonate, glucoheptonate, lactobionate, methanesulfonate and laurylsulfonate, etc. These salts include cations based on alkali metals or alkaline earth metals, such as sodium, lithium, potassium, calcium, magnesium, etc.; as well as non-toxic ammonium, quaternary ammonium cations and amine cations, including but not limited to ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, etc. (See SM Barge et al., Journal of Pharmaceutical Sciences (1977) 66, 1, which is incorporated herein by reference in its entirety at least for the compositions taught therein).

[0627] The administration of the compounds and compositions described herein, or pharmaceutically acceptable salts thereof, can be carried out using a therapeutically effective amount of the compounds and compositions as described herein, or pharmaceutically acceptable salts thereof, over a period of time that is effective to treat the condition. The effective amount of the compounds and compositions described herein, or pharmaceutically acceptable salts thereof, can be determined by one of ordinary skill in the art.

[0628] Those skilled in the art will appreciate that specific dosage levels and dosage frequencies for any particular subject may vary and depend on a variety of factors, including the activity of the specific compound employed, the metabolic stability and duration of action of the compound, the species, age, weight, general health, sex and diet of the subject, mode and time of administration, rate of excretion, drug combination and the severity of the particular condition.

[0629] The precise dose to be employed in the formulation will also depend on the route of administration and the severity of the disease or condition, and should be determined according to the judgment of the practitioner and the circumstances of each subject. Effective doses can be extrapolated from dose-response curves derived from in vitro or animal model test systems. Further, depending on the route of administration, one skilled in the art will know how to determine the dose that produces a plasma concentration in the cells, tissues and / or organs of the subject at the desired response level.

[0630] V. RNA Synthesis

[0631] Provided herein are in vitro methods for synthesizing capped RNA transcripts, including capped messenger RNA (mRNA) transcripts. The methods described herein include: (a) forming a reaction mixture comprising a compound as described herein (also referred to herein as a cap analog), a DNA template, and an RNA polymerase; and (b) incubating the reaction mixture under conditions that allow transcription of the DNA template to produce capped mRNA transcripts. In the methods described herein, the reaction mixture comprises NTPs, including ATP, CTP, GTP, and UTP. One or more NTPs in the in vitro transcription reaction mixture may be modified NTPs. Exemplary nucleosides with modified bases include, but are not limited to, inosine, 7-deazaguanosine, 7-methylguanosine, dihydrouridine, 2'-O-methylguanosine, 2'-fluoro-2'-deoxycytidine, pseudouridine, N1-methylpseudouridine, 5-methyluridine. In some methods, one or more uridines in the in vitro transcribed RNA are replaced by modified nucleosides. Optionally, some methods further comprise mixing the reaction mixture comprising the capped mRNA transcript with a mixture comprising Ca 2+ Incubate with DNase I in DNase I buffer.

[0632] Optionally, some methods further comprise treating the reaction mixture treated with DNA enzyme to eliminate proteins from the in vitro transcription reaction. Optionally, some methods further comprise subjecting the reaction mixture treated with DNA enzyme to phosphatase treatment. Optionally, the method further comprises subjecting the reaction mixture treated with DNA enzyme to one or more purification steps. The mRNA transcripts produced by the methods described herein can be purified using one or more purification techniques known to those skilled in the art. See Baronti et al. "A guide to large-scale RNA sample preparation", Anal. Bioanal. Chem. 410 (14): 3239-33252 (2018). For example, the mRNA transcripts can be purified by liquid chromatography (e.g., HPLC, reverse phase ion pairing HPLC (RP-IP-HPLC), anion exchange chromatography, cation exchange chromatography, affinity chromatography, size exclusion chromatography), precipitation, percolation, The mRNA can be purified by tangential flow filtration, oligo dT chromatography, silica membrane purification, and hydrophobic interaction chromatography, etc. The synthetic capped mRNA transcripts can be substantially free of impurities, such as DNA, protein, double-stranded RNA, and / or incomplete mRNA transcripts.

[0633] Also described herein are the resulting RNA molecules comprising a 5'-cap, wherein the 5'-cap comprises a compound as described herein. Optionally, the RNA molecule is a messenger RNA (mRNA) molecule. Optionally, the RNA molecule is a self-amplifying RNA (saRNA) molecule.

[0634] Also provided herein is a method for inducing a therapeutic effect in a subject, the method comprising administering to the subject an RNA molecule as described herein. The administered RNA may contain a certain amount of immunogenic double-stranded RNA (dsRNA). The amount of dsRNA is calculated per ug of the administered RNA.

[0635] As described in further detail herein, all of the 5' cap analogs described herein can be used for optimized in vivo translation of mRNA.

[0636] Further provided herein is a method of administering to an animal a dose of an mRNA molecule comprising a 5'-cap as described herein. Optionally, the 5'-cap comprises a compound selected from the group consisting of:

[0637]

[0638]

[0639]

[0640] The mRNA dosage optionally comprises less than 7ng of double-stranded RNA (dsRNA) per 1μg of mRNA, wherein the subject exhibits increased tolerance to the administered dose of mRNA compared to an equivalent dose of the mRNA comprising 7ng / μg or more dsRNA. Optionally, the increased tolerance is determined by measuring one or more of the following for a certain period of time before and after the administration: body weight, organ weight, aspartate aminotransferase (AST) level, alanine aminotransferase (ALT) level, C-reactive protein (CRP) level, procalcitonin (PCT) level, interleukin-6 (IL-6) level, erythrocyte sedimentation rate (ESR), serum amyloid A level, and serum ferritin level.

[0641] In some cases, the increased tolerance is measured by testing in a standard in vivo assay. As described above, the term "in vivo assay" refers to a method for detecting and / or measuring one or more compounds or molecules including compounds (e.g., mRNA molecules in a therapeutic dose) relative to a control to increase or decrease the ability of a characteristic (e.g., biomarker level). Optionally, in vivo assays as described herein can be used to determine the tolerance level of a subject to a given compound or molecule. Exemplary measurements for assessing tolerance include one or more of the following: body weight, organ weight, aspartate aminotransferase (AST) levels, alanine aminotransferase (ALT) levels, C-reactive protein (CRP) levels, procalcitonin (PCT) levels, interleukin-6 (IL-6) levels, erythrocyte sedimentation rate (ESR), serum amyloid A levels, and serum ferritin levels. Optionally, in vivo assays can be characterized as "standard in vivo assays" herein, and can be optionally performed using the conditions outlined in Examples 2 and 3 of the application.

[0642] In some cases, the increased tolerability is an increase of at least 20% over the tolerability of the administered dose unit as measured by testing in a standard in vivo assay, an increase of at least 25% over the tolerability of the administered dose unit as measured by testing in a standard in vivo assay, an increase of at least 30% over the tolerability of the administered dose unit as measured by testing in a standard in vivo assay, an increase of at least 35% over the tolerability of the administered dose unit as measured by testing in a standard in vivo assay, an increase of at least 40% over the tolerability of the administered dose unit as measured by testing in a standard in vivo assay, an increase of at least 45% over the tolerability of the administered dose unit as measured by testing in a standard in vivo assay, an increase of at least 50% over the tolerability of the administered dose unit as measured by testing in a standard in vivo assay, an increase of at least 10% over the tolerability of the administered dose unit as measured by testing in a standard in vivo assay, An increase of at least 55% over the tolerability of the administered dose unit as measured by testing in a standard in vivo assay, an increase of at least 60% over the tolerability of the administered dose unit as measured by testing in a standard in vivo assay, an increase of at least 65% over the tolerability of the administered dose unit as measured by testing in a standard in vivo assay, an increase of at least 70% over the tolerability of the administered dose unit as measured by testing in a standard in vivo assay, an increase of at least 75% over the tolerability of the administered dose unit as measured by testing in a standard in vivo assay, an increase of at least 80% over the tolerability of the administered dose unit as measured by testing in a standard in vivo assay, an increase of at least 85% over the tolerability of the administered dose unit as measured by testing in a standard in vivo assay, an increase of at least 90% over the tolerability of the administered dose unit as measured by testing in a standard in vivo assay, or an increase of at least 95% over the tolerability of the administered dose unit as measured by testing in a standard in vivo assay.

[0643] Optionally, the therapeutic dosage unit of the mRNA molecule comprises less than 6.9 ng / μg of double-stranded RNA (dsRNA), less than 6.8 ng / μg of double-stranded RNA (dsRNA), less than 6.7 ng / μg of double-stranded RNA (dsRNA), less than 6.6 ng / μg of double-stranded RNA (dsRNA), less than 6.5 ng / μg of double-stranded RNA (dsRNA), less than 6.4 ng / μg of double-stranded RNA (dsRNA), less than 6.3 ng / μg of double-stranded RNA (dsRNA), less than 6.2 ng / μg of double-stranded RNA (dsRNA), less than 6.1 ng / μg of double-stranded RNA (dsRNA), less than 6.0 ng / μg of double-stranded RNA (dsRNA). / μg of double-stranded RNA (dsRNA), less than 5.9ng / μg of double-stranded RNA (dsRNA), less than 5.8ng / μg of double-stranded RNA (dsRNA), less than 5.7ng / μg of double-stranded RNA (dsRNA), less than 5.6ng / μg of double-stranded RNA (dsRNA), less than 5.5ng / μg of double-stranded RNA (dsRNA), less than 5.4ng / μg of double-stranded RNA (dsRNA), less than 5.3ng / μg of double-stranded RNA (dsRNA), less than 5.2ng / μg of double-stranded RNA (dsRNA), less than 5.1ng / μg of double-stranded RNA (dsRNA), less than 5.0ng / μg of double-stranded RNA NA(dsRNA), less than 4.9ng / μg double-stranded RNA(dsRNA), less than 4.8ng / μg double-stranded RNA(dsRNA), less than 4.7ng / μg double-stranded RNA(dsRNA), less than 4.6ng / μg double-stranded RNA(dsRNA), less than 4.5ng / μg double-stranded RNA(dsRNA), less than 4.4ng / μg double-stranded RNA(dsRNA), less than 4.3ng / μg double-stranded RNA(dsRNA), less than 4.2ng / μg double-stranded RNA(dsRNA), less than 4.1ng / μg double-stranded RNA(dsRNA), less than 4.0ng / μg double-stranded RNA(dsRNA A), less than 3.9 ng / μg of double-stranded RNA (dsRNA), less than 3.8 ng / μg of double-stranded RNA (dsRNA), less than 3.7 ng / μg of double-stranded RNA (dsRNA), less than 3.6 ng / μg of double-stranded RNA (dsRNA), less than 3.5 ng / μg of double-stranded RNA (dsRNA), less than 3.4 ng / μg of double-stranded RNA (dsRNA), less than 3.3 ng / μg of double-stranded RNA (dsRNA), less than 3.2 ng / μg of double-stranded RNA (dsRNA), less than 3.1 ng / μg of double-stranded RNA (dsRNA), less than 3.0 ng / μg of double-stranded RNA (dsRNA), less than 2.9ng / μg double-stranded RNA (dsRNA), less than 2.8ng / μg double-stranded RNA (dsRNA), less than 2.7ng / μg double-stranded RNA (dsRNA), less than 2.6ng / μg double-stranded RNA (dsRNA), less than 2.5ng / μg double-stranded RNA (dsRNA), less than 2.4ng / μg double-stranded RNA (dsRNA), less than 2.3ng / μg double-stranded RNA (dsRNA), less than 2.2ng / μ g of double-stranded RNA (dsRNA), less than 2.1ng / μg of double-stranded RNA (dsRNA), less than 2.0ng / μg of double-stranded RNA (dsRNA), less than 1.9ng / μg of double-stranded RNA (dsRNA), less than 1.8ng / μg of double-stranded RNA (dsRNA), less than 1.7ng / μg of double-stranded RNA (dsRNA), less than 1.6ng / μg of double-stranded RNA (dsRNA), less than 1.5 ...8ng / μg of double-stranded RNA (dsRNA), less than 1.7ng / μg of double-stranded RNA (dsRNA), less than 1.6ng / μg of double-stranded RNA (dsRNA), less than 0.4 ng / μg of double-stranded RNA (dsRNA), less than 0.3 ng / μg of double-stranded RNA (dsRNA), less than 0.2 ng / μg of double-stranded RNA (dsRNA), less than 0.1 ng / μg of double-stranded RNA (dsRNA), less than 0.1 ng / μg of double-stranded RNA (dsRNA), less than 0.9 ng / μg of double-stranded RNA (dsRNA), less than 0.8 ng / μg of double-stranded RNA (dsRNA), less than 0.7 ng / μg of double-stranded RNA (dsRNA), less than 0.6 ng / μg of double-stranded RNA (dsRNA), less than 0.5 ng / μg of double-stranded RNA (dsRNA), less than 0.4 ng / μg of double-stranded RNA (dsRNA), less than 0.3 ng / μg of double-stranded RNA (dsRNA), less than 0.2 ng / μg of double-stranded RNA (dsRNA), or less than 0.1 ng / μg of double-stranded RNA (dsRNA). .

[0644] Also described herein are methods for increasing the in vivo translation of a polypeptide in a subject. The method comprises administering to the subject a therapeutic dosage unit comprising an effective amount of an mRNA encoding a polypeptide, wherein the mRNA comprises a 5'-cap having a formula according to any compound as described herein.

[0645] In some examples, the method comprises administering to the subject a therapeutic dosage unit comprising an effective amount of mRNA encoding a polypeptide, wherein the mRNA comprises a polypeptide having the formula m7 G 3'OMe pppA 1 2'OMe G'-cap, and wherein A 1It is adenosine, N6-methyladenosine, N6,N6-dimethyladenosine. 1 Can optionally include an LNA portion. Method for increasing polypeptide translation in a subject m7 G 3'OMe pppA 1 2'OMe The G compound may include one or more of the following compounds:

[0646] m7 G 3'OMe pppA 2'OMe pG:

[0647]

[0648] m7 G 3'OMe ppp m6 A 2'OMe pG:

[0649]

[0650] m7 G 3'OMe pppA 2',4'-LNA pG:

[0651]

[0652] m7 G 3'OMe ppp (diaminopurine) 2'OMe pG:

[0653]

[0654] According to the methods described herein, the therapeutic dosage unit administered is at least 20% lower than the therapeutic dosage unit required to elicit the same response in the subject when a control mRNA encoding the polypeptide is administered, wherein the control mRNA comprises a polypeptide having the formula m7 GpppA 1 2'OMe G's 5'-cap, where A 1 It is adenosine, N6-methyladenosine, 6,6-dimethyladenosine. 1 Optionally, an LNA moiety may be included. m7 GpppA 1 2'OMe The G compound may include one or more of the following compounds:

[0655] m7 GpppA 2'OMe pG:

[0656]

[0657] m7 Gppp m6 A 2'OMe pG:

[0658]

[0659] m7 GpppA 2',4'-LNA pG:

[0660]

[0661] m7 Gppp (diaminopurine) 2'OMe pG:

[0662]

[0663] You can choose control mRNA m7 GpppA 1 2'OMe G compound, such that the compound is administered m7 G 3' OMe pppA 1 2'OMe G, except that the control mRNA was m7 The G nucleotide lacks the 3'OMe moiety.

[0664] As described above, the therapeutic dosage unit administered can be at least 20% lower, at least 30% lower, at least 40% lower, at least 50% lower, at least 60% lower, at least 70% lower, at least 80% lower, at least 90% lower, or at least 95% lower than the therapeutic dosage unit required to elicit the same response in a subject when a control mRNA encoding the polypeptide is administered.

[0665] The subject may exhibit increased tolerance to the administered therapeutic dose unit as compared to the therapeutic dose unit required to elicit the same response in the subject when the control mRNA is administered, as measured by testing in a standard in vivo assay as described above, such as by using the conditions described in the Examples herein.

[0666] Optionally, the increased tolerability is an increase of at least 20% over the tolerability of the administered therapeutic dose unit as measured by testing in a standard in vivo assay, an increase of at least 25% over the tolerability of the administered therapeutic dose unit as measured by testing in a standard in vivo assay, an increase of at least 30% over the tolerability of the administered therapeutic dose unit as measured by testing in a standard in vivo assay, an increase of at least 35% over the tolerability of the administered therapeutic dose unit as measured by testing in a standard in vivo assay, an increase of at least 40% over the tolerability of the administered therapeutic dose unit as measured by testing in a standard in vivo assay, an increase of at least 45% over the tolerability of the administered therapeutic dose unit as measured by testing in a standard in vivo assay, an increase of at least 50% over the tolerability of the administered therapeutic dose unit as measured by testing in a standard in vivo assay, an increase of at least 10% over the tolerability of the administered therapeutic dose unit as measured by testing in a standard in vivo assay At least 55% increase in tolerability over the administered therapeutic dose unit as measured by testing in a standard in vivo assay, at least 60% increase in tolerability over the administered therapeutic dose unit as measured by testing in a standard in vivo assay, at least 65% increase in tolerability over the administered therapeutic dose unit as measured by testing in a standard in vivo assay, at least 70% increase in tolerability over the administered therapeutic dose unit as measured by testing in a standard in vivo assay, at least 75% increase in tolerability over the administered therapeutic dose unit as measured by testing in a standard in vivo assay, at least 80% increase in tolerability over the administered therapeutic dose unit as measured by testing in a standard in vivo assay, at least 85% increase in tolerability over the administered therapeutic dose unit as measured by testing in a standard in vivo assay, at least 90% increase in tolerability over the administered therapeutic dose unit as measured by testing in a standard in vivo assay, or at least 95% increase in tolerability over the administered therapeutic dose unit as measured by testing in a standard in vivo assay.

[0667] In some cases, the administered therapeutic mRNA dosage unit comprises less than 6.9 ng / μg of double-stranded RNA (dsRNA), less than 6.8 ng / μg of double-stranded RNA (dsRNA), less than 6.7 ng / μg of double-stranded RNA (dsRNA), less than 6.6 ng / μg of double-stranded RNA (dsRNA), less than 6.5 ng / μg of double-stranded RNA (dsRNA), less than 6.4 ng / μg of double-stranded RNA (dsRNA), less than 6.3 ng / μg of double-stranded RNA (dsRNA), less than 6.2 ng / μg of double-stranded RNA (dsRNA), less than 6.1 ng / μg of double-stranded RNA (dsRNA), less than 6.0 ng / μg of double-stranded RNA (dsRNA), less than 5.9ng / μg of double-stranded RNA (dsRNA), less than 5.8ng / μg of double-stranded RNA (dsRNA), less than 5.7ng / μg of double-stranded RNA (dsRNA), less than 5.6ng / μg of double-stranded RNA (dsRNA), less than 5.5ng / μg of double-stranded RNA (dsRNA), less than 5.4ng / μg of double-stranded RNA (dsRNA), less than 5.3ng / μg of double-stranded RNA (dsRNA), less than 5.2ng / μg of double-stranded RNA (dsRNA), less than 5.1ng / μg of double-stranded RNA (dsRNA), less than 5.0ng / μg of double-stranded RNA (dsRNA), less than 4.9 ng / μg double-stranded RNA (dsRNA), less than 4.8 ng / μg double-stranded RNA (dsRNA), less than 4.7 ng / μg double-stranded RNA (dsRNA), less than 4.6 ng / μg double-stranded RNA (dsRNA), less than 4.5 ng / μg double-stranded RNA (dsRNA), less than 4.4 ng / μg double-stranded RNA (dsRNA), less than 4.3 ng / μg double-stranded RNA (dsRNA), less than 4.2 ng / μg double-stranded RNA (dsRNA), less than 4.1 ng / μg double-stranded RNA (dsRNA), less than 4.0 ...0 NA), less than 3.9ng / μg double-stranded RNA (dsRNA), less than 3.8ng / μg double-stranded RNA (dsRNA), less than 3.7ng / μg double-stranded RNA (dsRNA), less than 3.6ng / μg double-stranded RNA (dsRNA), less than 3.5ng / μg double-stranded RNA (dsRNA), less than 3.4ng / μg double-stranded RNA (dsRNA), less than 3.3ng / μg double-stranded RNA (dsRNA), less than 3.2ng / μg double-stranded RNA (dsRNA), less than 3.1ng / μg double-stranded RNA (dsRNA), less than 3.0ng / μg double-stranded RNA (dsRNA), less than 2.9ng / μg double-stranded RNA (dsRNA), less than 2.8ng / μg double-stranded RNA (dsRNA), less than 2.7ng / μg double-stranded RNA (dsRNA), less than 2.6ng / μg double-stranded RNA (dsRNA), less than 2.5ng / μg double-stranded RNA (dsRNA), less than 2.4ng / μg double-stranded RNA (dsRNA), less than 2.3ng / μg double-stranded RNA (dsRNA), less than 2.2ng / μ g of double-stranded RNA (dsRNA), less than 2.1ng / μg of double-stranded RNA (dsRNA), less than 2.0ng / μg of double-stranded RNA (dsRNA), less than 1.9ng / μg of double-stranded RNA (dsRNA), less than 1.8ng / μg of double-stranded RNA (dsRNA), less than 1.7ng / μg of double-stranded RNA (dsRNA), less than 1.6ng / μg of double-stranded RNA (dsRNA), less than 1.5 ...8ng / μg of double-stranded RNA (dsRNA), less than 1.7ng / μg of double-stranded RNA (dsRNA), less than 1.6ng / μg of double-stranded RNA (dsRNA), less than 0.4 ng / μg of double-stranded RNA (dsRNA), less than 0.3 ng / μg of double-stranded RNA (dsRNA), less than 0.2 ng / μg of double-stranded RNA (dsRNA), less than 0.1 ng / μg of double-stranded RNA (dsRNA), less than 0.1 ng / μg of double-stranded RNA (dsRNA), less than 0.9 ng / μg of double-stranded RNA (dsRNA), less than 0.8 ng / μg of double-stranded RNA (dsRNA), less than 0.7 ng / μg of double-stranded RNA (dsRNA), less than 0.6 ng / μg of double-stranded RNA (dsRNA), less than 0.5 ng / μg of double-stranded RNA (dsRNA), less than 0.4 ng / μg of double-stranded RNA (dsRNA), less than 0.3 ng / μg of double-stranded RNA (dsRNA), less than 0.2 ng / μg of double-stranded RNA (dsRNA), or less than 0.1 ng / μg of double-stranded RNA (dsRNA). .

[0668] VI. Kit

[0669] Also provided herein is a kit for transcription. The kit may include any compound or composition described herein. For example, the kit may include one or more compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX, formula X, formula XI and / or formula XII. The kit may further include one or more additional reagents, such as reagents for RNA synthesis. Optionally, the kit may contain a compound as described herein (also referred to herein as a cap analog), a container and one or more reagents selected from one or more unmodified NTPs, one or more modified NTPs, RNA polymerase, reaction buffer, magnesium and DNA template. The kit may additionally include instructions for use of the kit (e.g., instructions for RNA synthesis), tools (e.g., syringes) and / or carriers for administering transcribed mRNA.

[0670] Example

[0671] Example 1: Compound Synthesis

[0672] The compounds described herein are prepared using the general procedures outlined below. The structures depicted herein may represent a specific isomer (e.g., a diastereomer). However, as described above, the structures depicted may represent a mixture of isomers. For example, thiolated compounds as described herein (e.g., Compound 3, Compound 6, Compound 9, Compound 13, Compound 18, Compound 19, Compound 20, Compound 21, and Compound 74) include two diastereomers. In some cases, the two diastereomers are separated and tested separately (as indicated in the examples below). However, unless otherwise stated, the diastereomers are not separated before testing.

[0673] Synthesis of compounds according to formula I, II, IV, VI, VIII, IX, X and XI

[0674] Compounds according to formula I, II, IV and VI terminated with a guanosine nucleotide are prepared according to the general method shown in Scheme 1. Compounds according to formula VIII (wherein the position corresponding to R2 in Scheme 1 can be OCH3) and compounds according to formula IX, X and XI are prepared similarly.

[0675] Scenario 1:

[0676]

[0677] General procedure 1:

[0678] To a stirred solution of N7-Me-GDP 1 (triethylammonium (TEA) salt, 1.5 mol equivalents of pApG dinucleotide 2) in 10% water / DMSO solution (10 mL per gram of N7-Me-GDP 1) at room temperature, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC.HCl salt; 2.4 mol equivalents of pApG dinucleotide 2) was added, followed by imidazole (4.5 mol equivalents of pApG dinucleotide 2). The resulting mixture was stirred at room temperature overnight (approximately 16-24 hours). The next day, magnesium chloride (3.15 M in water, 2.0 mol equivalents of pApG dinucleotide 2) was added to the above solution, followed by pApG dinucleotide 2 (TEA salt, 1 mol equivalent). The resulting solution was stirred at room temperature overnight (approximately 16 to 24 hours). The crude reaction mixture was then diluted 10x with water and purified by anion exchange chromatography (Fast Flow Q Sepharose (QFF) resin, 20% acetonitrile in water as buffer A, 1.5 M trimethylamine acetate (TEAA) in water as buffer B, 4 column volumes (CV) using a linear gradient from 25% to 45% buffer B, 1.5 CV hold at 45%). The desired products were combined and concentrated under vacuum, and the final product was precipitated as a sodium salt with sodium acetate and 95% anhydrous ethanol in water.

[0679] The synthesis of the following compounds followed the procedures described above and depicted in Scheme 1.

[0680] m7 Gppp m6 A 2'OMe pG (Compound 31):

[0681]

[0682] The compound shown above m7 Gppp m6 A 2'OMepG (Compound 31) was synthesized from N7-Me-GDP (0.40 g, 0.75 mmol), EDC (0.19 g, 0.975 mmol) and imidazole (0.07 g, 1.0 mmol) in 4.88 ml of 10% water in DMSO, 3.15 M magnesium chloride (0.32 mL, 1 mmol) and p(m6)ApG (0.46 g, 0.5 mmol) as described according to General Procedure 1. A solid product (0.421 g) was obtained (yield: 68.6%). NMR(500MHz,D2O)δ8.25(s,1H),7.99(s,1H),7.88(s,1H),5.96(d,J=5.2Hz,1H),5.80(d,J=3.5Hz,1H),5.78(d,J=5.3Hz,1H),4.87-4.91(m ,1H),4.66-4.68(m,1H),4.45-4.49(m,3H),4.38-4.41(m,3H),4.28-4 .36(m,4H),4.17-4.25(m,4H),3.97(s,3H),3.46(s,3H),2.98(s,3H). 31 P NMR(200MHz,D2O)0.38(s,1P),-10.85(d,J=12.1,1P),-10.94(d,J=12.1,1P),-22.22(t,J=18.2,1P). MS m / z=1159.2.

[0683] m7 G 3'Ome ppp m6 A 2'OMe pG (Compound 30):

[0684]

[0685] The compound shown above m7 G 3'Ome ppp m6 A 2'OMe pG (Compound 30) was synthesized from N7-Me-3'-Ome-GDP (2.86 g, 4.5 mmol), EDC (1.12 g, 5.85 mmol) and imidazole (0.41 g, 6.0 mmol) in 28.6 ml of 30% water in DMSO, 3.15 M magnesium chloride (1.90 mL, 6.0 mmol) and p(m6)ApG (2.76 g, 3.0 mmol) as described according to General Procedure 1. 3.092 g of solid product was obtained (yield: 83%). 1H NMR(500MHz,D2O)δ8.30(s,1H),8.09(s,1H),7.94(s,1H),6.00(d,J=5.5Hz,1H),5.80-5.83(m,2H),4.91-4.94(m,1H),4.65-4.66 (m,1H),4.49-4.52(m,2H),4.36-4.42(m,5H),4.18-4.33(m,4H),4.08-4.10(m,1H),4.01(s,3H),3.48-3.47(m,6H),3.08(s,3H). 31 P NMR (200MHz, D2O) 0.38 (s, 1P), -10.96 (d, J = 4.0, 1P), - 11.04 ( d, J = 8.1, 1P), - 22.27 ( t, J = 18.2, 1P). MS m / z=1173.2.

[0686] m7 GpppA 2',4'-LNA pG (Compound 1):

[0687]

[0688] Compound 1 was synthesized from N7-Me-GDP (0.30 g, 0.49 mmol), EDC (0.151 g, 0.79 mmol) and imidazole (0.101 g, 1.48 mmol) in 3.0 ml of 10% water in DMSO, magnesium chloride (62.4 mg in 0.21 mL water, 0.66 mmol) and p(LNA)ApG (0.298 g, 0.328 mmol) as described according to General Procedure 1. A solid product (0.283 g) was obtained (yield: 71%). 1 H NMR (500MHz, D2O): δ8.07(s,1H),7.95(s,1H),7.75(s,1H),5.85(d,J=4.2H z, 1H), 5.69 (d, J = 5.5Hz, 2H), 4.69 (m, 1H), 4.53-4.28 (m, 15H), 4.08 (s, 3H). 31 P NMR (200MHz, D2O): δ-1.47(1P),-10.98(2P),-22.41(1P). MS(ESI)C 32 H 42 N 15 O 24 Calculated value of P4: 1144.66, experimental value: 1142.9 [MH] - .

[0689] m7G 3'Ome pppA 2',4'-LNA pG (Compound 2):

[0690]

[0691] Compound 2 was synthesized from N7-Me-3'-Ome-GDP (0.30 g, 0.459 mmol), EDC (0.141 g, 0.734 mmol) and imidazole (0.0938 g, 1.377 mmol) in 3.0 ml of 10% water in DMSO, magnesium chloride (58.3 mg in 0.19 mL water, 0.612 mmol) and p(LNA)ApG (0.277 g, 0.306 mmol) as described according to General Procedure 1. A solid product (0.2573 g) was obtained (yield: 69%). 1 H NMR (500MHz, D2O): δ8.06 (s, 1H). 7.95(s,1H),7.75(s,1H),5.82(d,J=4.7Hz,1H),5.68(m,2H),4.90(m,1H),4.69-4.11(m,13H),4.09(s,3H),3.49(s,3H). 31 P NMR (200MHz, D2O): δ-1.46(1P),-10.98(2P),-22.30(1P). MS(ESI)C 33 H 44 N 15 O 24 Calculated value of P4: 1158.69, experimental value: 1156.4 [MH] - .

[0692] m7 GpppA 2'-4'-LNA p(s)G (Compound 3):

[0693]

[0694] Compound 3 was synthesized from N7-Me-GDP (0.2 g, 0.327 mmol), EDC (0.1 g, 0.523 mmol) and imidazole (0.067 g, 0.981 mmol) in 2.0 ml of 10% water in DMSO, magnesium chloride (50.9 mg, 0.536 mmol) and p(LNA)Ap(s)G (0.2 g, 0.218 mmol) as described according to General Procedure 1. A solid product (149.5 mg) was obtained (yield: 56%). Both diastereomers were purified by RP-HPLC, and the NMR / MS data are shown below.

[0695] m7 GpppA 2'-4'-LNA p(s)G:D1

[0696] Final yield -137.3 μmol; NMR (500 MHz, D2O) δ8.12 (s, 1H), 7.98 (s, 1H), 7.83 (s, 1H), 5.86 (d, J = 4.1, 1H), 5.76 (s, 1H), 5.72 (d, J = 4.6, 1H), 4.97 (s, 2H), 4.49-4.57 (m, 3H), 4.40-4.48 (m, 5H), 4.15-4.36 (m, 8H), 4.08 (s, 3H); 31P NMR (200 MHz, D2O) 55.13 (1P), -11.02 (2P), -22.39 (1P), MS m / z = 1159.8 (MH).

[0697] m7 GpppA 2'-4'-LNA p(s)G:D2

[0698] Final yield -130.4 μmol; NMR (500 MHz, D2O) δ8.11 (s, 1H), 7.95 (s, 1H), 7.86 (s, 1H), 5.84 (d, J = 4.2, 1H), 5.68 (m, 2H), 4.90 (m, 2H), 4.50-4.57 (m, 3H), 4.41-4.46 (m, 3H), 4.25-4.33 (m, 6H), 4.13-4.19 (m, 2H), 4.09 (s, 3H); 31P NMR (200 MHz, D2O) 56.19 (1P), -11.00 (2P), -22.42 (1P), MS m / z = 1157.9 (MH).

[0699] m7 GpppA 2'OMe-5'乙烯基 pG (Compound 4):

[0700]

[0701] Compound 4 was synthesized from N7-Me-GDP (0.0716 g, 0.117 mmol), EDC (0.0358 g, 0.187 mmol) and imidazole (0.024 g, 0.351 mmol) in 0.7 ml of 10% water in DMSO, 3.15 M magnesium chloride (0.05 mL, 0.156 mmol) and 5'-vinylphosphonate AG (0.07 g, 0.078 mmol) as described according to General Procedure 1. A solid product (67 mg) was obtained (yield: 71%). 1H NMR (500MHz, D2O): δ8.26(s,1H),8.11(s,1H),7.92(s,1H),6.62(m,1H),6.21(t,J=17.6Hz,1H) ,6.00(d,J=5.9Hz,1H),5.79(m,2H),4.54-4.35(m,7H),4.16(m,3H),4.02(s,3H),3.39(s,3H). 31 P NMR (200MHz, D2O): δ3.74(1P), -0.40(1P), -10.94(2P), -22.36(1P). MS(ESI)C 33 H 43 N 15 O 23 Calculated value of P4: 1141.68, experimental value: 1140.7 [MH] - .

[0702] m7 G 3'-Ome pppA 2'OMe-5'乙烯基 pG (Compound 5):

[0703]

[0704] Compound 5 was synthesized from N7-Me-3'-Ome-GDP (0.076 g, 0.117 mmol), EDC (0.0358 g, 0.187 mmol) and imidazole (0.024 g, 0.351 mmol) in 0.7 ml of 10% water in DMSO, 3.15 M magnesium chloride (0.05 mL, 0.156 mmol) and 5'-vinylphosphonate AG (0.07 g, 0.078 mmol) as described according to General Procedure 1. A solid product (70 mg) was obtained (yield: 73%). 1 H NMR (500MHz, D2O): δ8.27(s,1H),8.11(s,1H),7.93(s,1H),6.62(m,1H),6.21(t,J=17.5Hz,1H),6.00(d,J=5.9Hz,1H),5.82(d,J=5.45Hz,1H),5. 71(d,J=4.25Hz,1H),4.64(m,1H),4.48(m,1H),4.43(m,1H),4.35-4.23( m,3H),4.15(m,3H),4.08(m,1H),4.02(s,3H),3.46(s,3H),3.40(s,3H). 31P NMR (200MHz, D2O): δ3.85(1P), -0.39(1P), -10.91(2P), -22.30(1P). MS(ESI)C 34 H 45 N 15 O 23 Calculated value of P4: 1155.71, experimental value: 1155.5 [MH] - .

[0705] m7 GpppA 2'F p(s)G (Compound 6):

[0706]

[0707] Compound 6 was prepared as described according to General Procedure 1 from N7-Me-GDP (0.2 g, 0.327 mmol), EDC (0.100 g, 0.523 mmol) and imidazole (0.067 g, 0.981 mmol) in 2.0 ml of 10% water in DMSO, magnesium chloride (50.9 mg, 0.536 mmol) and pA 2'F p(s)G (0.198 g, 0.218 mmol) was synthesized. A solid product (155 mg) was obtained (yield: 62%). The two diastereomers were purified by RP-HPLC, and the NMR / MS data are shown below.

[0708] m7 GpppA 2'F p(s)G:D1

[0709] Final yield -24.4 μmol; NMR (500 MHz, D2O) δ8.24 (s, 1H), 7.99 (s, 1H), 7.81 (s, 1H), 6.09 (d, J = 15.9 Hz, 1H), 5.88 (d, J = 3.9 Hz, 1H), 5.70 (d, J = 6.5 Hz, 1H), 5.49-5.38 (m, 1H), 5.05-5.01 (m, 1H), 5.56 (t, J = 4.5 Hz, 2H), 4.49-4.33 (m, 7H), 4.26-4.20 (m, 4H), 4.04 (s, 3H).

[0710] 31P NMR (200MHz, D2O) 55.72(1P), -10.93(1P), -10.05(1P), -22.40(1P), MS m / z=1149.0(MH).

[0711] m7 GpppA 2'Fp(s)G:D2

[0712] Final yield -29.8 μmol; NMR (500 MHz, D2O) δ8.24 (s, 1H), 7.99 (s, 1H), 7.86 (s, 1H), 6.10 (d, J = 16.0 Hz, 1H), 5.88 (d, J = 3.9 Hz, 1H), 5.70 (d, J = 5.5 Hz, 1H), 5.42-5.31 (m, 1H), 5.07-4.99 (m, 1H), 4.57-4.44 (m, 6H), 4.42-4.21 (m, 7H), 4.19-4.16 (m, 1H), 4.04 (s, 3H).

[0713] 31P NMR (200MHz, D2O) 57.23 (1P), -10.97 (2P), -22.38 (1P), MS m / z=1148.8 (MH).

[0714] m7 Gppp (diaminopurine) 2'OMe pG (Compound 7):

[0715]

[0716] Compound 7 was synthesized from N7-Me-GDP (0.219 g, 0.358 mmol), EDC (0.11 g, 0.574 mmol) and imidazole (0.073 g, 1.076 mmol) in 2.2 ml of 10% water in DMSO, 3.15 M magnesium chloride (0.15 mL, 0.478 mmol) and DAP-G (0.22 g, 0.239 mmol) as described according to General Procedure 1. 191 mg of solid product was obtained (yield: 65%). 1 H NMR (500MHz, D2O): δ8.02(s,1H),7.98(s,1H),5.82(m,3H),4.90(m,1H),4.55(m,1H),4.52-4.20(m,13H),4.01(s,3H),3.45(s,3H). 31 P NMR (200MHz, D2O): δ-0.35(1P),-10.84(2P),-22.32(1P).

[0717] m7 G 3'Ome ppp (diaminopurine) 2'OMe pG (Compound 8):

[0718]

[0719] Compound 8 was synthesized from N7-Me-3'-Ome-GDP (0.233 g, 0.358 mmol), EDC (0.11 g, 0.574 mmol) and imidazole (0.073 g, 1.076 mmol) in 2.2 ml of 10% water in DMSO, 3.15 M magnesium chloride (0.15 mL, 0.478 mmol) and DAP-G (0.22 g, 0.239 mmol) as described according to General Procedure 1. A solid product (202 mg) was obtained (yield: 68%). 1 H NMR(500MHz,D2O): δ8.02(s,1H),7.98(s,1H),5.82(m,3H),4.93(m,1H),4.69( m,1H),4.49(m,1H),4.42-4.10(m,11H),3.68(s,3H),3.48(s,3H),3.46(s,3H). 31 P NMR (200MHz, D2O): δ-0.34(1P),-10.94(2P),-22.28(1P).

[0720] m7 G 3'OMe ppp (diaminopurine) 2'OMe p(s)G (Compound 9):

[0721]

[0722] Compound 9 was synthesized from N7-Me-3'-OMe-GDP (0.201 g, 0.327 mmol), EDC (0.100 g, 0.523 mmol) and imidazole (0.067 g, 0.981 mmol) in 2.0 ml of 10% water in DMSO, magnesium chloride (50.9 mg, 0.536 mmol) and pDAPm p(s)G (0.204 g, 0.218 mmol) as described according to General Procedure 1. The obtained solid product (65.4 mg) was obtained after anion exchange (Fast Flow Q Sepharose) and anion exchange (High Performance Q Sepharose) purification (yield: 25.2%). 1 H NMR (500MHz, D2O): δ8.05(s,1H),8.01-8.00(m,2H),5.86-5.79(m,3H),5.11-5.06(m,1H),4.64(t,J=4. 5Hz, 1H), 4.52-4.15 (m, 11H), 4.08-4.05 (m, 1H), 4.02 (d, J = 8.25Hz, 3H), 3.46-3.44 (m, 4H), 3.40 (s, 2H). 31P NMR(200MHz,D2O): δ56.76(1P),56.06(1P), -11.09(4P), -22.49(2P). MS m / z=1189.8(MH)

[0723] m7 G 3'Ome pppA 2'OMe p(s)G (Compound 21):

[0724]

[0725] Compound 21 (two diastereomers) was synthesized as described according to General Procedure 1. As shown below, the two diastereomers were prepared from pA(ps)G dinucleotides, which were prepared as a mixture of two diastereomers D1 and D2 (the chiral P atoms that produce D1 and D2 diastereomers are indicated by asterisks in the structures below). The diastereomers were separated by reverse phase chromatography using a Daisogel 150 x 20 mm SP-100-15-ODS-P column (Torrance, CA) under the following separation conditions: Buffer A: 100 mM triethylammonium bicarbonate (TEAB), Buffer B: acetonitrile (ACN). Gradient: 0% B x 1.5 column volumes (CV), 0-12.5% ​​B x 10CV. The D1 diastereomer (referred to as pA(ps)G D1) eluted first from the reverse phase column and the D2 diastereomer (referred to as pA(ps)GD2) eluted second from the reverse phase column. The final diastereomeric purity of each diastereomer was >99%.

[0726]

[0727] The obtained diastereomers of Compound 21 were designated as Compound 21D1 and Compound 21D2.

[0728] Compound 21D1 was synthesized from N7-Me-3'-OMe-GDP (0.119 g, 0.202 mmol), EDC (0.05 g, 0.262 mmol) and imidazole (0.018 g, 0.269 mmol) in 6.6 ml of 10% DMSO solution in water, magnesium chloride (0.085 mL, 0.269 mmol) and pA(ps)G D1 (0.1346 g, 0.134 mmol). The resulting compound was isolated and collected as a solid product (61.7 mg; yield: 37%). 1H NMR(500MHz,D2O)δ8.38(s,1H),8.12(s,1H),8.05(s,1H),6.00(d,J=6.0Hz,1 H),5.86(d,J=5.9Hz,1H),5.83(d,J=4.3Hz,1H),5.11-5.08(m,1H),4.82-4.73 (m,1H),4.56-4.52(m,2H),4.48(t,J=5.5Hz,1H),4.38-4.35(m,3H),4.32-4. 23(m,4H),4.20-4.17(m,1H),4.10(t,J=4.6Hz,1H),4.03(s,3H),3.47(m,6H). 31P NMR (200 MHz, D2O) 56.05 (s, 1P), -11.01, -11.10 (overlapping doublets, 2P), -22.33 (t, J=18.2, 1P). MS m / z=1173.8 (MH).

[0729] Use pA (ps) G D2 to repeat the method to isolate compound 21D2. Specifically, use N7-Me-3'-OMe-GDP (0.187g, 0.317mmol), EDC (0.079g, 0.413mmol) and imidazole (0.029g, 0.423mmol) in 1.87ml 10% DMSO solution in water, magnesium chloride (0.134mL, 0.423mmol) and pA (ps) G D2 (0.2173g, 0.212mmol) to perform synthesis. Obtain solid product (0.124mg) (yield: 47%). NMR(500MHz,D2O)δ8.38(s,1H),8.11(s,1H),8.01(s,1H),6.03(d,J=5.8Hz,1H),5.84(m,2H),5.08-5.06(m,1H),4.66(m,1H),4.58(m,2H ),4.52-4.50(t,J=4.9Hz,1H),4.45-4.43(T,J=5.4Hz,1H),4.40-4.20(m,8H),4.11-4.09(m,1H),4.04(s,3H),3.47(s,3H),3.44(m,3H). 31P NMR (200 MHz, D2O) 56.68 (s, 1P), -10.98, -11.07 (overlapping doublets, 2P), -22.29 (t, J=20.2, 1P). MS m / z=1174.0 (MH).

[0730] m7 G 2'OMe3'OMe pppA 2'OMe pG (Compound 25):

[0731]

[0732] Compound 25 was prepared as described according to General Procedure 1 from N-7-Me-2',3'-di-OMe-GDP (0.5 g, 0.36 mmol), EDC (0.12 g, 0.6 mmol) and imidazole (0.10 g, 1.4 mmol) in 5 mL of 30% water in DMSO, magnesium chloride (0.12 mL of a 3.15 MgCl2 solution, 0.48 mmol) and pA 2'OMe pG (0.2 g, 0.24 mmol) was used to synthesize the product, and a solid product (0.16 g) was obtained (yield: 57%). 1H NMRδ8.32(s,1),8.06(s,1),7.92(s,1),5.94(d,1,J=10Hz),5.80(d,1,J=10Hz),5.79(d,1,J=10Hz),4.89(m,1), 4.47(m,2),4.37(t,1,J=5Hz),4.33(m,4),4.24(m,2),4.14(m,4),4.02(s,3),3.48(s,3),3.42(s,3),3.40(s,3). 31Pδ-0.42(1P),-11.12(2P),-22.43(1P); MS m / z=1172.0(MH).

[0733] m7 G 2'OMe pppA 2'OMe pG (Compound 26):

[0734]

[0735] Compound 26 was prepared as described according to General Procedure 1 from N-7-Me-2'-OMe-GDP (0.20 g, 3 mmol), EDC (0.091 g, 0.47 mmol) and imidazole (0.06 g, 0.89 mmol) in 2.2 mL of 10% water in DMSO, magnesium chloride (0.13 mL of a 3.15 MgCl2 solution, 0.42 mmol) and pA 2'OMe pG (0.19 g, 0.21 mmol) was used to synthesize. A solid product (0.21 g) was obtained (yield: 78%). 1H NMR δ 8.34 (s, 1H), 8.09 (s, 1H), 7.92 (s, 1H), 5.96 (d, 1H, J = 9 Hz), 5.86 (d, 1H, J = 5 Hz), 5.80 (d, 1H, J = 9 Hz), 4.90 (m, 1H), 4.51 (d, 1H, J = 5 Hz), 4.48 (m, 2H), 4.38 (m, 2H), 4.33 (m, 1H), 4.27 (m, 2H), 4.23-4.16 (m, 5H), 4.02 (s, 3H), 3.52 (s, 3H), 3.41 (s, 3H). 31Pδ-0.43(1P),-11.06(2P),-22.39(1P); MS m / z=1157.9(MH).

[0736] m7 G 2'OMe3'OMe ppp m6 A 2'OMe pG (Compound 27):

[0737]

[0738] Compound 27 was prepared as described according to General Procedure 1 from N-7-Me-2',3'-di-OMe-GDP (0.5 g, 0.36 mmol), EDC (0.12 g, 0.6 mmol) and imidazole (0.10 g, 1.4 mmol) in 5 mL of 30% water in DMSO, magnesium chloride (0.12 mL of a 3.15 MgCl2 solution, 0.48 mmol) and p- m6 A 2'OMe pG (0.22 g, 0.24 mmol) was used to synthesize the product, and a solid product (0.18 g) was obtained (yield: 64%). 1 H NMRδ8.26(s,1),8.07(s,1),7.70(s,1)5.94(d,1,J=10Hz),5.80(d,1,J=10Hz),5.76(d,1j=5Hz),4.89( m,1),4.73,(m,1),4.21(m,1),4.18(m,2),4.14(t,2,J=5Hz),3.99(s,3)3.49(s,3),3.42(s,3),3.08(br s,3). 31Pδ-0.42(1P),-11.12(2P),-22.43(1P); MS m / z=1172.0(MH).

[0739] m7 G 2'OMe ppp m6 A 2'OMe pG (Compound 28):

[0740]

[0741] Compound 28 was prepared as described according to General Procedure 1 from N-7-Me-2'-OMe-GDP (0.20 g, 9.3 mmol), EDC (9.091 g, 0.47 mmol) and imidazole (0.06 g, 0.89 mmol) in 2.2 mL of 10% water in DMSO, magnesium chloride (0.13 mL of a 3.15 MgCl2 solution, 0.42 mmol) and p- m6 A 2'OMe pG (0.19 g, 0.21 mmol) was used to synthesize the product, and a solid product (0.17 g) was obtained (yield: 68%). 1H NMRδ8.28(s,1H),8.09(br s,1H),7.92(s,1H),5.96(d,1H,J=5Hz),5.84(d,1H,J=5Hz),5.82(d,1,J=9Hz),4.91(m,1H),4.49( m,3H),4.39(m,2H),4.25(m,2H),4.20-4.15(m,6H),4.00(s,3H),3.54(s,3H),3.46(s,3H),3.09(br s,3H). 31Pδ-0.40(1P),-11.06(2P),-22.37(1P); MS m / z=1174(M+H).

[0742] m7 G 3'SMe pppA 2'OMe pG (Compound 42):

[0743]

[0744] Compound 42 was prepared as described according to General Procedure 1 from N7-Me-3'-SMe-GDP (0.18 g, 0.29 mmol), EDC (0.09 g, 0.47 mmol) and imidazole (0.06 g, 0.90 mmol) in 1.8 mL of 10% water in DMSO, magnesium chloride (0.123 mL of a 3.15 M MgCl2 solution, 0.39 mmol) and pA. m pG (0.18 g, 0.19 mmol) was used to synthesize the product, and a solid product (0.161 g, 0.130 mmol) was obtained (yield: 67%). 1 H NMR(500MHz,D2O)δ8.37(s,1H),8.10(s,1H),7.92(s,1H),5.98(d,J=5.8,1H),5.81(m,2H),4.92(m,2H),4.57(d,J=4.7, 2H),4.47-4.51(m,4H),4.41(t,J=5.2,1H),4.29-4.40(m,3H),4.15-4.24(m,5H),4.01(s,3H),3.42(s,3H),2.12(s,3H). 31 P NMR(200MHz,D2O)-0.41(1P),-11.04(1P),-11.35(1P),-22.32(1P). MS m / z=1173.9(MH).

[0745] m7 G 2'OH,2'Me pppA 2'OMepG (Compound 43):

[0746]

[0747] Compound 43 was synthesized from N7-Me-2'Me 2'OH-GDP (0.502 g, 0.85 mmol), EDC (0.230 g, 1.2 mmol) and imidazole (0.153 g, 2.25 mmol) in 5 mL of 10% water in DMSO, magnesium chloride (0.317 mL of 3.15 M MgCl2 solution, 1 mmol) and pAmpG (0.454 g, 0.5 mmol) according to General Procedure 1. A solid product (0.437 g) was obtained (75% yield).

[0748] 1 H NMR (500MHz, D2O): δ8.36(S,1H),8.02(s,1H),7.93(s,1H),5.96(d,J=5.7Hz,1H),5.82(s,1H),5.81(s,1H),4.91(m,1H),4. 49(m,3H),4.39(t,J=5.1Hz,1H),4.34(m,1H),4.29(m,3H),4.20(m,3H),4.14(m,1H),4.03(s,3H),3.41(s,3H),1.02(s,3H). 31 P NMR (200MHz, D2O): δ-0.39(1P),-11.0(2P),-22.3(1P). MS m / z=1158.9(MH).

[0749] m 7 G 3'AZM ppp m6 A 2'OMe pG (Compound 45):

[0750]

[0751] m 7 G 3'AZM ppp m6 A 2'OMe pG was prepared as described according to General Procedure 1 from N-7-Me-3'-AZM-GDP (0.20 g, 0.3 mmol), EDC (0.098 g, 0.51 mmol) and imidazole (0.082 g, 1.2 mmol) in 3.0 mL of 30% water in DMSO, magnesium chloride (0.16 mL of a 3.15 MgCl2 solution, 0.5 mmol) and pA 2'OMepG (0.23 g, 0.25 mmol) was used to synthesize the product, and a solid product (0.086 g) was obtained (yield: 24%). 1 H NMR: δ8.28(s,1H),8.08(s,1H),7.91(s,1H),5.97(d,1H,J=10Hz),5.82-5.80(m,2H),4.91-4.88(m,2H),under D2O(3H),4.63(t,1H,J=5Hz),4.50-4.46(m,2H),4.43(s,1H),4.39-4.30(m,5H),4.24-4.17(m,4H),3.99(s,3H),3.45(s,3H),3.08(s,3H). 31 P NMRδ-0.40(1P),-11.08(2P),-22.42(1P). [M-3H+4Na] + Expected mass: 1303.12; [M-3H+4Na] + Detected: m / z = 1302.5 (M-3H+4Na).

[0752] m7 G 3'F ppp m6 A 2'OMe pG (Compound 49):

[0753]

[0754] Compound 49 was prepared as described according to General Procedure 1 from N-7-Me-3'-F-GDP (0.20 g, 0.27 mmol), EDC (0.083 g, 0.43 mmol) and imidazole (0.055 g, 0.81 mmol) in 2.2 mL of 10% water in DMSO, magnesium chloride (0.12 mL of a 3.15 MgCl2 solution, 0.38 mmol) and p- m6 A 2'OMe pG (0.176 g, 0.19 mmol) was used to synthesize the product, and a solid product (0.12 g) was obtained (yield: 55%). 1H NMRδ8.27(s,1H),8.09(br s,1H),7.92(s,1H),5.96(d,1H,J=9Hz),5.82(d,1,J=5Hz),5.80(d,1H,J=9Hz),5.32(d,1H,J=5Hz),5.22(d,1,J=5Hz),4.8 9(m,1H),4.72(m,1H),4.68(m,1H),4.48(m,2H),4.38(t,1H,J=5Hz),4.30-4.20(M,7H),4.02(s,3H),3.45(s,3H),3.10(br s,3H). MS m / z=1159.7(M+H).

[0755] m7 G 3'MOE ppp m6 A 2'OMe pG (Compound 50):

[0756]

[0757] Compound 50 was prepared as described according to General Procedure 1 from N-7-Me-3'-(2-methoxyethoxy)-GDP (0.030 g, 0.37 mmol), EDC (0.12 g, 0.6 mmol) and imidazole (0.10 g, 1.5 mmol) in 3.5 mL of 10% water in DMSO, magnesium chloride (0.15 mL of a 3.15 MgCl2 solution, 0.24 mmol) and p A. M6 2'OMe pG (0.11 g, 0.12 mmol) was used to synthesize the product to obtain a solid product (0.11 g) (yield: 65%). 1 H NMRδ8.21(s,1),8.06(br s,1),7.89(s,1),5.96(d,1,J=5.5Hz),5.82(s,1),5.81(d,1,J=5.5Hz),4.88(m,1),4.73(t,1,J=5.5Hz),4.60(t,1,J=4.7),4.47(m,1),4 .46(m,1),4.36(m,2),4.35(M,2),4.32(M,1),4.22(m,1),4.17(m,4),3.98(s,3),3.76(m,2),3.62(m,2),3.43(s,3),3.37(s,3),3.07(br s,3); 31Pδ-.40(1P),-11.12(2P),-22.45(1P); MS m / z=1215.8(MH).

[0758] m7 G 3'SMe ppp m6 A 2'OMe pG (Compound 52):

[0759]

[0760] Compound 52 was prepared as described according to General Procedure 1 from N7-Me-3'-SMe-GDP (0.18 g, 0.29 mmol), EDC (0.09 g, 0.47 mmol) and imidazole (0.06 g, 0.90 mmol) in 1.8 mL of 10% water in DMSO, magnesium chloride (0.123 mL of a 3.15 M MgCl2 solution, 0.39 mmol) and p-butylene glycol (0.100 g, 0.004 mmol). m6 A m pG (0.18 g, 0.19 mmol) was used for synthesis. A solid product (0.109 g, 0.087 mmol) was obtained. Final yield - 86.5 μmol, 194 μmol starting amount, 44.6%. NMR(500MHz,D2O)δ8.30(s,1H),8.07(s,1H),7.89(s,1H),5.97(d,J=5.4,1H),5.79(d,J=5.8),5.75(s,1H),4.91(m,2H),4.54(d,J=4.7 ,1H),4.45-4.50(m,3H),4.40(t,J=5.0,1H),4.24-4.33(m,2H),4.15-4.23(m,5H),3.97(s,3H),3.45(s,3H),3.06(bs,3H),2.1(s,3H). 31PNMR(200MHz,D2O)-0.42(1P),-11.02(1P),-11.37(1P),-22.31(1P). MS m / z=1187.8(MH).

[0761] m7 (L-sugar isomer)GpppA 2'OMe pG (Compound 75):

[0762]

[0763] Compound 75 was synthesized from N7-Me-L-GDP (0.31 g, 0.5 mmol), EDC (0.153 g, 0.8 mmol) and imidazole (0.106 g, 1.550 mmol) in 3.1 mL of 10% water in DMSO, magnesium chloride (0.212 g, 0.667 mmol) and pAmpG (0.30 g, 0.333 mmol) according to General Procedure 1. 218.07 μmol of product were obtained (yield: 65.5%). 1 H NMR (500MHz, D2O): δ8.30(s,1H),8.06(s,1H),7.87(s,1H),6.01(d,J=4.4,1H),5.77(m,2H),4.86(m,1H),4.73(m,1H),4.48-4. 46(m,2H),4.46-4.45(m,3H),4.43-4.42(m,1H)4.38-4.19(m,4H)4.00(s,3H),3.47(s,3H),1.90(s,1H),1.17(t,J=7.1Hz,1H). 31PNMR(200MHz,D2O): δ0.47(s,1P),-10.87(m,1P),-22.06(m,1P). C 32 H 42 N 15 O 24 Calculated value of P4 1144.66, experimental value 1144.0 [MH] negative mode.

[0764] m7 G 2'OH,2'Me ppp m6 A 2'OMe pG (Compound 76):

[0765]

[0766] Compound 76 was synthesized from N7-Me-2'Me 2'OH-GDP (0.502 g, 0.85 mmol), EDC (0.230 g, 1.2 mmol) and imidazole (0.153 g, 2.25 mmol) in 5 mL of 10% water in DMSO, magnesium chloride (0.317 mL of 3.15 M MgCl2 solution, 1 mmol) and pAmpG (0.406 g, 0.5 mmol) according to General Procedure 1. A solid product (0.522 g) was obtained (89% yield). 1H NMR (500MHz, D2O): δ8.28(S,1H),8.05(s,1H),7.89(s,1H),5.95(d,J=5. 4Hz,1H),5.80(d,J=5.75Hz,1H),5.77(S,1H),4.91-4.88(m,1H),4.81-4 .72(m,3H),4.50-4.46(m,2H),4.37(t,J=4.95Hz,1H),4.33-4.26(m,3H) ,4.25-4.18(m,3H),4.12-4.10(m,1H),4.00(s,3H),3.43(s,3H),3.06(br s,3H),1.00(s,3H). 31P NMR (200MHz, D2O): δ-0.40(1P),-10.99(2P),-22.31(1P). MS m / z=1195(M+Na).

[0767] m7 (L-Sugar isomer) Gppp m6 A 2'OMe pG (Compound 77):

[0768]

[0769] Compound 77 was prepared according to General Procedure 1 from N7-Me-L-GDP (0.31 g, 0.5 mmol), EDC (0.153 g, 0.8 mmol) and imidazole (0.106 g, 1.550 mmol) in 3.1 mL of 10% water in DMSO, magnesium chloride (0.212 g, 0.667 mmol) and p-butylene glycol (0.050 g, 0.08 mmol). m6 AmpG (0.31 g, 0.336 mmol) was used for synthesis, and 257.86 micromoles of product were obtained (yield: 76.7%). 1H NMR (500MHz, D2O): δ8.26(s,1H),8.05(s,1H),7.83(s,1H),6.03(d,J=3.6H z,1H),5.76(d,J=6.05Hz,1H)5.67(d,2.8Hz,1H),4.86(m,1H),4.69-4.67( t,J=5.5Hz,1H),4.46-4.41(m,5H),4.39-4.37(m,3H),4.34-4.31(m,5H),3 .98(s,3H),4.52(s,3H),3.00(bs,3H),1.90(s,1H),1.18(t,J=7.05Hz,1H).

[0770] 31P NMR (200MHz, D2O): δ0.47(s,1P), -10.92(m,1P), -22.11(m,1P). C 33 H 44 N 15 O 24 Calculated value for P4 1158.69, experimental value 1158.0 and 1159.9 [MH] negative mode.

[0771] m7 (Acyclic)Gppp m6 A 2'OMe pG: Compound 78

[0772]

[0773] Compound 78 was prepared according to General Procedure 1 from N7-methylacyclic GDP (0.100 g, 0.251 mmol), EDC (0.061 g, 320 mmol) and imidazole (0.054 g, 0.80 mmol) in 1.6 mL of 10% water in DMSO, magnesium chloride (0.110 mL of a 3.15 M MgCl2 solution, 1 mmol) and p- m6 AmpG (0.125 g, 0.173 mmol) was used to synthesize the product. A solid product (0.105 g) was obtained (55.0% yield). 1H NMR (500MHz, D2O): δ8.30(s,1H),8.08(s,1H),7.92(s,1H),6.00(d,J=5.8Hz,1H),5.82(d, J=5.7Hz,1H),5.52-5.45(q,J=10.95Hz,2H),4.95-4.91(m,1H),4.78-4.72(m,2H),4.53(br s,1H),4.48-4.44(m,2H),4.34-4.29(m,2H),4.25-4.21(m,3H),4.20-4.09(m,2H),3.99(s,3H),3.79(m,2H),3.45(s,3H),3.03(br s,3H). 31 P NMR (200MHz, D2O): δ-0.35(1P),-10.68(2P),-22.23(1P). MS m / z=1168.6(M+3Na).

[0774] Synthesis of compounds according to formula III:

[0775] According to the general method shown in Scheme 2, compounds according to Formula III terminated with an adenosine nucleotide are prepared.

[0776] Scenario 2:

[0777]

[0778] General procedure 2 (using p m6 A 2'OMe pA dinucleotide as pApA dinucleotide 3):

[0779] At room temperature, the modified N7-Me-GDP 1 (TEA salt, p m6 A 2'OMe EDC.HCl salt (pA dinucleotide, 1.5 mol equivalent) was added to a stirred solution of 10% water / DMSO (10 times the volume of N7-Me-GDP 1 by weight). m6 A 2'OMe pA dinucleotide 3 is 2.4 molar equivalents), followed by the addition of imidazole (p m6 A 2'OMe pA dinucleotide 3 is 4.5 molar equivalents). The resulting mixture was stirred at room temperature overnight (approximately 16-24 hours). The next day, magnesium chloride (3.15 M in water, based on p m6 A 2'OMe pA dinucleotide 3 is 2.0 molar equivalents), followed by the addition of modified p m6 A 2'OMepA dinucleotide 3 (TEA salt, 1 molar equivalent). The resulting solution was stirred at room temperature overnight (approximately 16 to 24 hours). The crude reaction mixture was then diluted with 10x water and purified by anion exchange chromatography (QFF resin, 20% acetonitrile in water as buffer A, 1.5M TEAA in water as buffer B, 4CV using a linear gradient from 25% to 45% buffer B, 1.5CV maintained at 45%). The desired products were combined and concentrated under vacuum, and the final product was precipitated in water with sodium acetate and 95% anhydrous ethanol in the form of a sodium salt.

[0780] The synthesis of the following compounds followed the procedures described above and depicted in Scheme 2.

[0781] m7 Gppp m6 A 2'OMe pA (Compound 10):

[0782]

[0783] Compound 10 was prepared as described according to General Procedure 2 from a solution of N7-Me-GDP (0.88 g, 1.5 mmol), EDC (0.46 g, 2.4 mmol) and imidazole (0.31 g, 4.5 mmol) in 13 mL DMSO, magnesium chloride (0.190 g in 0.64 mL water, 2 mmol) and p- m6 A 2'OMe pA (0.906 g, 1 mmol) was used to synthesize the product to obtain a solid product (0.355 g) (yield: 29%). 1 H NMR (500MHz, D2O): δ8.26(s,1H),8.23(s,1H),8.15(s,1H),7.91(s,1H),6.008(d,J=4.5Hz,1H),5.881(d ,J=4.5Hz,1H),5.761(d,J=3.5Hz,1H),4.84-4.88(m,1H),4.25-4.49(m,14H),3.96(s,3H),3.53(s,3H). 31 P NMR (200 MHz, D2O): δ -0.59 (1P), -10.99, -11.04, -11.09, -11.13 (overlapping double peaks, 2P), -22.50 (t, J = 16.2 Hz, 1P). MS (ESI) C 33 H 45 N 15 O 23 Calculated value for P4: 1143.70, found: 1144.7 [M+H] - .

[0784] m7 G 3'OMe ppp m6 A 2'OMe pA (Compound 11):

[0785]

[0786] Compound 11 was prepared as described according to General Procedure 2 from N7-Me-3'-OMe-GDP (0.63 g, 0.96 mmol), EDC (0.294 g, 1.536 mmol) and imidazole (0.196, 2.88 mmol) in 6.3 ml of 10% water in DMSO, magnesium chloride (122 mg in 0.41 mL water, 1.28 mmol) and p- m6 A 2'OMe pA (0.58 g, 0.64 mmol) was used to synthesize the product to obtain a solid product (0.46 g) (yield: 53%). 1 H NMR (500MHz, D2O): δ8.28(s,1H),8.24(s,1H),8.14(s,1H),7.93(s,1H),6. 013(d,J=4.5Hz,1H),5.911(d,J=5Hz,1H),5.741(d,J=4.5Hz,1H),4.87-4. 90(m,1H),4.59(t,J=4.5Hz,1H),4.45-4.52(m,3H),4.32-4.40(m,5H),4.1 6-4.25(m,4H),4.04(t,J=5Hz,1H),3.96(s,3H),3.52(s,3H),3.44(s,3H). 31 P NMR (200 MHz, D2O): δ -0.49 (1P), -10.95, -11.02, -11.04, -11.11 (overlapping double peaks, 2P), -22.37 (t, J = 16.2 Hz, 1P). 34 H 47 N 15 O 23 The calculated value of P4 is 1157.73, the experimental value is 1156.7 [MH].

[0787] Synthesis of compounds according to Formula V, Formula VII and Formula VIII:

[0788] Compounds according to formula V terminated with a uridine nucleotide were prepared according to the general method shown in Scheme 3. Compounds according to formula VII and VIII were prepared similarly.

[0789] Solution 3:

[0790]

[0791] General procedure 3:

[0792] To a stirred solution of N7-Me-GDP 1 (TEA salt, 1.5 mol equivalents of pApU dinucleotide) in 10% water / DMSO (volume 10 times the weight of N7-Me-GDP 1) at room temperature, EDC.HCl salt (2.4 mol equivalents of pApU dinucleotide 4) was added, followed by imidazole (4.5 mol equivalents of pApU dinucleotide 4). The resulting mixture was stirred at room temperature overnight (approximately 16-24 hours). The next day, magnesium chloride (3.15 M in water, 2.0 mol equivalents of pApU dinucleotide 4) was added to the above solution, followed by the addition of modified pApU dinucleotide 4 (TEA salt, 1 mol equivalent). The resulting solution was stirred at room temperature overnight (approximately 16 to 24 hours). The crude reaction mixture was then diluted with 10x water and purified by anion exchange chromatography (QFF resin, 20% acetonitrile in water as buffer A, 1.5M TEAA in water as buffer B, 4CV using a linear gradient from 25% to 45% buffer B, 1.5CV hold at 45%). The desired products were combined and concentrated under vacuum, and the final product was precipitated as a sodium salt with sodium acetate and 95% anhydrous ethanol in water.

[0793] m7 GpppA 2'4'LNA pU (Compound 15):

[0794]

[0795] Compound 15 was synthesized from N7-Me-GDP (0.341 g, 0.52 mmol), EDC (0.161 g, 0.84 mmol) and imidazole (0.109 g, 1.6 mmol) in 3.4 ml of 10% water in DMSO, magnesium chloride (0.254 mL of 3.15 M MgCl2 solution, 0.8 mmol) and p(LNA)ApU (0.355 g, 0.4 mmol) as described according to General Procedure 3. A solid product (0.2976 g) was obtained (yield: 63%). 1 H NMR (500MHz, D2O): δ8.13(s,2H),7.63(d,J=8.15Hz,1H),5.90(d,J=4.25Hz,1H),5.78(s,1H),5.65 (d,J=2.5Hz,1H),5.30(d,J=8.1Hz,1H),4.64(m,1H),4.56-4.25(m,12H),4.12(s,3H),4.07(m,1H).31 P NMR (200MHz, D2O): δ-1.85(1P),-11.02(2P),-22.37(1P). MS m / z=1102.7(MH).

[0796] m7 G 3'OMe pppA 2'4'LNA pU (Compound 16):

[0797]

[0798] Compound 16 was synthesized from N7-Me-3'-OMe-GDP (0.42 g, 0.60 mmol), EDC (0.184 g, 0.96 mmol) and imidazole (0.122 g, 1.8 mmol) in 4.2 ml of 10% water in DMSO, magnesium chloride (0.254 mL of 3.15 M MgCl2 solution, 0.8 mmol) and p(LNA)ApU (0.355 g, 0.4 mmol) as described according to General Procedure 3. A solid product (0.3281 g) was obtained (yield: 69%). 1 H NMR (500MHz, D2O): δ8.14(s,2H),7.64(d,J=8.15Hz,1H),5.88(d,J=4.7Hz,1H),5.80(s,1H),5.66(d,J=2.55Hz,1H),5.31(d,J =8.15Hz,1H),4.82(m,2H),4.71-4.67(m,2H),4.54-4.4.51(m,7H),4.48-4.27(m,3H),4.07(s,3H),4.05(m,2H),3.50(s,3H). 31 P NMR (200MHz, D2O): δ-1.83(1P),-10.98(2P),-22.32(1P). MS m / z=1117.9(MH).

[0799] m7 G 3'OMe pppA 2'F pU (Compound 17):

[0800]

[0801] Compound 17 was prepared as described according to General Procedure 3 from N7-Me-3'-OMe-GDP (0.42 g, 0.60 mmol), EDC (0.184 g, 0.96 mmol) and imidazole (0.122 g, 1.8 mmol) in 4.2 ml of 10% water in DMSO, magnesium chloride (0.254 mL of a 3.15 M MgCl2 solution, 0.8 mmol) and pA. 2'F pU (0.348 g, 0.4 mmol) was used to synthesize the product to obtain a solid product (0.2788 g) (yield: 59%). 1 H NMR (500MHz, D2O): δ8.33(s,1H),8.16(s,1H),7.70(d,J=8.1Hz,1H),6.23(dd,J=2.3Hz,14.8Hz,1H),5.84(m ,2H),5.60(d,J=8.15Hz,1H),5.48-5.36(m,1H),4.88(m,1H),4.78-4.11(m,13H),4.07(s,3H),3.48(s,3H). 31 P NMR (200MHz, D2O): δ-0.85(1P),-10.97(2P),-22.31(1P). MS m / z=1106.7(MH). m7 G 3'OMe pppA 2'OMe pU (Compound 22):

[0802]

[0803] Compound 22 was prepared as described according to General Procedure 3 from N7-Me-3'-OMe-GDP (2.81 g, 4.5 mmol), EDC (1.38 g, 7.2 mmol) and imidazole (0.95 g, 13.95 mmol) in 30 mL of 10% water in DMSO, magnesium chloride (1.9 mL of a 3.15 M MgCl2 solution, 6.0 mmol) and pA 2'OMepU (2.61 g, 3.0 mmol) was used to synthesize. A solid product (1.95 g, 1.64 mmol) was obtained (yield: 55%). NMR (500 MHz, D2O) δ 8.40 (s, 1H), 8.13 (s, 1H), 7.85 (d, J = 8.2, 1H), 6.04 (d, J = 5.8, 1H), 5.92 (d, J = 4.7), 5.78 (m, 2H), 4.61 (t, J = 4.6, 1H), 4.55 (m, 1H), 4.45 (t, J = 5.2, 1H), 4.17-4.38 (m, 10H), 4.07 (t, J = 4.9, 1H), 4.03 (s, 3H), 3.49 (s, 3H), 3.46 (s, 3H). 31P NMR(200MHz,D2O)-0.56(1P),-11.05(2P),-22.38(1P). MS m / z=1118.9(MH).

[0804] m7 Gppp m6 A 2'OMe pU (Compound 23):

[0805]

[0806] Compound 23 was prepared as described according to General Procedure 3 from N7-Me-GDP (2.93 g, 4.5 mmol), EDC (1.38 g, 7.2 mmol) and imidazole (0.95 g, 13.95 mmol) in 30 mL of 10% water in DMSO, magnesium chloride (1.9 mL of a 3.15 M MgCl2 solution, 6.0 mmol) and p- m6 A 2'OMe pU (2.65 g, 3.0 mmol) was used to synthesize the solid product (1.11 g, 0.94 mmol) (yield: 31%). NMR(500MHz,D2O)δ8.34(s,1H),8.13(s,1H),7.81(d,J=8.2,1H),6.04(d,J=5.7,1H),5.89(d,J=4.6,1H),5.81(d,J=3.7,1H),5.72(d, J=8.1,1H),4.55(m,1H),4.40-4.46(m,2H),4.32-4.39(m,4H),4.23-4.29(m,5H),4.17(m,1H),3.99(s,3H),3.50(s,3H),3.08(bs,3H). 31P NMR(200MHz,D2O)-0.57(1P),-11.01(2P),-22.41(1P). MSm / z=1118.7(MH).

[0807] m7 G 3'OMe ppp m6 A 2'OMe pU (Compound 24):

[0808]

[0809] Compound 24 was prepared as described according to General Procedure 3 from N7-Me-3'-OMe-GDP (5.8 g, 9.4 mmol), EDC (2.9 g, 15.0 mmol) and imidazole (2.0 g, 28.9 mmol) in 58 mL of 10% water in DMSO, magnesium chloride (4.0 mL of a 3.15 M MgCl2 solution, 12.4 mmol) and p- m6 A 2'OMe pU (5.5 g, 6.3 mmol) was used to synthesize. A solid product (3.71 g, 3.08 mmol) was obtained (yield: 49%). The final yield was -3084 μmol, 49.5%. NMR (500MHz, D2O) δ8.34 (s, 1H), 8.14 (bs, 1H), 7.82 (d, J = 8.2, 1H), 6.04 (d, J = 5. 8,1H),5.90(d,J=4.6,1H),5.79(d,J=4.2,1H),5.73(d,J=8.2,1H),4.95(m,1H) ,4.60(t,J=4.5,1H),4.55(m,1H),4.36-4.44(m,4H),4.33(m,2H),4.15-4.29(m ,7H),4.05(t,J=4.9,1H),3.99(s,3H),3.49(s,3H),3.45(s,3H),3.07(bs,3H). 31P NMR(200MHz,D2O)-0.56(1P),-11.08(2P),-22.40(1P). MS m / z=1132.8(MH).

[0810] m7 GpppA 2'F pU (Compound 33):

[0811]

[0812] Compound 33 was prepared as described according to General Procedure 3 by reacting N7-Me-GDP imidazolide with pA 2'F pU dinucleotide coupling was used for synthesis. 1H NMR (500MHz, D2O): δ8.30(s,1H),8.14(s,1H),7.68(d,J=8.1Hz,1H),6.18(dd,J=2.1Hz,14.7Hz,1H),5.82( dd,J=3.8Hz,11.2Hz,2H),5.58(d,J=8.1Hz,1H),5.45(m,1H),5.35(m,1H),4.56-4.11(m,11H),4.06(s,3H). 31 P NMR (200MHz, D2O): δ-0.89(1P),-11.01(2P),-22.36(1P).

[0813] Synthesis of additional compounds according to formula IV:

[0814] Certain compounds according to Formula IV were prepared according to the following general method (General Procedure 4), including the synthesis of pp m6 Activated imidazolides of ApG dinucleotides and synthesis of N7-Me 3'OMe guanosine 5'-phosphorothioate.

[0815] General Procedure 4:

[0816] pp m6 Synthesis of activated imidazolide of ApG dinucleotide:

[0817] The reaction mixture was purified by combining the reagents and stirring at room temperature for 22 hours using imidazole (2.20 g, 32.27 mmol) and EDC (2.59 g, 16.66 mmol) dissolved in 20 mL 90% DMSO 10% H2O. m6 Large-scale activation of ApG dinucleotide (5.0 g, 6.94 mmol) was performed. After activation, the addition of β-phosphate was completed by adding 1 M TBAP dissolved in DMF (85 mL, 85 mmol) and mixing at room temperature for 18 hours. The reaction solution was then double purified by reverse phase and anion exchange chromatography. ApG was activated with EDC (0.146 g, 0.94 mmol) and imidazole (0.128 g, 1.88 mmol). m6 ApG dinucleotide (0.5 g, 0.625 mmol) was used in the subsequent coupling reaction.

[0818] Synthesis of N7-Me 3'OMe Guanosine 5'-Phosphorothioate:

[0819] 5'OH 3'OMe guanosine was converted to 5'iodo 3'OMe guanosine using the Appel reaction. Specifically, the starting material 5'OH 3'OMe guanosine (1.00 g, 3.36 mmol) was dissolved in anhydrous NMP (10 mL), followed by the addition of imidazole (1.38 g, 20.2 mmol), TPP (2.65 g, 10.1 mmol) and iodine (2.55 g, 10.1 mmol). The reaction was stirred at 25 ° C for 3 hours and then transferred to 120 mL of a dichloromethane / water mixture (3: 1). The mixture was kept at 4 ° C overnight, at which point a white precipitate was formed. The precipitate was filtered out under reduced pressure and dried overnight in a vacuum dryer to obtain 5'iodo 3'OMe guanosine. The material can be used without further purification.

[0820] 5' iodo 3'OMe guanosine 5' phosphorothioate was used to complete the 5' phosphorothioate. 5' iodo 3'OMe guanosine (1.00 g, 2.45 mmol) was dissolved in 15 mL of 100 mM NaOH, followed by the addition of sodium thiophosphate (2.21 g, 12.30 mmol). The reaction mixture was heated at 50°C for 3 hours. The product was purified by reverse phase HPLC.

[0821] Use dimethyl sulfate to complete the N-7 methylation of 5' thiophosphate 3'OMe guanosine.5' thiophosphate 3'OMe guanosine (1.00g, 2.54mmol) is dissolved in 10mL 0.5M NaOAc pH 4.0 buffer, then dimethyl sulfate (0.64g, 5.09mmol) is added in batches within one hour.1M NaOH is used as required to maintain pH at about 4.0.Deionized water is used to dilute the reaction volume 10 times, and then it is washed twice with the ethyl acetate of equal volume (100mL).Reaction is purified by anion exchange chromatography (QFF resin), and the product as triethylamine (TEA) salt is obtained.

[0822] m7 G 3'OMe5'-硫代 ppp m6 A 2'OMe Synthesis of pG (Compound 12):

[0823]

[0824] Compound 12 was prepared as described in General Procedure 4 by reacting N7-Me 3'OMe guanosine 5'-phosphorothioate with pp in the presence of MgCl2. m6 A 2'OMe pG dinucleotide activated imidazolide coupling synthesis. As described above, pp m6 A 2' OMeThe activated imidazolide of pG dinucleotide was used as a solution [0.625mmol / 5mL] in 3.44mL 90% DMSO 10% H2O, while N7-Me 3'OMe guanosine 5' thiophosphate (150.0mg, 367 micromoles) and 3.15M magnesium chloride (232uL, 734μmol) were added. The components were mixed and stirred at room temperature overnight. The product was purified by anion exchange chromatography using QFF resin and then by QHP anion exchange chromatography. The final yield after precipitation was 45.6%, obtaining 196.53mg white solid product. 1 H NMR (500MHz, D2O): δ8.29(s,1H),8.04(s,1H),7.93(s,1H),5.996(d,J=6.2Hz,1H),5.821(d,J=5 .9Hz,1H),5.704(d,J=5.5Hz,1H),4.89-4.92,(m,1H),4.74(t,J=3.6Hz),4.48-4.52,(m,1H),4. 43-4.47(m,1H),4.38-4.40(m,2H),4.30-4.34(m,2H),4.21-4.24(m,1H),4.18-4.20(m,2H),4.0 0(t,J=3.75Hz,1H),3.97(s,3H),3.47(s,3H),3.39(s,3H),3.26,(q,J=6.4Hz,2H),3.05,(s,3H). 31 P NMR (200MHz, D2O): δ7.85 (d, J = 16.36Hz, 1P), 0.34 (s, 1P), -11.17, (d, J = 18.18Hz, 1P), -23.22 (d, J = 18.12Hz, 1P). C 34 H 48 N 15 O 23 The calculated value of P4S is 1190.17, the experimental value is 1189.17 [MH].

[0825] m7 G 3'OMe pp(s)p m6 A 2'OMe Synthesis of pG* (Compound 13):

[0826]

[0827] * m7 G 3'OMe pp(s)p m6 A 2'OMepG contains a chiral phosphorothioate moiety and is separated into two diastereomers:

[0828] m7 G 3'OMe pp(s Rp ) m6 A 2'OMe pG and m7 G 3'OMe pp(s sp ) m6 A 2'OMe pG.

[0829] To a stirred suspension of β-S-3′-OMe-GDP (1.11 g, 1.61 mmol) in DMSO (8 mL) was added p- m6 A m pG-imidazole (0.62 g, 0.81 mmol) was then added magnesium chloride (0.51 mL 3.15 M MgCl2 solution, 1.61 mmol). The reaction was carried out and purified by anion exchange chromatography as described in General Procedure 1. A pure mixture of diastereomers was obtained and concentrated under vacuum to remove acetonitrile. The resulting solution was diluted 5 times with water and purified using reverse phase chromatography (Waters Nova-Pak C18 preparative column, 6 μm, 19 mm x 300 mm, WAT025822, 50 mM ammonium acetate, pH 6.0 as buffer A, acetonitrile as buffer B, using a linear gradient of 0% to 5% buffer B over 10 column volumes). The desired products were combined and concentrated under vacuum, and the final product was precipitated in water with sodium acetate and 95% anhydrous ethanol as a sodium salt. The solid product was obtained in the form of pure diastereoisomers, D1: 0.04 mmol, D2: 0.05 mmol, and the total yield of D1+D2 was 11.5%.

[0830] m7 G 3'OMe pp(s)p m6 A 2'OMe pD1

[0831] 1H NMR(500MHz,D2O)δ8.37(s,1H),8.11(s,1H),7.94(s,1H),6.02(d,J=5. 7,1H),5.86(d,J=4.1,1H),5.83(d,J=5.6,1H),4.96(m,1H),4.71(m,1H) ,4.47-4.53(m,3H),4.42-4.44(m,2H),4.36(m,1H),4.21-4.30(m,5H),4 .13(t,J=4.6,1H),4.02(s,3H),3.47(s,3H),3.46(s,3H),3.08(bs,3H); 31 P NMR (200MHz, D2O) 30.49 (1P), -0.37 (1P), -11.92 (2P); MS m / z = 1187.5 (MH).

[0832] m7 G 3'OMe pp(s)p m6 A 2'OMe pD2

[0833] 1 H NMR(500MHz,D2O)δ8.34(s,1H),8.12(s,1H),7.95(s,1H),6.01(d,J=5.8,1H),5.83(m,2H),4.96(m,1H),4.42-4.55(m ,3H),4.32-4.39(m,4H),4.19-4.28(m,4H),4.14(t,J=4.6,1H),4.03(s,3H),3.48(s,3H),3.47(s,3H),3.08(bs,3H). 31 P NMR (200MHz, D2O) 30.38 (1P), -0.41 (1P), -11.95 (2P); MS m / z=1187.6 (MH).

[0834] Synthesis of additional compounds according to formula VI:

[0835] Certain compounds according to Formula VI were prepared according to the following general method (General Procedure 5), including the synthesis of ppA 2'OMe Activated imidazolides of pG dinucleotides and synthesis of N7-Me 3'OMe guanosine 5'-phosphorothioate.

[0836] General Procedure 5:

[0837] pA 2'OMe Synthesis of activated imidazolide of pG dinucleotide:

[0838] pA was performed using imidazole (696.5 mg, 10.23 mmol) and EDC (1.01 g, 5.28 mmol) dissolved in 10 mL 90% DMSO 10% H2O by combining the reagents and stirring at room temperature for 2 hours. 2'OMe Activation of pG dinucleotide (2.0 g, 2.20 mmol). After activation, addition of β-phosphate was accomplished by adding 1 M TBAP dissolved in DMF (38.20 mL, 38.20 mmol) and mixing at room temperature for 18 hours to generate ppA 2'OMe pG. The reaction solution was then double purified by reverse phase and anion exchange chromatography. ppA was activated with EDC (0.214 g, 1.375 mmol) and imidazole (0.187 g, 2.75 mmol). 2' OMe pG (1 g, 0.917 mmol) was used in the subsequent coupling reaction.

[0839] Synthesis of N7-Me 3'OMe Guanosine 5'-Phosphorothioate:

[0840] 5'OH 3'OMe guanosine was converted to 5'iodo 3'OMe guanosine using the Appel reaction. The starting material 5'OH 3'OMe guanosine (1.00 g, 3.36 mmol) was dissolved in anhydrous NMP (10 mL), followed by the addition of imidazole (1.38 g, 20.2 mmol), TPP (2.65 g, 10.1 mmol) and iodine (2.55 g, 10.1 mmol). The reaction was stirred at 25 °C for 3 hours and then transferred to 120 mL of a dichloromethane / water mixture (3: 1). The mixture was kept at 4 °C overnight, at which point a white precipitate formed. The precipitate was filtered out under reduced pressure and dried overnight in a vacuum desiccator to obtain 5'iodo 3'OMe guanosine. The material was used without further purification.

[0841] 5' iodo 3'OMe guanosine 5' phosphorothioate was used to complete the 5' phosphorothioate. 5' iodo 3'OMe guanosine (1.00 g, 2.45 mmol) was dissolved in 15 mL of 100 mM NaOH, followed by the addition of sodium thiophosphate (2.21 g, 12.30 mmol). The reaction mixture was heated at 50°C for 3 hours. The product was purified by reverse phase HPLC.

[0842] Use dimethyl sulfate to complete the N-7 methylation of 5' thiophosphate 3'OMe guanosine.5' thiophosphate 3'OMe guanosine (1.00g, 2.54mmol) is dissolved in 10mL 0.5M NaOAc pH 4.0 buffer, then dimethyl sulfate (0.64g, 5.09mmol) is added in batches within one hour.1M NaOH is used as required to maintain pH at about 4.0.Deionized water is used to dilute the reaction volume 10 times, and then it is washed twice with the ethyl acetate of equal volume (100mL).Reaction is purified by anion exchange chromatography (QFF resin), and the product as triethylamine (TEA) salt is obtained.

[0843] m7 G 3'OMe p(s)ppA 2'OMe Synthesis of pG (Compound 18):

[0844]

[0845] Compound 18 was prepared as described in General Procedure 5 by reacting N7-Me 3'OMe guanosine 5'-phosphorothioate with ppA in the presence of MgCl2. 2'OMe pG dinucleotide activated imidazolide coupling synthesis. As described above, ppA 2'OMe The activated imidazolide of pG dinucleotide was used as a solution [0.917mmol / 10mL] in 1.1mL 90% DMSO 10% H2O, while N7-Me 3'OMe guanosine 5' thiophosphate (43mg, 67 micromoles) and 3.15M magnesium chloride (43uL, 134μmol) were added. The components were mixed and stirred at room temperature overnight. The product was purified by anion exchange chromatography using QFF resin and then by QHP anion exchange chromatography. The final yield after precipitation was 43.3%, and 29μmol of product was obtained. 1 H NMR (500MHz, D2O): δ8.40 (s, 1H), 8.17 (d, J = 3.1Hz, 1H), 7.98 (d, J = 5.8Hz, 1H), 6.00(d,J=5.85Hz,1H),5.86-5.81(m,2H),4.97-4.88(m,1H),4.69-4.68(m,2H ),4.66-4.65(m,2H),4.45-4.37(m,4H),4.33-4.30(m,2H),4.28-4.22(m,2H), 4.15-4.10(m,1H),4.05-4.03(d,J=8.15,3H),3.48-3.42(m,6H),1.93(s,1H). 31P NMR (200MHz, D2O): δ43.90-43.28(dd,1P)0.39(s,1P),-11.23(t,1P),-23.66(m,1P). C 33 H 44 N 15 O 23 The calculated value of P4S is 1174.75, the experimental value is 1174 and 1175.7 [MH] negative mode.

[0846] m7 G 3'OMe pp(s)pA 2'OMe Synthesis of pG* (Compound 19):

[0847]

[0848] * m7 G 3'OMe pp(s)pA 2'OMe pG contains a chiral phosphorothioate moiety and is separated into two diastereomers: m7 G 3'OMe pp(s Rp )pA 2'OMe pG and m7 G 3'OMe pp(s Sp )pA 2'OMe pG.

[0849] To a stirred suspension of β-S-3′-OMe-GDP (0.98 g, 1.42 mmol) in DMSO (7 mL) was added pA 2'OMe pG-imidazole (0.54 g, 0.71 mmol) was then added magnesium chloride (0.45 mL 3.15 M MgCl2 solution, 1.42 mmol). The reaction was carried out and purified by anion exchange chromatography as described in General Procedure 1. A pure mixture of diastereomers was obtained and concentrated under vacuum to remove acetonitrile. The resulting solution was diluted 5 times with water and purified using reverse phase chromatography (Waters Nova-Pak C18 preparative column, 6 μm, 19 mm x 300 mm, WAT025822, 50 mM ammonium acetate, pH 6.0 as buffer A, acetonitrile as buffer B, using a linear gradient of 0% to 5% buffer B over 10 column volumes). The desired products were combined and concentrated under vacuum, and the final product was precipitated in water with sodium acetate and 95% anhydrous ethanol as a sodium salt. Solid products were obtained in the form of pure diastereoisomers, D1: 0.06 mmol, D2: 0.07 mmol, final yield -19% (D1+D2).

[0850] m7 G 3'OMe pp(s)pA 2'OMe pD1

[0851] 1 H NMR(500MHz,D2O)δ8.45(s,1H),8.14(s,1H),7.96(s,1H),6.04(d,J=6.0,1H),5.88(d,J=4.2,1H),5.85(d,J=5.8,1H),4.98(m,1H) ,4.49-4.53(m,3H),4.41-4.45(m,2H),4.36(m,1H),4.19-4.28(m,5H),4.15(t,J=4.8,1H),4.04(s,3H),3.48(s,3H),3.44(s,3H); 31 PNMR(200MHz,D2O)30.46(1P),-0.35(1P),-11.90(2P); MS m / z=1173.8(MH).

[0852] m7 G 3'OMe pp(s)pA 2'OMe pG D2:

[0853] 1 H NMR(500MHz,D2O)δ8.42(s,1H),8.14(s,1H),7.97(s,1H),6.03(d,J=6.0,1H),5.85(m,2H),4.98(m,1H),4.51- 4.55(m,3H),4.36-4.48(m,3H),4.19-4.30(m,5H),4.16(t,J=4.7,1H),4.06(s,3H),3.49(s,3H),3.45(s,3H); 31 P NMR (200MHz, D2O) 30.36 (1P), -0.41 (1P), -11.91 (2P); MS m / z=1173.8 (MH).

[0854] m7 G 3'OMe ppp(s)A 2'OMe Synthesis of pG (Compound 20):

[0855]

[0856] In a clean glass container, N7-methyl-3'-O-methyl-GDP (480 μmol) was suspended in DMSO containing 10% water at 25°C with vigorous stirring. EDC-HCl was then added, followed immediately by imidazole. The reaction was then stirred at 25°C, monitored by analytical anion exchange ultra-high performance liquid chromatography (AX-UHPLC), and the reaction was completed between 8 and 18 hours. 5'-O-thiophosphoryl-2'-O-methyladenosyl-(3'-O-phosphoryl-O-5')-guanosine (240 μmol) and aqueous magnesium chloride were added to the activated N7-methyl-3'-O-methyl-GDP. The coupling reaction was stirred at 25°C and monitored by analytical AX-UHPLC. The reaction was determined to be complete by the remaining no more than 5% of the dinucleotide starting material. The resulting crude reaction was diluted with water to 20 times the crude volume and purified by anion exchange chromatography using QFF agarose resin and 30-60% 1.5MTEAA in 20% acetonitrile aqueous solution. The fractions obtained by analytical AX-UHPLC with a purity of> 80% were combined and partially evaporated to remove acetonitrile. The combined fractions were then diluted with 6-8 volumes of water and further purified by reverse phase chromatography using C18 resin and 0-10% acetonitrile in 100mMTEAA (pH 6-7). The fractions obtained by analytical AX-UHPLC with a purity of> 97% were combined and evaporated, and the product was reduced to a viscous oil. The trinucleotides were converted to sodium salt form by first adding 3M sodium acetate to the oil after RP, and gradually adding 95% ethanol in water to precipitate the trinucleotides in sodium salt form. The precipitate was washed twice with 95% ethanol, the supernatant was decanted, and the precipitate was resuspended in nuclease-free water. Residual ethanol was removed by rotary evaporation and the solution was adjusted to 100 mM final concentration in water (130 μmol, 54% yield). 1 H NMRδ(D2O,500MHz)8.44(s,1H),8.08(s,1H),7.93(s,1H),6.00(m,1H),5.83(m,2H),4.95(m,1H),4.68(m,1H),4.50( m,2H),4.42(m,1H),4.37(m,1H),4.33-4.25(m,3H),4.20(m,3H),4.12(m,1H),4.01(s,3H),3.45(s,3H),3.41(s,3H). 31 P NMRδ (D2O, 200MHz) 43.70 (d, J = 24.2Hz, 1P), -0.41 (s, 1P), -11.12 (d, J = 24.2Hz, 1P), -23.56 (dd, J = 24Hz, 24Hz, 1P).

[0857] m7 G 3'OMe pppA 2'OMe5'硫代 Synthesis of pG (Compound 73):

[0858]

[0859] The synthesis and processing of the α-phosphorothioate trinucleotide cap compound 73 was carried out similarly to that of the α-phosphorothioate (α-PS) analog compound 20. 1 H NMRδ(D2O,500MHz)8.21(s,1H),8.02(s,1H),7.93(s,1H),5.93(d,J=5Hz,1H),5.79(m,2H),4.81(m,1H),4.70(m,1H),4.6 4(m,1H),4.50(m,2H),4.42(m,3H),4.33(m,1H),4.21(m,3H),4.08(t,J=5Hz,1H),4.00(s,3H),3.46(s,3H),3.42(s,3H). 31 P NMRδ (D2O, 200MHz) 7.66 (d, J = 26.2Hz, 1P), -0.56 (s, 1P), -11.08 (d, J = 18.2Hz, 1P), -23.15 (dd, J = 20Hz, 26.2Hz, 1P).

[0860] m7 G 3'OMe ppp m6 A 2'OMe Synthesis of p(s)G* (Compound 74):

[0861]

[0862] * m7 G 3'OMe ppp m6 A 2'OMe p(s)G contains a chiral phosphorothioate moiety and is separated into two diastereoisomers: m7 G 3'OMe ppp m6 A 2'OMe p(s Rp )G and m7 G 3'OMe ppp m6 A 2'OMe p(s Sp )G.

[0863] The p m6 A 2'OMe p SThe G dinucleotide was purified by reverse phase chromatography to separate the diastereomers (Daisogel SP-100-15-ODS-P, 100 mM TEAB as buffer A, acetonitrile as buffer B, using a linear gradient from 0% to 11% buffer B over 11 column volumes).

[0864] Compound 74 (D1) was prepared as described according to General Procedure 1 from N7-Me-3'-OMe-GDP (0.19 g, 0.30 mmol), EDC (0.07 g, 0.39 mmol) and imidazole (0.03 g, 0.40 mmol) in 1.9 mL of 10% water in DMSO, magnesium chloride (0.13 mL of a 3.15 M MgCl2 solution, 0.40 mmol) and p- m6 A 2'OMe p S G (0.2 g, 0.20 mmol) was used to synthesize. A solid product (0.12 g, 0.09 mmol) was obtained. The final yield was 94.8 μmol, 47.7%. 1 H NMR(500MHz,D2O)δ8.29(s,1H),8.07(s,1H),8.02(s,1H),5.98(d,J=5.8,1H),5.83(d,J =5.8,1H),5.79(d,J=4.2,1H),5.08(m,1H),4.70(t,J=5.5,1H),4.65(t,J=4.6,1H),4.5 5(m,1H),4.51(t,J=4.1,1H),4.46(t,J=5.3,1H),4.37(m,3H),4.34(m,1H),4.25(m,3H) ,4.18(m,1H),4.06(t,J=4.7,1H),3.98(s,3H),3.48(s,3H),3.45(s,3H),3.05(bs,3H). 31 P NMR (200MHz, D2O) 55.91 (1P), -11.09 (2P), -22.42 (1P), MS m / z = 1188.8 (MH).

[0865] Compound 74 (D2) was prepared as described according to General Procedure 1 from N7-Me-3'-OMe-GDP (0.19 g, 0.30 mmol), EDC (0.07 g, 0.39 mmol) and imidazole (0.03 g, 0.40 mmol) in 1.9 mL of 10% water in DMSO, magnesium chloride (0.13 mL of a 3.15 M MgCl2 solution, 0.40 mmol) and p- m6 A 2'OMe p SG (0.2 g, 0.20 mmol) was used to synthesize. A solid product (0.14 g, 0.11 mmol) was obtained. The final yield was -112.3 μmol, 55.9%. NMR(500MHz,D2O)δ8.29(s,1H),8.06(s,1H),7.96(s,1H),6.00(d,J=5.5,1H) ,5.79(m,2H),5.06(m,1H),4.69(t,J=5.2,1H),4.64(t,J=4.6,1H),4.56(m,1H ),4.47(t,J=4.5,1H),4.29(m,1H),4.39(m,1H),4.35(m,3H),4.18-4.27(m,4 H), 4.07 (t, J = 4.7, 1H), 4.00 (s, 3H), 3.46 (s, 3H), 3.44 (s, 3H), 3.054 (bs, 3H).

[0866] 31 P NMR(200MHz,D2O)56.79(1P),-11.05(2P),-22.40(1P). MS m / z=1187.8(MH). m7 G 3'OMe ppppA 2'OMe Synthesis of pG (Compound 79):

[0867]

[0868] Compound 79 was synthesized according to this procedure: imidazole (696.50 mg, 10.23 mmol) and EDC (1.01 g, 5.28 mmol) dissolved in 8 mL 90% DMSO 10% H2O were used to prepare the precipitate by combining the reagents and stirring at room temperature for 22 hours. m6 A 2'OMe Large-scale activation of pG dinucleotide (2.0 g, 2.20 mmol). After activation, the addition of β-phosphate was accomplished by adding 1 M TBAP dissolved in DMF (38.20 mL, 38.20 mmol) and mixing at room temperature for 18 hours. The reaction solution was then double purified by reverse phase and anion exchange chromatography. m6 A 2'OMe pG dinucleotides were used in subsequent coupling reactions as needed.

[0869] N7-Me 3'-OMe GDP (369.60 mg, 0.764 mmol) was activated with imidazole (161.35 mg, 2.37 mmol) and EDC (234 mg, 1.22 mmol) dissolved in 90% DMSO 10% H2O (3.70 mL). The activation reaction was allowed to proceed for approximately 18 hours to produce 97% conversion of imidazole-activated N7-Me 3'-OMe GDP. To the same solution was added pp m6 A 2'OMe pG dinucleotide (400 mg, 0.500 mmol) and magnesium chloride (324 uL, 3.15 M). The coupling reaction was stirred for about 48 hours. The reaction mixture was purified using anion exchange chromatography. 1 H NMR (500MHz, D2O): δ8.40(s,1H),8.10(s,1H),7.88(s,1H),5.97(d,J=6Hz,1H),5.85 (d,J=4.25Hz,1H),5.80(d,J=5.8Hz,1H)4.90(m,1H)4.86(t,J=5.5Hz,1H)4.69(t,J= 4.65Hz,1H)4.48(m,2H),4.49-4.40(m,3H)4.38(bs,1H)4.32-4.26(m,1H)4.23-4.16 (m,4H)4.15-4.11(m,1H)4.04(s,3H)3.46(s,3H)3.36(s,3H)3.34(s,3H)1.9(s,1H).

[0870] 31 P NMR (200MHz, D2O): δ0.40 (s, 1P), 10.84-1.98 (t, 1P), 22.15-22.47 (m, 1P).

[0871] C 33 H 45 N 15 O 27 Calculated value for P5 1238.67, experimental value 1237.3 and 1238.6 [MH] negative mode.

[0872] m7 G 3'OMe pppp m6 A 2'OMe Synthesis of pG (Compound 80):

[0873]

[0874] The mixture was stirred at room temperature for 22 hours and purified by purifying with imidazole (2.20 g, 32.27 mmol) and EDC (2.59 g, 16.66 mmol) dissolved in 20 mL 90% DMSO 10% H2O. m6 A 2'OMe Large-scale activation of pG dinucleotide (5.0 g, 6.94 mmol) was initiated to synthesize N7-Me-3'Ome guanosine pppp m6 A 2'OMe pG. After activation, the addition of the β-phosphate was accomplished by adding 1 M TBAP in DMF (85 mL, 85 mmol) and mixing at room temperature for 18 hours. The reaction solution was then doubly purified by reverse phase and anion exchange chromatography. m6 A 2'OMe pG dinucleotides are used in coupling reactions as needed to produce the final compounds.

[0875] N7-Me 3'-OMe GDP (354.2 mg, 0.750 mmol) was activated with imidazole (153.6 mg, 2.325 mmol) and EDC (230 mg, 1.2 mmol) dissolved in 90% DMSO 10% H2O (3.54 mL). The activation reaction was continued for about 18 hours to produce 97% conversion of imidazole-activated N7-Me 3'-OMe GDP. To the same solution was added pp m6 A 2'OMe pG dinucleotide (400 mg, 0.500 mmol) and magnesium chloride (317.46 uL, 3.15 M) were added and the coupling reaction was allowed to continue for about 48 hours. The reaction mixture was purified using anion exchange chromatography. 1 H NMR (500MHz, D2O): δ8.32(s,1H),8.08(s,1H),7.86(s,1H),6.44(s,1H),5.97(d,J=5.5Hz,1H)5.83(d,J=4.15Hz,1H),5.78(d,J=5 .75Hz,1H)4.48-4.45(m,4H),4.42-4.32(m,2H)4.10-4.09(m,1H)4.01(s,3H),3.45(s,3H)3.40(s,2H),3.06(bs,1H),1.9(s,1H). 31 P NMR (200MHz, D2O): δ0.43(s,1P), -10.85(m,1P), -22.21(m,1P). C 34 H 47 N 15 O 27 Calculated value of P5 1252.70, experimental value 1251.6 [MH] negative mode.

[0876] m7 G 3'OMe p(s)pp m6 A 2'OMe Synthesis of pG (Compound 81):

[0877]

[0878] pp m6 Synthesis of activated imidazolide of ApG dinucleotide:

[0879] The reaction mixture was purified by combining the reagents and stirring at room temperature for 22 hours using imidazole (2.20 g, 32.27 mmol) and EDC (2.59 g, 16.66 mmol) dissolved in 20 mL 90% DMSO 10% H2O. m6 A 2'OMe Large scale activation of pG dinucleotide (5.0 g, 6.94 mmol). After activation, the addition of β-phosphate was accomplished by adding 1 M TBAP dissolved in DMF (85 mL, 85 mmol) and mixing at room temperature for 18 hours. The reaction solution was then double purified by reverse phase and anion exchange chromatography. The material was then precipitated using 2% by volume of the starting material NaClO4 (100 mg) and 500 mL of acetone. The precipitate was a white solid (6 g). m6 A 2'OMe pG dinucleotides were used in subsequent coupling reactions as needed.

[0880] Synthesis of N7-Me 3'OMe guanosine 5'-phosphorothioate:

[0881] 5'OH 3'Ome guanosine (1 g, 3.36 mmol) was used to carry out N7-methylation of 5' thiophosphorylguanosine. The starting material was methylated using CH3I (1.25 mL, 20.07 mmol) dissolved in 10 mL DMF. The reaction was stirred at room temperature for more than four days. Over a four-day period, the reaction mixture became a clear yellow liquid from a turbid suspension. The reaction mixture was then concentrated to 2.5 mL and pulped with 50 mL dichloromethane to precipitate a white / yellow solid. The solid was vacuum filtered until no visible liquid was seen.

[0882] 5'phosphorothioate of N7-Me 3'OMe guanosine (1 g, 3.2 mmol) was completed. The reaction was carried out under argon using dry material. A TMP solution of PSCl3 (487 uL, 4.8 mmol) and 2,6-lutidine (1118 uL, 4.6 mmol) was added at 0°C. The reaction was completed after 8-9 hours. The reaction was then quenched with 1.5 M TEAA to obtain a pH of 5-6. The product was purified by anion exchange chromatography using QFF resin, and the product was obtained as a TEA salt.

[0883] Compound 81 was prepared by reacting N7-Me 3'OMe guanosine 5'-phosphorothioate with pp in the presence of MgCl2. m6 A 2'OMe pG dinucleotide activated imidazolide coupling synthesis. m6 A 2'OMe The activated imidazolide of pG dinucleotide was used as a solution [0.625mmol / 5mL] in 3.44mL 90% DMSO 10% H2O, while N7-Me 3'OMe guanosine 5' thiophosphate (184mg, 287 micromoles) and 3.15M magnesium chloride (182uL, 574μmol) were added. The components were mixed and stirred at room temperature for 4.5 days. The product was purified by anion exchange chromatography using QFF resin and then by QHP anion exchange chromatography. The final yield after precipitation was 1.805mL (100mM), 177μmol (5494.42OD). 1 HNMR (500MHz, D2O): δ8.30(s,1H),8.05(s,1H),7.92(d,J=4.4Hz,1H),5.96(d,J=5.75H z,1H),5.81(t,J=4.91Hz,1H)5.77-5.76(dd,J=3.9Hz,3.15Hz,1H)4.94-4.89(m,1H),4 .63-4.58(m,1H),4.58-4.52(m,2H)4.46-4.34(m,4H),4.3-4.2(m,4H),4.09-4.05(m,1 H), 3.97-3.95 (d, J = 9.95Hz, 3H), 3.44-42 (m, J = 2.35Hz, 6H), 3.05 (bs, 1H), 1.9 (s, 1H). 31 P NMR (200MHz, D2O): δ43.86-43.27(dd,1P)0.40(s,1P),-11.16(t,1P),23.51(m,1P). C 34 H 47 N 15O 23 The calculated value of P4S is 1189.79, the experimental value is 1189 and 1187.8 [MH] negative mode.

[0884] Example 2: mRNA Synthesis

[0885] mRNAs comprising each cap analog, including compounds as described herein as well as control examples, were synthesized for further testing. See Table 1 for the analogs synthesized.

[0886] Table 1. Synthetic mRNA

[0887]

[0888]

[0889]

[0890]

[0891]

[0892]

[0893]

[0894]

[0895]

[0896]

[0897]

[0898]

[0899]

[0900]

[0901] Example 3: In vitro performance of cap analogs

[0902] The cap analogs described herein were tested in vitro using a commercially available wheat germ extract cell-free translation system (PROMEGAL4380; Promega Corporation, Madison, WI). For determination, 20 ng / μL of luciferase mRNA capped with the cap analogs listed in Table 1 was mixed with the translation components of the wheat germ extract system. The components were reacted at room temperature for two hours to allow protein production. The crude protein mixture was subjected to a luciferin substrate and incubated in the dark for 10 minutes. The total luciferase signal in a 96-well plate was collected in the form of relative luminescence units (RLU). Blank wells containing only luciferase and wheat germ extract controls without luciferase mRNA were used as system controls. Figure 1 The measured relative luminescence results are shown in , showing the RLU values.

[0903] Example 4: In vivo performance of cap analogs

[0904] At the beginning of the study, female CD-1 mice aged 8-9 weeks were randomly divided into groups of five animals based on body weight (Charles River Laboratories, Discovery Research Services North Carolina). Lipid nanoparticle formulations including mRNA (capped using the cap analogs listed in Table 1, N1-methylpseudouridine-5'-triphosphate (N1-me-PsU) modified firefly luciferase (Fluc) mRNA) (LNP: mRNA) test articles were diluted in PBS to achieve a single bolus of 1 mg / kg delivery via tail vein injection. During the duration of the study, the body weight of each mouse was measured once a day, and blood was drawn twice for serum analysis by the Mouse Cytokine / Chemokine 26-Plex ProcartaPlex Panel 1 of the Luminex platform (Thermo Fisher Scientific; Waltham, MA). At six time points after mRNA injection (3, 6, 9, 12, 24, and 48 hours after injection), luciferase activity was measured by whole-body bioluminescence imaging on an IVIS Spectrum CT system by Perkin Elmer (Greenville, SC). D-luciferin (150 mg / kg total) was delivered by intraperitoneal injection 10 minutes before each imaging. Figure 2 The measured luciferase expression results are shown in Figure , showing the integrated flux from 3 to 48 hours. For representative compounds, Figure 3 Representative animals from five animals per group are shown across five imaging time points after LNP:mRNA and luciferin injection (3 hours, 6 hours, 9 hours, 12 hours and 24 hours after injection). The luminescence intensity scale is on the left.

[0905] When the lipid nanoparticle formulation comprising mRNA produced according to Example 2 and luciferin was injected into mice, the m7 GpppA 2'OMe In vivo luciferase expression was comparable or increased in mice injected with LNPs containing mRNAs including the novel cap analogs described herein, compared to mRNA containing pG (control). Figure 2 .

[0906] and m7 GpppA 2'OMe Compared with pG (control), m7 G 3'OMe ppp m6 A 2'OMe pG (compound 30), m7 G 3'Ome pppA 2'OMe pG (Compound 29), m7 G 3'OMe pppA 2',4'-LNA pG (compound 2), m7 G 2'4'-LNA pppA 2'OMe pG (compound 32), m7 G 3'OMe ppp (diaminopurine) 2'OMe pG (compound 8), m7 GpppA 2',4'-LNA pG (compound 1) and m7 Gppp m6 A 2'OMe pG (Compound 31) showed increased luciferase expression in vivo. m7 Gppp m6 A 2'OMe pG (compound 31) showed equivalent in vivo luciferase expression. m7 GpppA 2'OMe The analogs described herein exhibit increased or comparable in vivo translation compared to pG(control).

[0907] The data obtained from the luciferase expression experiment described above were selected to be classified to display m7 Compounds having a 3'OH group on the G portion and m7Direct comparison between the same compounds with 3'OMe modification on the G moiety. Figure 4 Surprisingly, for every comparison tested and analyzed, m7 3'OMe modification on G leads to increased translation in vivo. Figure 4 As shown, m7 GpppA 2'OMe pG(control) relative to m7 G 3'Ome pppA 2'OMe pG (compound 29) was measured, and the compound was m7 G has a 3'OMe group m7 GpppA 2'OMe pG(control) (first column); m7 Gppp m6 A 2'OMe pG (compound 31) relative to m7 G 3'OMe ppp m6 A 2'OMe pG (compound 30) was measured in m7 G has a 3'OMe group m7 Gppp m6 A 2'OMe pG (compound 31) (second column); m7 GpppA 2',4'-LNA pG (compound 1) relative to m7 G 3'OMe pppA 2',4'- LNA pG (compound 2) was measured in m7 G has a 3'OMe group m7 GpppA 2',4'-LNA pG(Compound 1) (third column); and m7 Gppp (diaminopurine) 2'OMe pG (compound 7) relative to m7 G 3'OMe ppp (diaminopurine) 2' OMe pG (compound 8) was measured in m7 G has a 3'OMe group m7 Gppp (diaminopurine) 2' OMe pG (Compound 7) (fourth column). In each of these examples, m7 3'OMe modification on G results in increased luciferase expression in vivo and, therefore, increased translation.

[0908] With m7 GpppA 2'OMe-5'乙烯基 pG (compound 4; in m7 Compared with the lack of 3'OMe group on G, m 7 G 3'- OMe pppA 2'OMe-5'乙烯基 pG (compound 5) obtained a similar increase in luciferase expression in vivo; 7 G 2'OMe pppA 2'OMe pG (compound 26; in m7 Compared with the lack of 3'OMe group on G, m 7 G 2'OMe3'OMe pppA 2'OMe pG (compound 25) obtained a similar increase in luciferase expression in vivo; and compared with m 7 G 2'OMe ppp m6 A 2'OMe pG (compound 28; in m7 Compared with the lack of 3'OMe group on G, m 7 G 2'OMe3'OMe ppp m6 A 2'OMe A similar increase in luciferase expression in vivo was obtained with pG (compound 27). Figure 2 .

[0909] The compounds and methods of the appended claims are not limited to the scope of the specific compounds and methods described herein, and the methods are intended to be an illustration of several aspects of the claims, and any compounds and methods that are functionally equivalent are within the scope of the present disclosure. In addition to the compounds and methods shown and described herein, various modifications to the compounds and methods are intended to fall within the scope of the appended claims. Further, although only certain representative compounds, methods, and aspects of these compounds and methods are specifically described, other compounds and methods are also intended to fall within the scope of the appended claims. Therefore, the combination of steps, elements, components, or ingredients may be explicitly mentioned herein, but even if not explicitly stated, all other combinations of steps, elements, components, and ingredients are included.

Claims

1. A compound having the formula: or a stereoisomer thereof, wherein: is a single bond or a double bond; R1 is H or CH3; R2 is H, and R3 is OCH3 or F, or R2 and R3 are covalently bonded together and together with the intermediate atom form a 2'-O,4'-C methylene bridge; X1 is O or CH; X2 is CH2 or CH; X3 is O or S; Each independent Y is H + or cations; and n is 0, 1, 2, 3, or 4, Wherein when X1 is CH, X2 is CH, and It's a double bond.

2. The compound according to claim 1, wherein the compound has the following structure: or a stereoisomer thereof.

3. The compound according to claim 1, wherein the compound has the following structure: or a stereoisomer thereof.

4. The compound according to claim 1, wherein the compound has the following structure: or a stereoisomer thereof.

5. The compound according to claim 1, wherein the compound has the following structure: or a stereoisomer thereof.

6. The compound according to claim 1, wherein the compound has the following structure: or a stereoisomer thereof.

7. The compound according to claim 1, wherein the compound has the following structure: or a stereoisomer thereof.

8. A compound having the formula: or a stereoisomer thereof, wherein: R1 is H or CH3; X1 is O or S; Each independent Y is H + or cations; and n is 0, 1, 2, 3, or 4, When X1 is S, R1 is CH3.

9. The compound according to claim 8, wherein the compound has the following structure: or a stereoisomer thereof.

10. The compound according to claim 8, wherein the compound has the following structure: or a stereoisomer thereof.

11. The compound according to claim 8, wherein the compound has the following structure: or a stereoisomer thereof.

12. A compound having the formula: or a stereoisomer thereof, wherein: R1 is H or CH3; Each independent Y is H + or cations; and n is 0, 1, 2, 3 or 4.

13. The compound according to claim 12, wherein the compound has the following structure: or a stereoisomer thereof.

14. The compound according to claim 12, wherein the compound has the following structure: or a stereoisomer thereof.

15. A compound having the formula: or a stereoisomer thereof, wherein: R1 is H or CH3; X1, X2 and X3 are each independently selected from O and S, wherein when one of X1, X2 or X3 is S, the rest of X1, X2 and X3 are O; Each independent Y is H + or cations; and n is 0, 1, 2, 3 or 4.

16. The compound according to claim 15, wherein the compound has the following structure: or a stereoisomer thereof.

17. The compound according to claim 15, wherein the compound has the following structure: or a stereoisomer thereof.

18. The compound according to claim 15, wherein the compound has the following structure: or a stereoisomer thereof.

19. The compound according to claim 15, wherein the compound has the following structure: or a stereoisomer thereof.

20. A compound having the formula: or a stereoisomer thereof, wherein: R1 is H or CH3; R2 is H and R3 is F, or R2 and R3 are covalently bonded together and together with the intermediate atom form a 2'-O,4'-C methylene bridge; Each independent Y is H + or cations; and n is 0, 1, 2, 3, or 4, Wherein when R2 is H and R3 is F, R1 is not H.

21. The compound according to claim 20, wherein the compound has the following structure: or a stereoisomer thereof.

22. The compound according to claim 20, wherein the compound has the following structure: or a stereoisomer thereof.

23. The compound according to claim 20, wherein the compound has the following structure: or a stereoisomer thereof.

24. A compound having the formula: or a stereoisomer thereof, wherein: R1 is H or CH3; X1, X2, X3 and X4 are each independently selected from O and S; Each independent Y is H + or cations; and n is 0, 1, 2, 3, or 4, Among them, one of X1, X2, X3 and X4 is S.

25. The compound according to claim 24, wherein the compound has the following structure: or a stereoisomer thereof.

26. The compound of claim 24, wherein the compound has the following structure: or a stereoisomer thereof.

27. The compound of claim 24, wherein the compound has the following structure: or a stereoisomer thereof.

28. The compound of claim 24, wherein the compound has the following structure: or a stereoisomer thereof.

29. The compound of claim 24, wherein the compound has the following structure: or a stereoisomer thereof.

30. The compound of claim 24, wherein the compound has the following structure:

31. A compound having the formula: or a stereoisomer thereof, wherein: R1 and R2 are each independently selected from H and CH3; Each independent Y is H + or cations; and n is 0, 1, 2, 3, or 4, wherein at least one of R1 or R2 is CH3.

32. The compound of claim 31, wherein the compound has the following structure: or a stereoisomer thereof.

33. The compound of claim 31, wherein the compound has the following structure: or a stereoisomer thereof.

34. The compound of claim 31, wherein the compound has the following structure: or a stereoisomer thereof.

35. A compound having the formula: or a stereoisomer thereof, wherein: R1 and R2 are each independently selected from H and CH3; Each independent Y is H + or cations; and n is 0, 1, 2, 3 or 4.

36. The compound of claim 35, wherein the compound has the following structure: or a stereoisomer thereof.

37. The compound of claim 35, wherein the compound has the following structure: or a stereoisomer thereof.

38. The compound of claim 35, wherein the compound has the following structure: or a stereoisomer thereof.

39. The compound of claim 35, wherein the compound has the following structure: or a stereoisomer thereof.

40. A compound having the formula: or a stereoisomer thereof, wherein: R1 is H or CH3; R2 is OH, F, substituted or unsubstituted alkoxy or thio; R3 is H or CH3; Each independent Y is H + or cations; and n is 0, 1, 2, 3 or 4, Wherein when R2 is OH, R1 is not H.

41. The compound of claim 40, wherein the compound has the following structure: or a stereoisomer thereof.

42. The compound of claim 40, wherein the compound has the structure: or a stereoisomer thereof.

43. The compound of claim 40, wherein the compound has the following structure:

44. The compound of claim 40, wherein the compound has the structure: or a stereoisomer thereof.

45. The compound of claim 40, wherein the compound has the following structure: or a stereoisomer thereof.

46. ​​The compound of claim 40, wherein the compound has the following structure: or a stereoisomer thereof.

47. The compound of claim 40, wherein the compound has the structure: or a stereoisomer thereof.

48. A compound having the formula: or a stereoisomer thereof, wherein: R1 is H and CH3; Each independent Y is H + or cations; and n is 0, 1, 2, 3 or 4.

49. The compound of claim 48, wherein the compound has the following structure: or a stereoisomer thereof.

50. The compound of claim 48, wherein the compound has the structure: or a stereoisomer thereof.

51. A compound having the formula: or a stereoisomer thereof, wherein: R1 is H and CH3; Each independent Y is H + or cations; and n is 0, 1, 2, 3 or 4.

52. The compound of claim 51, wherein the compound has the following structure: or a stereoisomer thereof.

53. The compound of claim 51, wherein the compound has the structure: or a stereoisomer thereof.

54. A compound having the formula: or a stereoisomer thereof, wherein: R1 and R2 are each independently selected from H and CH3; Each independent Y is H + or cations; and n is 0, 1, 2, 3, 4 or 5.

55. The compound of claim 54, wherein the compound has the following structure: or a stereoisomer thereof.

56. The compound of claim 54, wherein the compound has the structure: or a stereoisomer thereof.

57. A compound according to any one of claims 1 to 56, wherein the compound is a deuterated form of the compound.

58. A compound selected from the group consisting of: or a stereoisomer thereof.

59. A pharmaceutical composition comprising a compound according to any one of claims 1 to 58 and a pharmaceutically acceptable carrier.

60. An RNA molecule comprising a 5'-cap, wherein the 5'-cap comprises a compound according to any one of claims 1 to 58.

61. The RNA molecule of claim 60, wherein the RNA molecule is a messenger RNA (mRNA) molecule or a self-amplifying RNA (saRNA) molecule.

62. A method of inducing a therapeutic effect in a subject, the method comprising administering to the subject an RNA molecule according to claim 60 or 61.

63. A method of administering to an animal a therapeutic dosage unit of an mRNA molecule comprising a 5'-cap, wherein the 5'-cap comprises a compound according to any one of claims 1 to 58.

64. The method of claim 63, wherein the therapeutic dosage unit of the mRNA molecule comprises less than 7 ng / μg of double-stranded RNA (dsRNA).

65. The method of claim 64, wherein the subject exhibits increased tolerance to an administered therapeutic dose unit of the mRNA molecule comprising 7 ng / μg or more of dsRNA compared to an equivalent therapeutic dose unit of the mRNA molecule.

66. The method of claim 65, wherein the increased tolerance is determined by measuring one or more of the following: body weight, organ weight, aspartate aminotransferase (AST) levels, alanine aminotransferase (ALT) levels, C-reactive protein (CRP) levels, procalcitonin (PCT) levels, interleukin-6 (IL-6) levels, erythrocyte sedimentation rate (ESR), serum amyloid A levels, and serum ferritin levels before and after the administration for a period of time.

67. The method of claim 65 or 66, wherein the increased tolerance is measured by testing in a standard in vivo assay.

68. The method of any one of claims 65 to 67, wherein the increased tolerability is an increase of at least 20% over the tolerability of the administered dose unit as measured by testing in a standard in vivo assay, an increase of at least 25% over the tolerability of the administered dose unit as measured by testing in a standard in vivo assay, an increase of at least 30% over the tolerability of the administered dose unit as measured by testing in a standard in vivo assay, an increase of at least 35% over the tolerability of the administered dose unit as measured by testing in a standard in vivo assay, an increase of at least 40% over the tolerability of the administered dose unit as measured by testing in a standard in vivo assay, an increase of at least 45% over the tolerability of the administered dose unit as measured by testing in a standard in vivo assay, an increase of at least 50% over the tolerability of the administered dose unit as measured by testing in a standard in vivo assay, an increase of at least 50% over the tolerability of the administered dose unit as measured by testing in a standard in vivo assay, The tolerability of the dose unit administered is increased by at least 55%, as measured by testing in a standard in vivo assay, ...

69. The method of any one of claims 65 to 68, wherein the therapeutic dosage unit of the mRNA molecule comprises less than 6.9 ng / μg of double-stranded RNA (dsRNA), less than 6.8 ng / μg of double-stranded RNA (dsRNA), less than 6.7 ng / μg of double-stranded RNA (dsRNA), less than 6.6 ng / μg of double-stranded RNA (dsRNA), less than 6.5 ng / μg of double-stranded RNA (dsRNA), less than 6.4 ng / μg of double-stranded RNA (dsRNA), less than 6.3 ng / μg of double-stranded RNA (dsRNA), less than 6.2 ng / μg of double-stranded RNA (dsRNA), less than 6.1 ng / μg of double-stranded RNA (dsRNA), less than 6. g of double-stranded RNA (dsRNA), less than 6.0 ng / μg of double-stranded RNA (dsRNA), less than 5.9 ng / μg of double-stranded RNA (dsRNA), less than 5.8 ng / μg of double-stranded RNA (dsRNA), less than 5.7 ng / μg of double-stranded RNA (dsRNA), less than 5.6 ng / μg of double-stranded RNA (dsRNA), less than 5.5 ng / μg of double-stranded RNA (dsRNA), less than 5.4 ng / μg of double-stranded RNA (dsRNA), less than 5.3 ng / μg of double-stranded RNA (dsRNA), less than 5.2 ng / μg of double-stranded RNA (dsRNA), less than 5.1 ng / μg of double-stranded RNA A(dsRNA), less than 5.0ng / μg double-stranded RNA(dsRNA), less than 4.9ng / μg double-stranded RNA(dsRNA), less than 4.8ng / μg double-stranded RNA(dsRNA), less than 4.7ng / μg double-stranded RNA(dsRNA), less than 4.6ng / μg double-stranded RNA(dsRNA), less than 4.5ng / μg double-stranded RNA(dsRNA), less than 4.4ng / μg double-stranded RNA(dsRNA), less than 4.3ng / μg double-stranded RNA(dsRNA), less than 4.2ng / μg double-stranded RNA(dsRNA), less than 4.1ng / μg double-stranded RNA(dsRN A), less than 4.0 ng / μg of double-stranded RNA (dsRNA), less than 3.9 ng / μg of double-stranded RNA (dsRNA), less than 3.8 ng / μg of double-stranded RNA (dsRNA), less than 3.7 ng / μg of double-stranded RNA (dsRNA), less than 3.6 ng / μg of double-stranded RNA (dsRNA), less than 3.5 ng / μg of double-stranded RNA (dsRNA), less than 3.4 ng / μg of double-stranded RNA (dsRNA), less than 3.3 ng / μg of double-stranded RNA (dsRNA), less than 3.2 ng / μg of double-stranded RNA (dsRNA), less than 3.1 ng / μg of double-stranded RNA (dsRNA), less than 3.0ng / μg of double-stranded RNA (dsRNA), less than 2.9ng / μg of double-stranded RNA (dsRNA), less than 2.8ng / μg of double-stranded RNA (dsRNA), less than 2.7ng / μg of double-stranded RNA (dsRNA), less than 2.6ng / μg of double-stranded RNA (dsRNA), less than 2.5ng / μg of double-stranded RNA (dsRNA), less than 2.4ng / μg of double-stranded RNA (dsRNA), less than 2.3ng / μg of double-stranded RNA A(dsRNA), less than 2.2ng / μg double-stranded RNA(dsRNA), less than 2.1ng / μg double-stranded RNA(dsRNA), less than 2.0ng / μg double-stranded RNA(dsRNA), less than 1.9ng / μg double-stranded RNA(dsRNA), less than 1.8ng / μg double-stranded RNA(dsRNA), less than 1.7ng / μg double-stranded RNA(dsRNA), less than 1.6ng / μg double-stranded RNA(dsRNA), less than 1.5 ng / μg of double-stranded RNA (dsRNA), less than 1.4 ng / μg of double-stranded RNA (dsRNA), less than 1.3 ng / μg of double-stranded RNA (dsRNA), less than 1.2 ng / μg of double-stranded RNA (dsRNA), less than 1.1 ng / μg of double-stranded RNA (dsRNA), less than 1.0 ng / μg of double-stranded RNA (dsRNA), less than 0.9 ng / μg of double-stranded RNA (dsRNA), less than 0.8 ng / μg of double-stranded RNA RNA (dsRNA), less than 0.7 ng / μg double-stranded RNA (dsRNA), less than 0.6 ng / μg double-stranded RNA (dsRNA), less than 0.5 ng / μg double-stranded RNA (dsRNA), less than 0.4 ng / μg double-stranded RNA (dsRNA), less than 0.3 ng / μg double-stranded RNA (dsRNA), less than 0.2 ng / μg double-stranded RNA (dsRNA), or less than 0.1 ng / μg double-stranded RNA (dsRNA).

70. A method of administering to an animal a therapeutic dosage unit of an mRNA molecule comprising a 5'-cap, wherein the 5'-cap comprises a compound selected from the group consisting of: or a stereoisomer thereof, wherein said therapeutic dosage unit of said mRNA molecule comprises less than 7 ng / μg of double-stranded RNA (dsRNA), wherein the subject exhibits increased tolerability to the administered therapeutic dosage unit of the mRNA molecule compared to an equivalent therapeutic dosage unit of the mRNA molecule comprising 7 ng / μg or more dsRNA.

71. The method of claim 70, wherein the increased tolerance is determined by measuring one or more of the following: body weight, organ weight, aspartate aminotransferase (AST) levels, alanine aminotransferase (ALT) levels, C-reactive protein (CRP) levels, procalcitonin (PCT) levels, interleukin-6 (IL-6) levels, erythrocyte sedimentation rate (ESR), serum amyloid A levels, and serum ferritin levels before and after the administration for a certain period of time.

72. The method of claim 70 or 71, wherein the increased tolerance is measured by testing in a standard in vivo assay.

73. The method of any one of claims 70 to 72, wherein the increased tolerability is an increase of at least 20% over the tolerability of the administered dose unit as measured by testing in a standard in vivo assay, an increase of at least 25% over the tolerability of the administered dose unit as measured by testing in a standard in vivo assay, an increase of at least 30% over the tolerability of the administered dose unit as measured by testing in a standard in vivo assay, an increase of at least 35% over the tolerability of the administered dose unit as measured by testing in a standard in vivo assay, an increase of at least 40% over the tolerability of the administered dose unit as measured by testing in a standard in vivo assay, an increase of at least 45% over the tolerability of the administered dose unit as measured by testing in a standard in vivo assay, an increase of at least 50% over the tolerability of the administered dose unit as measured by testing in a standard in vivo assay, an increase of at least 50% over the tolerability of the administered dose unit as measured by testing in a standard in vivo assay, The tolerability of the dose unit administered is increased by at least 55%, as measured by testing in a standard in vivo assay, ...

74. The method of any one of claims 70 to 73, wherein the therapeutic dosage unit of the mRNA molecule comprises less than 6.9 ng / μg of double-stranded RNA (dsRNA), less than 6.8 ng / μg of double-stranded RNA (dsRNA), less than 6.7 ng / μg of double-stranded RNA (dsRNA), less than 6.6 ng / μg of double-stranded RNA (dsRNA), less than 6.5 ng / μg of double-stranded RNA (dsRNA), less than 6.4 ng / μg of double-stranded RNA (dsRNA), less than 6.3 ng / μg of double-stranded RNA (dsRNA), less than 6.2 ng / μg of double-stranded RNA (dsRNA), less than 6.1 ng / μg of double-stranded RNA (dsRNA), less than 6. g of double-stranded RNA (dsRNA), less than 6.0 ng / μg of double-stranded RNA (dsRNA), less than 5.9 ng / μg of double-stranded RNA (dsRNA), less than 5.8 ng / μg of double-stranded RNA (dsRNA), less than 5.7 ng / μg of double-stranded RNA (dsRNA), less than 5.6 ng / μg of double-stranded RNA (dsRNA), less than 5.5 ng / μg of double-stranded RNA (dsRNA), less than 5.4 ng / μg of double-stranded RNA (dsRNA), less than 5.3 ng / μg of double-stranded RNA (dsRNA), less than 5.2 ng / μg of double-stranded RNA (dsRNA), less than 5.1 ng / μg of double-stranded RNA A(dsRNA), less than 5.0ng / μg double-stranded RNA(dsRNA), less than 4.9ng / μg double-stranded RNA(dsRNA), less than 4.8ng / μg double-stranded RNA(dsRNA), less than 4.7ng / μg double-stranded RNA(dsRNA), less than 4.6ng / μg double-stranded RNA(dsRNA), less than 4.5ng / μg double-stranded RNA(dsRNA), less than 4.4ng / μg double-stranded RNA(dsRNA), less than 4.3ng / μg double-stranded RNA(dsRNA), less than 4.2ng / μg double-stranded RNA(dsRNA), less than 4.1ng / μg double-stranded RNA(dsRN A), less than 4.0 ng / μg of double-stranded RNA (dsRNA), less than 3.9 ng / μg of double-stranded RNA (dsRNA), less than 3.8 ng / μg of double-stranded RNA (dsRNA), less than 3.7 ng / μg of double-stranded RNA (dsRNA), less than 3.6 ng / μg of double-stranded RNA (dsRNA), less than 3.5 ng / μg of double-stranded RNA (dsRNA), less than 3.4 ng / μg of double-stranded RNA (dsRNA), less than 3.3 ng / μg of double-stranded RNA (dsRNA), less than 3.2 ng / μg of double-stranded RNA (dsRNA), less than 3.1 ng / μg of double-stranded RNA (dsRNA), less than 3.0ng / μg of double-stranded RNA (dsRNA), less than 2.9ng / μg of double-stranded RNA (dsRNA), less than 2.8ng / μg of double-stranded RNA (dsRNA), less than 2.7ng / μg of double-stranded RNA (dsRNA), less than 2.6ng / μg of double-stranded RNA (dsRNA), less than 2.5ng / μg of double-stranded RNA (dsRNA), less than 2.4ng / μg of double-stranded RNA (dsRNA), less than 2.3ng / μg of double-stranded RNA A(dsRNA), less than 2.2ng / μg double-stranded RNA(dsRNA), less than 2.1ng / μg double-stranded RNA(dsRNA), less than 2.0ng / μg double-stranded RNA(dsRNA), less than 1.9ng / μg double-stranded RNA(dsRNA), less than 1.8ng / μg double-stranded RNA(dsRNA), less than 1.7ng / μg double-stranded RNA(dsRNA), less than 1.6ng / μg double-stranded RNA(dsRNA), less than 1.5 ng / μg of double-stranded RNA (dsRNA), less than 1.4 ng / μg of double-stranded RNA (dsRNA), less than 1.3 ng / μg of double-stranded RNA (dsRNA), less than 1.2 ng / μg of double-stranded RNA (dsRNA), less than 1.1 ng / μg of double-stranded RNA (dsRNA), less than 1.0 ng / μg of double-stranded RNA (dsRNA), less than 0.9 ng / μg of double-stranded RNA (dsRNA), less than 0.8 ng / μg of double-stranded RNA RNA (dsRNA), less than 0.7 ng / μg double-stranded RNA (dsRNA), less than 0.6 ng / μg double-stranded RNA (dsRNA), less than 0.5 ng / μg double-stranded RNA (dsRNA), less than 0.4 ng / μg double-stranded RNA (dsRNA), less than 0.3 ng / μg double-stranded RNA (dsRNA), less than 0.2 ng / μg double-stranded RNA (dsRNA), or less than 0.1 ng / μg double-stranded RNA (dsRNA).

75. A method for increasing the in vivo translation of a polypeptide in a subject, the method comprising administering to the subject a therapeutic dosage unit comprising an effective amount of an mRNA encoding a polypeptide, wherein the mRNA comprises a 5'-cap having the formula: or a stereoisomer thereof, wherein the therapeutic dosage unit administered is at least 20% lower than the therapeutic dosage unit required to elicit the same response in the subject when a control mRNA encoding the polypeptide is administered, wherein the control mRNA comprises a 5'-cap having the formula: or a stereoisomer thereof.

76. A method for increasing the in vivo translation of a polypeptide in a subject, the method comprising administering to the subject a therapeutic dosage unit comprising an effective amount of an mRNA encoding a polypeptide, wherein the mRNA comprises a 5'-cap having the formula: or a stereoisomer thereof, wherein the therapeutic dosage unit administered is at least 20% lower than the therapeutic dosage unit required to elicit the same response in the subject when a control mRNA encoding the polypeptide is administered, wherein the control mRNA comprises a 5'-cap having the formula: or a stereoisomer thereof.

77. A method for increasing the in vivo translation of a polypeptide in a subject, the method comprising administering to the subject a therapeutic dosage unit comprising an effective amount of an mRNA encoding a polypeptide, wherein the mRNA comprises a 5'-cap having the formula: or a stereoisomer thereof, wherein the dose administered is at least 20% lower than the therapeutic dose units required to elicit the same response in the subject when a control mRNA encoding the polypeptide is administered, wherein the control mRNA comprises a 5'-cap having the formula: or a stereoisomer thereof.

78. A method for increasing the in vivo translation of a polypeptide in a subject, the method comprising administering to the subject a therapeutic dosage unit comprising an effective amount of an mRNA encoding a polypeptide, wherein the mRNA comprises a 5'-cap having the formula: or a stereoisomer thereof, wherein the therapeutic dosage unit administered is at least 20% lower than the therapeutic dosage unit required to elicit the same response in the subject when a control mRNA encoding the polypeptide is administered, wherein the control mRNA comprises a 5'-cap having the formula: or a stereoisomer thereof.

79. The method of any one of claims 75 to 78, wherein the subject exhibits increased tolerance to the administered therapeutic dose unit compared to the therapeutic dose unit required to elicit the same response in the subject when the control mRNA is administered, as measured by testing in a standard in vivo assay.

80. The method of claim 79, wherein the increased tolerability is an increase of at least 20% over the tolerability of the administered therapeutic dose unit as measured by testing in a standard in vivo assay, an increase of at least 25% over the tolerability of the administered therapeutic dose unit as measured by testing in a standard in vivo assay, an increase of at least 30% over the tolerability of the administered therapeutic dose unit as measured by testing in a standard in vivo assay, an increase of at least 35% over the tolerability of the administered therapeutic dose unit as measured by testing in a standard in vivo assay, an increase of at least 40% over the tolerability of the administered therapeutic dose unit as measured by testing in a standard in vivo assay, an increase of at least 45% over the tolerability of the administered therapeutic dose unit as measured by testing in a standard in vivo assay, an increase of at least 50% over the tolerability of the administered therapeutic dose unit as measured by testing in a standard in vivo assay, an increase of at least 10% over the tolerability of the administered therapeutic dose unit as measured by testing in a standard in vivo assay, The tolerability of the administered therapeutic dose unit may be increased by at least 55% as measured by testing in a standard in vivo assay, by at least 60% as measured by testing in a standard in vivo assay, by at least 65% as measured by testing in a standard in vivo assay, by at least 70% as measured by testing in a standard in vivo assay, by at least 75% as measured by testing in a standard in vivo assay, by at least 80% as measured by testing in a standard in vivo assay, by at least 85% as measured by testing in a standard in vivo assay, by at least 90% as measured by testing in a standard in vivo assay, or by at least 95% as measured by testing in a standard in vivo assay.

81. The method of any one of claims 75 to 80, wherein the administered therapeutic dosage unit comprises less than 6.9 ng / μg of double-stranded RNA (dsRNA), less than 6.8 ng / μg of double-stranded RNA (dsRNA), less than 6.7 ng / μg of double-stranded RNA (dsRNA), less than 6.6 ng / μg of double-stranded RNA (dsRNA), less than 6.5 ng / μg of double-stranded RNA (dsRNA), less than 6.4 ng / μg of double-stranded RNA (dsRNA), less than 6.3 ng / μg of double-stranded RNA (dsRNA), less than 6.2 ng / μg of double-stranded RNA (dsRNA), less than 6.1 ng / μg of double-stranded RNA (dsRNA). RNA (dsRNA), less than 6.0 ng / μg double-stranded RNA (dsRNA), less than 5.9 ng / μg double-stranded RNA (dsRNA), less than 5.8 ng / μg double-stranded RNA (dsRNA), less than 5.7 ng / μg double-stranded RNA (dsRNA), less than 5.6 ng / μg double-stranded RNA (dsRNA), less than 5.5 ng / μg double-stranded RNA (dsRNA), less than 5.4 ng / μg double-stranded RNA (dsRNA), less than 5.3 ng / μg double-stranded RNA (dsRNA), less than 5.2 ng / μg double-stranded RNA (dsRNA), less than 5.1 ng / μg double-stranded RNA (dsRNA), less than 5. sRNA), less than 5.0ng / μg double-stranded RNA (dsRNA), less than 4.9ng / μg double-stranded RNA (dsRNA), less than 4.8ng / μg double-stranded RNA (dsRNA), less than 4.7ng / μg double-stranded RNA (dsRNA), less than 4.6ng / μg double-stranded RNA (dsRNA), less than 4.5ng / μg double-stranded RNA (dsRNA), less than 4.4ng / μg double-stranded RNA (dsRNA), less than 4.3ng / μg double-stranded RNA (dsRNA), less than 4.2ng / μg double-stranded RNA (dsRNA), less than 4.1ng / μg double-stranded RNA (dsRNA) , less than 4.0 ng / μg of double-stranded RNA (dsRNA), less than 3.9 ng / μg of double-stranded RNA (dsRNA), less than 3.8 ng / μg of double-stranded RNA (dsRNA), less than 3.7 ng / μg of double-stranded RNA (dsRNA), less than 3.6 ng / μg of double-stranded RNA (dsRNA), less than 3.5 ng / μg of double-stranded RNA (dsRNA), less than 3.4 ng / μg of double-stranded RNA (dsRNA), less than 3.3 ng / μg of double-stranded RNA (dsRNA), less than 3.2 ng / μg of double-stranded RNA (dsRNA), less than 3.1 ng / μg of double-stranded RNA (dsRNA), less than 3.0ng / μg of double-stranded RNA (dsRNA), less than 2.9ng / μg of double-stranded RNA (dsRNA), less than 2.8ng / μg of double-stranded RNA (dsRNA), less than 2.7ng / μg of double-stranded RNA (dsRNA), less than 2.6ng / μg of double-stranded RNA (dsRNA), less than 2.5ng / μg of double-stranded RNA (dsRNA), less than 2.4ng / μg of double-stranded RNA (dsRNA), less than 2.3ng / μg of double-stranded RNA A(dsRNA), less than 2.2ng / μg double-stranded RNA(dsRNA), less than 2.1ng / μg double-stranded RNA(dsRNA), less than 2.0ng / μg double-stranded RNA(dsRNA), less than 1.9ng / μg double-stranded RNA(dsRNA), less than 1.8ng / μg double-stranded RNA(dsRNA), less than 1.7ng / μg double-stranded RNA(dsRNA), less than 1.6ng / μg double-stranded RNA(dsRNA), less than 1.5 ng / μg of double-stranded RNA (dsRNA), less than 1.4 ng / μg of double-stranded RNA (dsRNA), less than 1.3 ng / μg of double-stranded RNA (dsRNA), less than 1.2 ng / μg of double-stranded RNA (dsRNA), less than 1.1 ng / μg of double-stranded RNA (dsRNA), less than 1.0 ng / μg of double-stranded RNA (dsRNA), less than 0.9 ng / μg of double-stranded RNA (dsRNA), less than 0.8 ng / μg of double-stranded RNA RNA (dsRNA), less than 0.7 ng / μg double-stranded RNA (dsRNA), less than 0.6 ng / μg double-stranded RNA (dsRNA), less than 0.5 ng / μg double-stranded RNA (dsRNA), less than 0.4 ng / μg double-stranded RNA (dsRNA), less than 0.3 ng / μg double-stranded RNA (dsRNA), less than 0.2 ng / μg double-stranded RNA (dsRNA), or less than 0.1 ng / μg double-stranded RNA (dsRNA).

82. A method for synthesizing a trinucleotide compound, the method comprising: (1) N7-methyl-guanosine-5'-diphosphate having the following structure: in X1 and X2 are each independently selected from the group consisting of O and S; X3 is O; R1 and R2 are each independently selected from H, OH, N3, F, substituted or unsubstituted alkoxy and thio, wherein R1 and R2 are optionally combined to form a heterocycle, combining with an activating reagent and imidazole to form an activated intermediate; and (2) a salt reagent and a dinucleotide having the following structure: in is a single bond or a double bond; X4 and X6 are each independently selected from the group consisting of O and S; X5 is O, S or CH; X7 is CH or CH2; R3 is OH, OMe, F, and R4 is H, or wherein R3 and R4 are covalently bonded together and together with the intermediate atom form a 2'-0,4'-C methylene bridge; and B1 and B2 are each independently selected from the group consisting of a purine ring and a pyrimidine ring, is added to the activated intermediate to form the trinucleotide compound having the following structure: The method described therein is a one-pot synthesis method.

83. A method for synthesizing a trinucleotide compound, the method comprising: (1) A dinucleotide having the following structure: in is a single bond or a double bond; X4 is O; X6 is O or S; X5 is O, S or CH; X7 is CH or CH2; R3 is OH, OMe, F, and R4 is H, or wherein R3 and R4 are covalently bonded together and together with the intermediate atom form a 2'-0,4'-C methylene bridge; and B1 and B2 are each independently selected from the group consisting of a purine ring and a pyrimidine ring, Mixed with an activating reagent and imidazole to form an activated phosphoimidazolide having the following structure: as well as (2) a salt reagent and a compound having the following structure: in X1 and X2 are each independently selected from the group consisting of O and S; X3 is S; R1 and R2 are each independently selected from H, OH, N3, F, substituted or unsubstituted alkoxy and thio, wherein R1 and R2 are optionally combined to form a heterocycle, is added to the activated phosphoimidazole to form the trinucleotide compound having the following structure:

84. A method for synthesizing a trinucleotide compound, the method comprising: (1) a dinucleotide diphosphate having the following structure: in is a single bond or a double bond; X3 is O; X4 and X6 are each independently selected from O and S; X5 is O, S or CH; X7 is CH or CH2; R3 is OH, OMe, F, and R4 is H, or wherein R3 and R4 are covalently bonded together and together with the intermediate atom form a 2'-0,4'-C methylene bridge; and B1 and B2 are each independently selected from the group consisting of a purine ring and a pyrimidine ring, Mixed with an activating reagent and imidazole to form an activated phosphoimidazolide having the following structure: as well as (2) a salt reagent and a compound having the following structure: in X1 and X2 are each independently selected from O and S; and R1 and R2 are each independently selected from H, OH, N3, F, substituted or unsubstituted alkoxy and thio, wherein R1 and R2 are optionally combined to form a heterocycle, is added to the activated phosphoimidazole to form the trinucleotide compound having the following structure: The method described therein is a one-pot synthesis method.

Citation Information

Cited By

  • Lotus nucleoside cap analogue and application thereof

    CN116478226A

  • A locked nucleoside cap analogue and its application

    CN116478226B

  • Capped polynucleotide, capped mRNA and composition thereof, pharmaceutical protein and preparation method and application thereof, and pharmaceutical preparation

    CN118108781A